pyrroles has been researched along with tofacitinib in 920 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (2.72) | 29.6817 |
| 2010's | 697 (75.76) | 24.3611 |
| 2020's | 198 (21.52) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, DL; Ball, DJ; Beals, CR; Beckius, GE; Blumenkopf, TA; Borie, DC; Brissette, WH; Brown, MF; Casavant, JM; Changelian, PS; Conklyn, MJ; Des Etages, SG; Doty, JL; Elliott, EA; Finco-Kent, D; Fisher, DA; Fisher, MB; Flanagan, ME; Gaweco, AS; Hayes, LS; Higgins, J; Hines, M; Holm, B; Johnson, KS; Kawabata, TT; Kent, CR; Koslov, ER; Kudlacz, EM; Larson, M; Lillie, BM; Littman, BH; Magna, HA; Magnuson, KS; Martin, WH; McCurdy, SP; Milici, AJ; Morris, RE; Moyer, JD; Munchhof, MJ; Nelms, LF; O'Shea, JJ; Paniagua, R; Perry, BD; Reitz, B; Rizzuti, BJ; Saltarelli, MJ; Sawyer, PS; Shang-Poa, C; Si, MS; Smith, JF; Strelevitz, TJ; Su, C; Subramanyam, C; Sun, J; Whipple, DA; Woodworth, TG; Yoon, K; Zagouras, P; Zhou, YJ | 1 |
| Andresen, C; Changelian, P; Conklyn, M; Kudlacz, E | 1 |
| Borie, DC; Changelian, PS; O'Shea, JJ | 1 |
| Ball, DA; Borie, DC; Brissette, WH; Campbell, A; Changelian, PS; Elliott, EA; Flores, MG; Hawkins, J; Higgins, JP; Holm, B; Kudlacz, EM; Larson, MJ; Lau, M; Morris, RE; Paniagua, R; Reitz, BA; Rousvoal, G; Si, MS; Zhang, S | 1 |
| Borie, DC; Campbell, A; Changelian, PS; Paniagua, R; Prakash, C; Reitz, BA | 1 |
| Thompson, JE | 1 |
| Aalami, O; Borie, DC; Campbell, A; Changelian, PS; Flores, MG; Paniagua, R; Reitz, BA; Rousvoal, G; Si, MS; Zhang, S | 1 |
| Ball, DJ; Borie, DC; Brissette, WH; Campbell, A; Changelian, PS; Elliott, EA; Flores, MG; Higgins, JP; Kudlacz, EM; Larson, MJ; Reitz, BA; Rousvoal, G; Zhang, S | 1 |
| Berry, GJ; Borie, DC; Changelian, PS; Flores, MG; Lau, M; Reitz, BA; Rousvoal, G; Si, MS; Zhang, S | 1 |
| Hampton, T | 1 |
| Audoly, L; Changelian, P; Kudlacz, EM; Milici, AJ; Zwillich, S | 1 |
| Andresen, C; Changelian, P; Conklyn, M; Kudlacz, E; Whitney-Pickett, C | 1 |
| Cortes, JE; Estrov, Z; Gaikwad, A; Kantarjian, HM; Manshouri, T; Nussenzveig, RH; Prchal, J; Quintás-Cardama, A; Verstovsek, S | 1 |
| Brennan, D; Chan, G; Chow, V; Gaston, R; Krishnaswami, S; Mendez, R; Ni, G; Pescovitz, MD; Pirsch, J; Swan, S; van Gurp, E; Wang, C; Weimar, W | 1 |
| Chen, Z; Costanzi, S; Deflorian, F; Ghoreschi, K; Jiang, JK; Leister, W; Liu, EH; Nguyen, DT; O'Shea, JJ; Perreira, M; Pesu, M; Smith, J; Thomas, CJ | 1 |
| Baan, CC; Chan, G; Klepper, M; Korevaar, SS; Schoordijk-Verschoor, W; van Gurp, EA; Weimar, W | 1 |
| Boy, MG; Chan, G; Changelian, PS; Chow, VF; Clucas, AT; Gaweco, AS; Krueger, JG; Wang, C; Wilkinson, BE; Zwillich, SH | 1 |
| Kameda, H; Takeuchi, T | 1 |
| Hayashi, T; Sumida, T | 1 |
| Cannon, C; Chan, G; Gruben, D; Krishnaswami, S; Lawendy, N; Swan, S; Wang, R | 1 |
| West, K | 1 |
| Bloom, BJ; Breedveld, FC; Burgos-Vargas, R; Coombs, JH; Fletcher, MP; Gruben, D; Kremer, JM; Krishnaswami, S; Wilkinson, B; Zerbini, CA; Zwillich, SH | 1 |
| Bloom, BJ; Breedveld, FC; Burgos-Vargas, R; Coombs, JH; Fletcher, MP; Gruben, D; Kremer, JM; Wilkinson, B; Zerbini, CA; Zwillich, SH | 1 |
| Brennan, DC; Bromberg, JS; Busque, S; Chan, G; Fisher, RA; Hariharan, S; Klintmalm, G; Lawendy, N; Leventhal, J; Mulgaonkar, S; Peddi, VR; Shah, T; Slakey, D; Steinberg, S; Vincenti, F; Wang, C | 1 |
| Boggon, TJ; Cornejo, MG; Mercher, T | 1 |
| Baan, CC; Chan, G; Korevaar, SS; Mol, W; Quaedackers, ME; van Gurp, EA; van Ijcken, WF; Weimar, W | 1 |
| French, J; Friberg, LE; Gupta, P; Karlsson, MO; Krishnaswami, S | 1 |
| Joo, KM; Jung, YS; Kang, H; Lee, DS; Lee, HY; Lee, J; Oh, K | 1 |
| Chow, V; Cohen, S; Labadie, RR; Wilkinson, B; Zwillich, SH | 1 |
| Opar, A | 1 |
| Cooper, JE; Wiseman, AC | 1 |
| Benson, TE; Chrencik, JE; Day, JE; Emmons, TL; Fischer, HD; Gormley, JA; Hall, T; Hirsch, JL; Huang, HC; Jacobsen, EJ; Kiefer, JR; Korniski, B; Leone, JW; Leung, IK; Patny, A; Sommers, CD; Tenbrink, RE; Tomasselli, AG; Weinberg, RA; Williams, JM | 1 |
| Baan, CC; Chan, G; Korevaar, SS; Kraaijeveld, R; Quaedackers, ME; Sewgobind, VD; van der Laan, LJ; Weimar, W | 1 |
| Byoun, OJ; Garmaa, N; Lee, DS; Lee, HY; Oh, K; Park, HB; Seo, MW | 1 |
| Djamali, A; Gordon, RD; Legendre, C; Pietrangeli, CE | 1 |
| Kremer, J; Krishnaswami, S; Riese, RJ | 1 |
| Busque, S; Chan, G; Krishnaswami, S; Lamba, M; Melcher, M; Tafti, B | 1 |
| Hasegawa, E; Konoeda, F; Morita, R; Muto, G; Shichita, T; Sugiyama, Y; Suzuki, N; Yoshida, H; Yoshimura, A | 1 |
| Blumenkopf, TA; Brissette, WH; Brown, MF; Casavant, JM; Changelian, PS; Doty, JL; Elliott, EA; Fisher, MB; Flanagan, ME; Hines, M; Kent, C; Kudlacz, EM; Lillie, BM; Magnuson, KS; McCurdy, SP; Munchhof, MJ; Perry, BD; Sawyer, PS; Shang-Poa, C; Strelevitz, TJ; Subramanyam, C; Sun, J; Whipple, DA | 1 |
| Bryant, BR; Chen, J; Jacobson, S; Janik, JE; Jiang, JK; Ju, W; Morris, JC; Oh, U; Sato, N; Tagaya, Y; Thomas, CJ; Waldmann, TA; Zhang, M | 1 |
| Gulati, P; Venkataramanan, R; Vijayakrishnan, L | 1 |
| Chan, G; Krishnaswami, S; Kudlacz, E; Wang, R | 1 |
| Falchetto, R; Hermes, E; Nuninger, F; Tavares, GA; Thoma, G; Vangrevelinghe, E; Zerwes, HG | 1 |
| Alsup, JW; Dowty, ME; Gadina, M; Ghoreschi, K; Ghosh, S; Head, RD; Jesson, MI; Kishore, N; LaBranche, TP; Lee, JL; Li, X; Meyer, DM; Minnerly, JC; O'Shea, JJ; Radi, ZA; Steward-Tharp, SM; Storer, CE; Tanaka, M; Thomas, CJ; Warner, JD | 1 |
| French, JL; Hutmacher, MM; Krishnaswami, S; Menon, S | 1 |
| Ishibashi, H; Izumi, Y; Jiuchi, Y; Komori, A; Maeda, Y; Migita, K; Miyashita, T; Motokawa, S; Nakamura, M; Torigoshi, T | 1 |
| Nakamura, H; Suzuki, M; Tanaka, Y; Toyoizumi, S; Zwillich, SH | 1 |
| Garber, K | 2 |
| French, J; Gruben, D; Tan, H; Thomas, N | 1 |
| Chastain, EM; Getts, DR; Getts, MT; Martin, A; Miller, SD; Shankar, S; Wood, K | 1 |
| Ishibashi, H; Izumi, Y; Jiuchi, Y; Kawakami, A; Koga, T; Komori, A; Maeda, Y; Migita, K; Miyashita, T; Motokawa, S; Nakamura, M; Sato, J; Torigoshi, T; Yamasaki, S | 1 |
| Aiba, Y; Ishibashi, H; Izumi, Y; Jiuchi, Y; Kawakami, A; Koga, T; Komori, A; Maeda, Y; Migita, K; Miyashita, T; Nakamura, M; Yamasaki, S | 1 |
| Asakawa, M; Chiba, K; Kawasumi, M; Kobayashi, T; Miyamoto, T; Mori, T; Morioka, H; Toyama, Y; Yoshida, H; Yoshimura, A | 1 |
| Connell, CA; Cutolo, M; Fleischmann, R; Genovese, MC; Gruben, D; Kanik, KS; Krishnaswami, S; Lee, EB; Sadis, S; Wallenstein, G; Wilkinson, BE; Zwillich, SH | 1 |
| Vincenti, F; Wojciechowski, D | 2 |
| Cohen, S; Connell, CA; French, JL; Gomez-Reino, J; Gruben, D; Kanik, KS; Kremer, JM; Krishnaswami, S; Pascual-Ramos, V; Wallenstein, G; Wilkinson, BE; Zwillich, SH | 1 |
| Regens, AL; Yazici, Y | 1 |
| Boyle, DL; Corr, M; Firestein, GS; Rosengren, S | 1 |
| Ishii, K; Iwata, S; Kubo, S; Maeshima, K; Miyahara, H; Nakano, K; Ohishi, M; Saito, K; Tanaka, S; Tanaka, Y; Yamaoka, K; Yoshimatsu, H | 1 |
| Balagué, C; Godessart, N; Pont, M; Prats, N | 1 |
| Alvey, C; Dowty, ME; Fahmi, OA; Gupta, P; Krishnaswami, S; Riese, RJ; Walsky, RL; Wang, R | 1 |
| Fukaya, T; Inoue, H; Kimura, A; Morita, R; Sekiya, T; Shichita, T; Yoshida, H; Yoshimura, A | 1 |
| Tanaka, Y | 3 |
| Fu, J; Shankar, S; Srivastava, RK; Tang, SN | 1 |
| Fleischmann, R | 3 |
| Maeshima, K; Maeshima, Y; Tanaka, Y; Yamaoka, K | 1 |
| Ammerman, NC; Bishai, WR; Guo, H; Lun, S; Maiga, M; Winglee, K | 1 |
| Foulks, GN; Klamerus, KJ; Li, JZ; Liew, SH; Nichols, KK; Zhang, M | 1 |
| Kubo, S; Maeshima, K; Sonomoto, K; Tanaka, Y; Yamaoka, K | 1 |
| Lomonte, AB; Zerbini, CA | 1 |
| Cooper, SR; Huang, JF; Liew, SH; McDowell, M; Pickering, EH; Rittenhouse, KD; Sace, F; Yafawi, R; Zhang, M | 1 |
| Vincenti, F | 1 |
| Budde, K; Busque, S; Chan, G; Cibrik, D; Cohney, S; Friedewald, J; Kim, YS; Krishnaswami, S; Kudlacz, E; Lan, SP; Lawendy, N; O'Connell, P; Tedesco Silva, H; Vincenti, F; Weimar, W; Yoshida, A | 1 |
| Allen, GE; Chong, SC; Cutcutache, I; Gan, A; Goh, C; Heng, HL; Koo, GC; Lee, KA; Lim, LC; Lim, ST; Loong, S; Ng, CC; Ong, CK; Ong, WS; Poon, SL; Quek, R; Rajasegaran, V; Rozen, S; Tan, D; Tan, L; Tan, P; Tan, SY; Tang, T; Tao, M; Tay, K; Teh, BT; Yap, SP; Yeoh, KW; Yu, W | 1 |
| Ostermeier, E; Roll, P; Tony, HP | 1 |
| Dabade, TS; Feldman, SR; Gustafson, CJ; Kwatra, SG | 1 |
| Bradley, JD; Connell, CA; Cush, J; Fleischmann, R; Gruben, D; Kanik, KS; Kremer, J; Schulze-Koops, H; Wallenstein, GV; Zwillich, SH | 1 |
| Bradley, JD; Cohen, S; Fleischmann, R; Forejtova, S; García Meijide, JA; Gruben, D; Koncz, T; Krishnaswami, S; Lee, EB; van Vollenhoven, RF; Wagner, S; Wallenstein, GV; Wilkinson, B; Zwillich, SH | 1 |
| Fox, DA | 1 |
| Ghosh, S; Niezychowski, W; Panes, J; Rousell, S; Sandborn, WJ; Su, C; Vranic, I | 1 |
| Bailey, SA; Bansal, PN; Bollinger, CS; Bonar, SL; Guzova, JA; Happa, FA; Head, RD; Hegen, M; Jesson, MI; Kishore, N; LaBranche, TP; Mbalaviele, G; Meyer, DM; Radi, ZA; Stewart, ZS; Storer, CE; Symanowicz, PT; Thompson, JM; Wellen, JW; Wilkie, DP; Zhan, Y | 1 |
| de Lartigue, J | 1 |
| Buonanno, M; Gupta, P; Harness, JA; Krishnaswami, S; Langley, RG; Menter, A; Papp, KA; Strober, B; Tan, H; Wolk, R | 1 |
| Chan, C; Ivashkiv, LB; Xu, K; Yarilina, A | 1 |
| Baan, CC; Chan, G; Kho, MM; Mol, WM; Quaedackers, ME; Vafadari, R; Weimar, W | 1 |
| Perrier, C; Rutgeerts, P | 1 |
| Heinzl, S | 1 |
| Tanaka, Y; Yamaoka, K | 3 |
| Traynor, K | 1 |
| Crow, JM | 1 |
| Steiger, B; Yazici, Y | 1 |
| Hiroi, T; Perera, LP; Perera, PY; Waldmann, TA; Yokoyama, S | 1 |
| Broscheit, C; Egli, A; Humar, A; Kumar, D; O'Shea, D | 1 |
| Harness, J; Mamolo, C; Menter, A; Tan, H | 1 |
| Miossec, P | 1 |
| Benda, B; Blanco, R; Bradley, J; Burmester, GR; Charles-Schoeman, C; Gruben, D; Koncz, T; Krishnaswami, S; Mebus, C; Soma, K; Wallenstein, G; Wollenhaupt, J; Zerbini, C; Zwillich, SH | 1 |
| Rutgeerts, P; Vermeire, S | 1 |
| van Vollenhoven, RF | 1 |
| D'Haens, G; Löwenberg, M | 1 |
| Benda, B; Bradley, JD; Cardiel, MH; Cohen, S; Connell, CA; Fleischmann, R; Gruben, D; Keystone, E; Kremer, J; Krishnaswami, S; Nash, P; Song, YW; Tanaka, Y; Tegzová, D; van der Heijde, D; Wallenstein, G; Wyman, BT; Zerbini, C; Zwillich, SH | 1 |
| Reinke, T | 1 |
| Burmester, GR; Feist, E | 1 |
| Bissonnette, R; Bolduc, C; Khan, S; Lamba, M; Lan, S; Papp, K; Ports, WC | 1 |
| Ahn, Y; Chang, BH; Druker, BJ; Fleischman, AG; Glover, J; Gray, NS; Gutierrez, A; Jamieson, CH; Kelliher, MA; Kleppe, M; Levine, RL; Look, AT; Ma, W; Moriggl, R; Müller, M; Neuberg, DS; Ngo, VN; Sanda, T; Staudt, LM; Tatarek, J; Tyner, JW; Weng, AP; Yang, Y; Yost, A; Zhou, W | 1 |
| Bushmakin, AG; Cappelleri, JC; Harness, J; Mamolo, C | 1 |
| Bradley, JD; Brosnan, MJ; Connell, CA; Kim, HY; Lee, SH; Luo, Z; Mandel, D; McInnes, IB; Song, YW; Zuckerman, A; Zwillich, SH | 1 |
| Fujii, Y; Sengoku, T | 1 |
| Simmons, DL | 1 |
| Bannwarth, B; Kostine, M; Poursac, N | 1 |
| Alsina, MM; Muñoz-Santos, C; Ortiz-Ibáñez, K | 1 |
| Koch, S; Peyrin-Biroulet, L; Vuitton, L | 1 |
| Annabi, B; Levros, LC; Pelletier-Bonnier, É; Zgheib, A | 1 |
| Aline-Fardin, A; Bouchekioua, A; Cervera, P; Coppo, P; de Wever, O; Douay, L; Gaulard, P; Gespach, C; Jeziorowska, D; Louache, F; Mercher, T; Nyga, R; Scourzic, L; Solary, E; Vainchenker, W; Zhang, Y | 1 |
| Scott, LJ | 1 |
| Hussar, DA | 1 |
| Baan, C; Mannon, RB; van Gelder, T; Vincenti, F | 1 |
| Coskun, M; Nielsen, OH; Pedersen, J; Salem, M | 1 |
| Gordon, KB; Lingam, P; Nwe, S | 1 |
| Zand, MS | 1 |
| Buonanno, M; Clark, JD; Harness, J; Kawabata, T; Langley, RG; Menter, A; Papp, K; Strober, B; Tan, H; Valdez, H; Wolk, R | 1 |
| Kawalec, P; Mikrut, A; Pilc, A; Wiśniewska, N | 1 |
| Anver, MR; Awasthi, P; Bamford, R; Butcher, DO; Chen, J; Discepolo, V; Feigenbaum, L; Golubeva, YG; Jabri, B; St Claire, MB; Thomas, CJ; Waldmann, TA; Zhang, X | 1 |
| Conaghan, PG; Rakieh, C | 1 |
| Choi, IA; Kim, JW; Lee, EB; Lee, EY; Song, YW | 1 |
| Eguchi, K; Izumi, M; Izumi, Y; Jiuchi, Y; Kawakami, A; Kozuru, H; Migita, K; Motokawa, S; Nakamura, M; Nishino, Y; Nonaka, F; Satomura, K; Torigoshi, T | 1 |
| Iwata, S; Kondo, M; Kubo, S; Tanaka, Y; Yamagata, K; Yamaoka, K; Zhao, J | 1 |
| Bradley, J; Fleischmann, R; Genovese, M; Gruben, D; Hall, S; Isaacs, JD; Koncz, T; Kremer, J; Krishnaswami, S; Li, ZG; Martin-Mola, E; Riese, R; Wallenstein, G; Zwillich, SH | 1 |
| Boy, M; Chan, G; Chow, V; Krishnaswami, S; Wang, C | 1 |
| Gadina, M; Ghoreschi, K | 1 |
| Chan, EW; Chui, CS; He, Y; Lau, WC; Man, KK; Wong, AY; Wong, IC; Worsley, AJ | 1 |
| Bartholomew, P; Elwell, M; Radi, Z; Vogel, WM | 1 |
| Aittomäki, S; Pesu, M | 1 |
| Furumoto, Y; Gadina, M; Ghoreschi, K; Gutermuth, J; Katz, SI; Linton, JT; O'Shea, JJ; Okiyama, N; Tsai, WL; Villarroel, VA | 1 |
| Dowty, ME; Ghosh, S; Jesson, MI; Kishore, N; Krishnaswami, S; Lee, J; Meyer, DM | 1 |
| Berhan, A | 1 |
| Bandy, JL; Boyce, EG; O'Dell, KM; Vyas, D | 1 |
| Dannenberg, AJ; Elchaki, R; Falcone, DJ; Khan, KM; Kothari, P; Mesraoua, R; Pestana, R | 1 |
| Bushmakin, AG; Cappelleri, JC; Mamolo, C; Stewart, M | 1 |
| Waldmann, TA | 1 |
| Gadina, M | 1 |
| Arito, M; Beppu, M; Endo, W; Iizuka, N; Kato, T; Kurokawa, MS; Nakamura, H; Okamoto, K; Omoteyama, K; Sato, T; Suematsu, N | 1 |
| Chauhan, SK; Dana, R; Hua, J; Huang, JF; Kodati, S; Sadrai, Z; Stevenson, W | 1 |
| Chen, Y; Liang, F; Shi, P; Wang, Q; Wei, D; Xiao, X; Yao, L; Yin, X; Zhang, X | 1 |
| Buch, MH; Gaujoux-Viala, C; Gossec, L; Landewé, R; Nam, J; Ramiro, S; Smolen, JS | 1 |
| Bauer, S; Gehringer, M; Laufer, SA; Pfaffenrot, E | 1 |
| Cuzzoni, E; De Iudicibus, S; De Lorenzo, E; Decorti, G; Piscianz, E; Tommasini, A; Valencic, E | 1 |
| Clark, JD; Flanagan, ME; Telliez, JB | 1 |
| Bosque, A; Detorio, M; Gavegnano, C; Montero, C; Planelles, V; Schinazi, RF | 1 |
| Akiyama, Y; Araki, Y; Kayama, H; Kitaura, H; Mimura, T; Miyazaki, T; Miyoshi, F; Sato, K; Takeda, K; Yokota, K | 1 |
| Fukuyo, S; Hirata, S; Kubo, S; Maeshima, K; Saito, K; Sonomoto, K; Suzuki, K; Tanaka, Y; Yamaoka, K | 1 |
| MacFarlane, LA; Todd, DJ | 1 |
| Maneiro, JR; Salgado, E | 1 |
| Chan, GL; Dowty, ME; Krishnaswami, S; Lin, J; Prakash, C; Ryder, TF; Vaz, A; Walker, GS; Wang, W | 1 |
| Ghosh, S; Niezychowski, W; Panes, J; Sandborn, WJ; Vranic, I; Wang, W | 1 |
| de Vries-van Melle, ML; Schreurs, W; van Beuningen, HM; van den Berg, WB; van der Kraan, PM; van Osch, GJ; Vitters, EL | 1 |
| Buonanno, M; Menter, A; Papp, KA; Tan, H; Tyring, S; Wolk, R | 1 |
| Albrecht, C; Ansari, AA; Brameier, M; Byrareddy, SN; Dunbar, P; Khowawisetsut, L; Little, DM; Mayne, AE; Pattanapanyasat, K; Russo, R; Takahashi, Y; Villinger, F; Villinger, T; Walter, L | 1 |
| So, A; Varisco, PA | 1 |
| Liang, Y; Liu, YY; Pan, HF; Peng, H; Xia, Y; Xu, WD; Yang, XK; Ye, DQ; Zhu, Y | 1 |
| Izumi, M; Izumi, Y; Jiuchi, Y; Kawahara, C; Kawakami, A; Kozuru, H; Migita, K; Motokawa, S; Nakamura, M; Nakamura, T; Sakai, T | 1 |
| Fraser, K | 1 |
| Benda, B; Curtis, JR; Gruben, D; Komuro, Y; Lee, EB; Nakamura, H; Nduaka, CI; Riese, RJ; Silverfield, J; Soma, K; Wang, L; Wollenhaupt, J; Wood, SP; Zwillich, SH | 1 |
| Ikari, K; Inoue, E; Ishida, O; Koenuma, N; Koyama, T; Momohara, S; Ochi, K; Sakuma, Y; Taniguchi, A; Yamanaka, H; Yano, K; Yoshida, S | 1 |
| Bushmakin, AG; Cappelleri, JC; Mamolo, CM | 1 |
| Han, G | 1 |
| Dewenter, M; Döker, S; El-Armouche, A | 1 |
| Carmona, L; Gomez-Reino, JJ; Maneiro, JR; Salgado, E; Souto, A | 1 |
| Fellowes, A; Hanna, DM; Hansford, JR; Mechinaud, F; Vedururu, R | 1 |
| Armstrong, AW; Hsu, L | 1 |
| FitzGerald, DJ; Ghoreschi, K; O'Shea, JJ; Onda, M; Pastan, IH; Steward-Tharp, S; Thomas, C | 1 |
| Craiglow, BG; King, BA | 3 |
| Bradley, JD; Fleischmann, R; Gruben, D; Hall, S; Koncz, T; Krishnaswami, S; Lee, EB; van Vollenhoven, RF; Wallenstein, GV; Wilkinson, B; Zang, C; Zwillich, SH | 1 |
| Chew, R; Kawabata, T; Krishnaswami, S; Mortensen, E; Riese, R; Valdez, H; Winthrop, KL; Yamanaka, H | 1 |
| Benda, B; Cohen, S; Gomez-Reino, JJ; Krishnaswami, S; Kwok, K; Nduaka, CI; Radominski, SC; Riese, R; Soma, K; Valdez, H; Wang, L; Wood, SP | 1 |
| Kalra, S; Kaur, K; Kaushal, S | 1 |
| Boy, MG; Hutmacher, MM; Isaacs, JD; Kowalski, K; Krishnaswami, S; Lan, S; Menon, S; Nduaka, C; Riese, R; Zuckerman, A | 1 |
| Boland, BS; Chang, JT; Sandborn, WJ | 1 |
| Abbasian, M; Cathers, B; Chamberlain, P; Delker, S; Jackson, P; Mahmoudi, A; Muir, J; Pagarigan, B; Raheja, N | 1 |
| Bauer, SM; Forster, M; Gehringer, M; Laufer, SA; Pfaffenrot, E | 1 |
| Iwata, S; Nakayamada, S; Sakata, K; Tanaka, Y; Wang, SP; Yamaoka, K | 1 |
| Burmester, GR; Gruben, D; Mebus, CA; Strand, V; Wallenstein, GV; Zerbini, CA; Zwillich, SH | 1 |
| Cheng, S; Coleman, M; Guo, A; Lu, P; Ma, J; Wang, YL | 1 |
| Aerts, S; Cools, J; Cox, L; de Bock, CE; Degryse, S; Demeyer, S; Fiers, M; Geerdens, E; Gianfelici, V; Gielen, O; Hulselmans, G; Jacobs, K; Meijerink, JP; Mentens, N; Tousseyn, T | 1 |
| Harada, T; Nakamura, H | 1 |
| Kwok, SK | 1 |
| Bae, SC; Lee, YH; Song, GG | 2 |
| Bartlett, M; de Vicente, J; Hekmat-Nejad, M; Henningsen, R; Hermann, JC; Jin, S; Kuglstatter, A; Lemoine, R; Li, H; Lovey, AJ; Menke, J; Niu, L; Patel, V; Petersen, A; Setti, L; Shao, A; Soth, M; Tivitmahaisoon, P; Vu, MD | 1 |
| Leonardi, CL; Sobell, JM | 1 |
| Dhiman, V; Dixit, A; Giri, K; Mullangi, R; Sharma, K; Zainuddin, M | 1 |
| Carmona, L; Gómez-Reino, JJ; Maneiro, JR; Mera, A; Salgado, E; Souto, A | 1 |
| Boyle, DL; Bradley, J; Firestein, GS; Hodge, J; Kaplan, I; Kavanaugh, A; Krishnaswami, S; Luo, Z; Mandel, D; Mease, P; Rosengren, S; Shurmur, R; Singhal, AK; Soma, K; Wei, N | 1 |
| Foley, P; Kelly, JB; Strober, BE | 1 |
| Bachinsky, M; Bissonnette, R; Foley, P; Griffiths, CE; Gupta, P; Iversen, L; Mallbris, L; Proulx, J; Romiti, R; Rottinghaus, ST; Sofen, H; Tan, H; Valdez, H; Wolk, R | 1 |
| Beysen, C; Charles-Schoeman, C; Davignon, J; Fleischmann, R; Hellerstein, MK; Kaplan, IV; Luo, Z; McInnes, IB; Milad, M; Riese, R; Schwartz, H; Turner, SM; Zuckerman, A | 1 |
| Amrein, KE; Cowan, CA; Ebeling, M; Gérard, R; Hudak, CS; Kiialainen, A; Lee, YK; Meyer, CA; Moisan, A; Prummer, M; Schinzel, RT; Truong, HH; Xia, F; Zhang, JD; Zoffmann, S | 1 |
| Arito, M; Beppu, M; Endo, W; Kato, T; Koizumi, H; Kurokawa, MS; Okamoto, K; Omoteyama, K; Suematsu, N | 1 |
| Nakamura, H; Takeuchi, T; Tanaka, Y; Toyoizumi, S; Yamanaka, H; Zwillich, S | 1 |
| Emery, P | 1 |
| Jiang, XH; Wang, NN; Zhang, DL | 1 |
| Akashi, K; Kageyama, G; Matsuki, F; Morinobu, A; Nishimura, K; Saegusa, J | 1 |
| Jeen, YT; Park, SC | 1 |
| Dhiman, V; Giri, KK; Mullangi, R; S, VK; Sharma, K; Zainuddin, M | 1 |
| Budde, K; Busque, S; Chan, G; Lamba, M; Lawendy, N; O'Connell, PJ; Russ, G; Silva, HT; Tortorici, MA; Vincenti, F; Wang, W; Yoshida, A | 1 |
| Bushmakin, AG; Cappelleri, JC; Healey, P; Mamolo, C; Panés, J; Su, C | 1 |
| Bianchi, L; Buonomo, O; Chimenti, MS; Chimenti, S; Chiricozzi, A; Faleri, S; Saraceno, R | 1 |
| Collins, FS; Davis, SR; Erdos, MR; Furumoto, Y; Gadina, M; Jiang, K; Kanno, Y; O'Shea, JJ; Parker, SC; Restifo, NP; Roychoudhuri, R; Ruan, Y; Sartorelli, V; Tang, Z; Vahedi, G | 1 |
| Husstedt, IW; Luger, TA; Ständer, S; Tsianakas, A; von Köckritz, A; Zeidler, C | 1 |
| Bingham, CO; Fan, H; Gomez-Reino, J; Hodge, J; Hrycaj, P; Lee, EB; Mebus, C; Neal, J; Racewicz, A; Silverfield, J; Soma, K; Wang, T; Wilkinson, B; Winthrop, KL | 1 |
| Goldenberg, G; Mansouri, Y | 1 |
| Bukowski, J; Hammond, C; Isaacs, JD; Kivitz, AJ; Kremer, JM; Lee, SK; Li, H; Nasonov, EL; Raber, S; Schulman, SL; Simon-Campos, JA; Tony, HP; Vlahos, B; Zuckerman, A | 1 |
| Aungier, SR; Cartwright, AJ; Ito, K; Midwood, KS; To, WS | 1 |
| Benda, B; Curtis, JR; Geier, J; Kaplan, IV; Kwok, K; Lee, EB; Riese, R; Soma, K; Wang, L | 1 |
| Buonanno, M; Papp, KA; Pariser, D; Tan, H; Tyring, SK; Valdez, H; Valenzuela, F; Wang, J; Wolk, R | 1 |
| Mitch, WE; Wang, Y; Yan, J; Yang, J; Zhang, Z | 1 |
| Bachelez, H; Chimenti, S; Gupta, P; Kubanov, A; Lee, JH; Papacharalambous, J; Proulx, J; Strohal, R; Tan, H; Tawadrous, M; Valdez, H; Valenzuela, F; van de Kerkhof, PC; Wolk, R; Yakusevich, V | 1 |
| Karam, S; Wali, RK | 1 |
| Abe, M; Buonanno, M; Elewski, B; Feldman, SR; Gottlieb, AB; Gupta, P; Lan, S; Langley, R; Luger, T; Menter, MA; Papp, KA; Proulx, J; Thaci, D; Wolk, R | 1 |
| Bäumer, W; Cook, E; Ehling, S; Fukuyama, T | 1 |
| Bäumer, W; Fukuyama, T; Qi, Y; Tschernig, T; Volmer, DA | 1 |
| King, BA; Levy, LL; Urban, J | 1 |
| Byun, JH; Ko, SK; Lee, EK; Lee, MY; Lee, SM; Park, SK; Park, SY | 1 |
| Bonefeld, CM; Fredholm, S; Geisler, C; Gniadecki, R; Iversen, L; Jønson, L; Kopp, KL; Krejsgaard, T; Lindahl, LM; Litvinov, IV; Mongan, NP; Nastasi, C; Odum, N; Petersen, DL; Sasseville, D; Sibbesen, NA; Wasik, MA; Willerslev-Olsen, A; Woetmann, A | 1 |
| Bissonnette, R; Feldman, SR; Gupta, P; Johnson, TR; Ports, WC; Tan, H | 1 |
| Koo, J; Levin, E; McAndrew, R | 1 |
| Cantrell, W; Elewski, BE; Seminario-Vidal, L | 1 |
| Bananis, E; Burmester, G; Charles-Schoeman, C; Fleischmann, R; Hendrikx, T; Kwok, K; Nash, P; Soma, K; Zerbini, CA | 1 |
| Bujak, A; Dymek, B; Dzwonek, K; Grygielewicz, P; Gunerka, P; Lamparska-Przybysz, M; Pietrucha, T; Stanczak, A; Turowski, P; Wieczorek, M | 1 |
| Cardiel, MH; Gomez-Reino, JJ; Gul, A; Kwok, K; Lukic, T; Mortensen, E; Park, SH; Ponce de Leon, D; Riese, R; Tanaka, Y; Valdez, H; Winthrop, KL | 1 |
| Fearon, U; Gao, W; McCormick, J; McGarry, T; Orr, C; Veale, DJ | 1 |
| Niezychowski, W; Panés, J; Sandborn, WJ; Su, C; Yu, D; Zhang, H | 1 |
| Dorhoi, A | 1 |
| Ahidjo, BA; Bishai, WR; Bougoudogo, F; Cheung, L; Lun, S; Maiga, M; Maiga, MC; Pelly, S | 1 |
| Abdelhameed, AS; Alam, P; Khan, RH | 1 |
| Afable Ii, M; Bilori, B; Clemente, MJ; Jerez, A; Maciejewski, JP; Patel, B; Thota, S | 1 |
| Alpini, G; Kumar, N; Meng, F; Mishra, J; Verma, RK | 1 |
| Hiroi, T; Kaminuma, O; Perera, LP; Perera, PY; Terawaki, S; Waldmann, TA; Watanabe, N; Yokoyama, S | 1 |
| Connell, C; Fleischmann, R; Gruben, D; Kanik, KS; Kremer, J; Strand, V; Wallenstein, G; Zwillich, SH | 1 |
| Abbott, B; Weatherspoon, CA; Weatherspoon, D | 1 |
| Danese, S; Grisham, M; Hodge, J; Telliez, JB | 1 |
| Dhayalan, A; King, BA | 1 |
| Day, AS; Eliadou, E; Gearry, RB; Inns, SJ; Rowbotham, DS; Schultz, M; Thompson-Fawcett, MW; Walmsley, R | 1 |
| Cendón, C; Chang, HD; Di Ceglie, I; Douni, E; Gómez, L; Kamradt, T; Llop-Guevara, A; Madarena, F; Porras, M; Rinotas, V; Román, J; Siracusa, F; van Lent, PL | 1 |
| Ahadieh, S; Boy, M; Checchio, T; French, J; Geier, J; Gómez-Reino, JJ; Hoffman, E; Krishnaswami, S; Menon, S; Riese, R; Strand, V; Tensfeldt, TG | 1 |
| Ishimori, A; Sakimoto, T | 1 |
| Bae, SC; Lee, YH | 2 |
| Bonefeld, CM; Fredholm, S; Geisler, C; Gniadecki, R; Iversen, L; Kilian, M; Koralov, SB; Krejsgaard, T; Lindahl, LM; Litvinov, IV; Mongan, NP; Nastasi, C; Odum, N; Petersen, DL; Sasseville, D; Wasik, MA; Willerslev-Olsen, A; Woetmann, A | 1 |
| Hirose, T; Morishima, Y; Sugiyama, N; Takeuchi, T; Tanaka, Y; Toyoizumi, S; Yamanaka, H; Yuasa, H; Zwillich, S | 1 |
| Abdelhameed, AS; Ajmal, MR; Alam, P; Khan, RH | 1 |
| Asahina, A; Etoh, T; Igarashi, A; Imafuku, S; Nagaoka, M; Ohtsuki, M; Saeki, H; Shibasaki, Y; Tomochika, Y; Toyoizumi, S | 1 |
| Bardazzi, F; Di Lernia, V | 1 |
| Feldman, SR; Gardner, A; Gupta, P; Krueger, JG; Langley, RG; Luo, Y; Mallbris, L; Mebus, C; Papp, KA; Tan, H; Tatulych, S; Thaci, D; Torii, H; Tyring, S; Wolk, R | 1 |
| Warren, RB; Yiu, ZZ | 1 |
| Fleischmann, R; Gruben, D; Koncz, T; Lee, EB; Strand, V; van Vollenhoven, RF; Wallenstein, G; Wilkinson, B; Zwillich, SH | 1 |
| Tavakolpour, S | 2 |
| Alvey, C; Fletcher, T; Kushner, J; Lamba, M; Stock, TC; Wang, R | 1 |
| Bowes, MA; Bradley, JD; Conaghan, PG; Fuerst, T; Hrycaj, P; Irazoque-Palazuelos, F; Soma, K; Soto-Raices, O; van der Heijde, D; Wilkinson, B; Wu, C; Wyman, BT; Xie, Z; Zhang, R; Østergaard, M | 1 |
| Vincenti, F; Webber, AB | 1 |
| Clark, JD; Cueto, I; Fuentes-Duculan, J; Krueger, J; O'Neil, SP; Reddy, PS; Rottinghaus, ST; Suárez-Fariñas, M; Tan, H; Tatulych, S; Valdez, H; von Schack, D; Wang, CQ; Whitley, MZ; Wolk, R | 1 |
| Boy, M; Charles-Schoeman, C; Geier, J; Gonzalez-Gay, MA; Kaplan, I; Luo, Z; Riese, R; Zuckerman, A | 1 |
| Bhamidipati, RK; Mullangi, R; Srinivas, NR | 1 |
| Curtis, JR; Gerber, R; Gruben, D; Harnett, J; Koenig, A | 1 |
| Bernatsky, S; Curtis, JR; Winthrop, KL; Xie, F; Yun, H | 1 |
| Cyrus Khojasteh, S; Driscoll, JP; Fan, PW; Hop, CE; Le, H; Ma, S; Wong, S | 1 |
| Sonomoto, K; Tanaka, Y | 1 |
| Cerise, JE; Christiano, AM; Clynes, R; de Jong, A; Jabbari, A; Mackay-Wiggan, J; Nguyen, N; Ulerio, G | 1 |
| Femia, AN; Kurtzman, DJ; Lin, J; Merola, JF; Patel, M; Vleugels, RA; Wright, NA | 1 |
| Boy, M; Chan, G; Chow, V; Krishnaswami, S | 1 |
| Alvey, CW; Chan, G; Krishnaswami, S; Lamba, M; Lawendy, N; Wang, R | 1 |
| Alvey, C; Dowty, ME; Feng, B; Kaplan, I; Klamerus, KJ; Krishnaswami, S; Li, L; Shi, H; Wang, R | 1 |
| Alvey, CW; Checchio, T; Krishnaswami, S; Peterson, M; Riese, R; Shi, H; Wang, T; Yuan, Y | 1 |
| Alvey, CW; Krishnaswami, S; Menon, S; Petit, W; Riese, R; Shi, H; Wang, R | 1 |
| Archer, TP; Ghosh, S; Moran, GW | 1 |
| Amaya-Guerra, M; Cather, J; Gupta, P; Kaszuba, A; Krueger, JG; Leonardi, C; Mallbris, L; Menter, MA; Nadashkevich, O; Papp, KA; Pariser, DM; Tan, H; Tatulych, S; Tsai, TF; Valdez, H; Wohlrab, J | 1 |
| Candilera, V; De Iudicibus, S; Decorti, G; Loganes, C; Paron, G; Piscianz, E; Tommasini, A; Valencic, E | 1 |
| Christensen, R; Hossain, A; Kotb, A; Maxwell, LJ; Mudano, AS; Shah, NP; Singh, JA; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Bevivino, G; Izzo, R; Monteleone, G | 1 |
| Yamaoka, K | 3 |
| Bushmakin, AG; Cappelleri, JC; Healey, P; Panés, J; Su, C | 1 |
| Bernatsky, S; Curtis, JR; Xie, F; Yun, H | 1 |
| Di Lernia, V | 1 |
| Iwata, S; Tanaka, Y | 1 |
| Bianchi, L; Chimenti, S; D'Adamio, S; Galluzzo, M; Servoli, S; Talamonti, M | 1 |
| Mallbris, L; Mamolo, C; Papacharalambous, J; Paul, C; Tan, H; Valdez, H; Valenzuela, F | 1 |
| Bolaños, N; Cruzado, JM; de Ramon, L; Draibe Bordignon, J; Goma, M; Grinyó, JM; Merino, A; Ripoll, È; Torras, J | 1 |
| Chen, Y; Clowse, ME; Feldman, SR; Frazier, D; Geier, J; Isaacs, JD; Kimball, AB; Marren, A; Proulx, J; Strand, V; Warren, RB; Xibillé, D | 1 |
| Abramovits, W; Carviel, JL; Gupta, AK | 1 |
| Kawahito, Y | 1 |
| Biswas, P; Genovese, MC; Gruben, D; Jones, TV; Riese, R; Takiya, L; van Vollenhoven, RF; Wang, L; Wilkinson, B; Zwillich, SH | 1 |
| Gerdes, S; Gläser, R; Mrowietz, U; Schröder, O | 1 |
| Bissonnette, R; Gooderham, M; Mallbris, L; Mamolo, C; Papacharalambous, J; Papp, KA; Ports, WC; Poulin, Y; Purohit, V; Raman, M; Wang, C | 1 |
| Abdalrahman, Z; Blanco, L; Brooks, SR; Furumoto, Y; Gadina, M; Hoffmann, V; Kaplan, MJ; Mast, L; Nunez, L; O'Shea, JJ; Remaley, AT; Sciumè, G; Smith, CK; Thacker, SG; Trier, AM; Tsai, WL; Zhao, W | 1 |
| Boy, M; Charles-Schoeman, C; Geier, J; Gonzalez-Gay, MA; Kwok, K; Riese, R; Soma, K; Wicker, P; Zuckerman, A | 1 |
| Fleischmann, R; Gruben, D; Kanik, K; Keystone, E; Koncz, T; Kremer, J; Krishnaswami, S; Tanaka, Y; Wallenstein, G; Wilkinson, B; Zwillich, SH | 1 |
| Croasdell, G; Walker, G | 1 |
| Dulai, PS; Sandborn, WJ | 1 |
| Anisfeld, A; Chen, C; Chen, Y; Curtis, JR; Geier, J; Krishnaswami, S; Strengholt, S; Zhang, R | 1 |
| Ahlehoff, O; Egeberg, A; Hansen, PR; Qureshi, AA; Robertson, D; Strober, BE; Tan, H; Valdez, H; Wolk, R; Wu, JJ | 1 |
| Leonardi, CL | 1 |
| Kerdel, FA | 1 |
| Gordon, K; Griffins, CE; Mrowietz, U; Tallman, A; Tan, H; Valdez, H; Wolk, R | 1 |
| Conwell, S; Fang, E; Hekmatnejad, M; Kutach, A; Lok, SM; Shaw, D; Swinney, DC | 1 |
| Alpert, A; Awisat, A; Boulman, N; Ginsberg, S; Kaly, L; Rimar, D; Rosner, I; Rozenbaum, M; Shen-Orr, SS; Slobodin, G; Starosvetsky, E; Zilber, K | 1 |
| Gruben, D; Kremer, JM; Krishnaswami, S; Strand, V; Wallenstein, GV; Zwillich, SH | 1 |
| Alvarez, HA; Chara, O; Cura Costa, E; Engel, K; Fiehn, C; Goldbach-Mansky, R; Günther, C; König, N; Lee-Kirsch, MA; Schuster, M; Tüngler, V; Wolf, C | 1 |
| Bauer, SM; Breit, B; Eib, J; Forster, M; Gehringer, M; Heinzlmeir, S; Jung, M; Klaeger, S; Kuster, B; Laufer, S; Lumbroso, A; Metzger, E; Ostrovskyi, D; Pfaffenrot, E; Rumpf, T; Schmidtkunz, K; Schüle, R; Sippl, W; Slynko, I; Wenzler, S | 1 |
| Iwata, S; Kubo, S; Nakayamada, S; Tanaka, Y | 1 |
| Bourret, JA; Claxton, L; Gerber, RA; Jenks, M; Mendelsohn, AM; Moynagh, D; Singh, A; Taylor, M; Wallenstein, G | 1 |
| Bachinsky, M; Griffiths, CE; Kircik, L; Mallbris, L; Mamolo, C; Rottinghaus, ST; Sofen, H; Tan, H; Vender, R | 1 |
| Christopher-Stine, L; Paik, JJ | 1 |
| Augustin, M; Buonanno, M; de la Cruz, C; Feldman, SR; Gooderham, M; Kaur, M; Lan, S; Mallbris, L; Mamolo, C; Tatulych, S; Thaçi, D; Valdez, H | 1 |
| Cerise, JE; Chen, JC; Christiano, AM; Craiglow, BG; Jabbari, A; Kennedy Crispin, M; King, BA; Ko, JM; Li, S; Marinkovich, MP; Oro, AE; Shankar, G; Urban, JR; Winge, MC | 1 |
| Kanai, T; Mizuno, S; Naganuma, M; Nanki, K; Sugimoto, S | 1 |
| Ball, DJ; Chapin, RE; Koza-Taylor, PH; Kumpf, SW; Mark Vogel, W; Potter, DM; Radi, ZA | 1 |
| Bissonnette, R; Draelos, Z; Feldman, SR; Gooderham, M; Iversen, L; Mamolo, C; Papp, KA; Ports, WC; Purohit, V; Soung, J; Wang, C | 1 |
| Gupta, V; Lehner, MD; Miralpeix, M; Pearson, J; Plumb, J; Ramis, I; Singh, D; Southworth, T | 1 |
| Fukui, S; Horai, Y; Ichinose, K; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Nakamura, H; Sato, T; Umeda, M | 1 |
| Lam, S | 1 |
| Ando, S; Asai, M; Goshima, F; Ito, Y; Kawada, JI; Kimura, H; Murata, T; Sato, Y; Shimizu, N; Suzuki, M; Torii, Y; Watanabe, T | 1 |
| Bananis, E; Connell, CA; Fleischmann, R; Hwang, LJ; Mease, PJ; Schwartzman, S; Soma, K; Takiya, L | 1 |
| Chen, P; Gui, L; Huang, W; Liu, F; Tang, F; Wang, J; Wang, Y; Xin, M; Zhao, X | 1 |
| Abraham, C; Dulai, PS; Sandborn, WJ; Vermeire, S | 1 |
| Bannert, B; Erlacher, M; Fischer, K; Janowska, I; Kunze, M; Kyburz, D; Lorenzetti, R; Rizzi, M; Staniek, J; Strohmeier, V; Thiel, J; Troilo, A; Venhoff, N; Voll, RE | 1 |
| Craiglow, BG; King, BA; Liu, LY | 3 |
| Craiglow, BG; Dai, F; King, BA; Liu, LY | 1 |
| Ferreira, SB; Scheinberg, M | 1 |
| Hossain, A; Mudano, AS; Singh, JA; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Danese, S; Olivera, P; Peyrin-Biroulet, L | 2 |
| Braun, J | 1 |
| Conrado, D; Cook, J; Dikranian, A; Dowty, ME; Furst, DE; Hutmacher, MM; Krishnaswami, S; Lamba, M; Nduaka, C; Stock, T | 1 |
| Fujii, T; Fujita, N; Horiuchi, K; Ishii, K; Matsumoto, M; Miyamoto, T; Nakamura, M; Suzuki, S; Tsuji, T; Watanabe, K; Yagi, M | 1 |
| Chen, C; Gerber, R; Gruben, D; Harnett, J; Koenig, AS | 1 |
| Choi, J; King, B; Lee, AI | 1 |
| Jansen, JP; Smiechowski, B; Spurden, D; Vieira, MC; Wallenstein, GV; Zwillich, SH | 1 |
| Friedman, MA; Winthrop, KL | 1 |
| Cohen, SB; Sivaraman, P | 1 |
| Dygai, AM; Minakova, MY; Miroshnichenko, LA; Polyakova, TY; Simanina, EV; Stavrova, LA; Udut, EV; Udut, VV; Zhdanov, VV; Zyuz'kov, GN | 1 |
| Aletaha, D; Gruben, D; Krishnaswami, S; Mebus, C; Smolen, JS; Zwillich, SH | 1 |
| Siegmund, B; Sonnenberg, E | 1 |
| Asmawidjaja, PS; Boor, PPC; de Ruiter, PE; Kwekkeboom, J; Lubberts, E; van der Laan, LJW | 1 |
| Bañon-Maneus, E; Campistol, JM; Diekmann, F; Hierro-Garcia, N; Martina, MN; Moya Rull, D; Ramirez Bajo, MJ; Revuelta, I; Rovira, J | 1 |
| Abdelhameed, AS; Ajmal, MR; Khan, RH; Nusrat, S; Zakariya, SM; Zaman, M | 1 |
| Ensor, CR; Iasella, CJ; Lakkis, FG; McDyer, JF; Moore, CA; Smith, RB; Venkataramanan, R; Zeevi, A | 1 |
| Bliddal, H; Boers, M; Brock, B; Christensen, R; Dossing, A; Eric Furst, D; Heller Asmussen, K; Luta, G; Schjødt Jørgensen, T; Tarp, S; Tarp, U; Thirstrup, S | 1 |
| Ahmad Nasrollahi, S; Firooz, A; Hashemi, A; Nassiri Kashani, M; Samadi, A | 1 |
| DeMasi, R; Kwok, K; Nduaka, C; Schulze-Koops, H; Strand, V; Wallenstein, G; Wang, L | 1 |
| Chae, JH; Choi, M; Choi, SA; Kang, JA; Kang, SJ; Kim, SY; Kim, Y; Kwon, SH; Lee, CR; Lee, DH; Lim, BC; Park, EB; Park, JD; Park, SG; Park, SH; Seo, J; Suh, DI; Ye, M | 1 |
| Guo, H; Leng, X; Liu, Y; Luo, S; Luo, X; Mo, C; Su, Z; Wang, Y; Zhou, Y; Zou, Q | 1 |
| Frank-Bertoncelj, M; Gay, S | 1 |
| Calama, E; Carreño, C; De Alba, J; Domènech, A; Miralpeix, M; Prats, N; Ramis, I | 1 |
| Ceovic, R; Gulin, SJ; Kostovic, K; Mokos, ZB | 1 |
| Dejaco, C; Fasching, P; Fessler, J; Graninger, W; Stradner, M | 1 |
| Cheng, LP; Deng, W; Wang, JL; Wang, TC; Wu, FH | 1 |
| Deodhar, A; Drescher, E; Fleishaker, D; Hendrikx, T; Kanik, KS; Li, D; Menon, S; van der Heijde, D; Wei, JC | 1 |
| Bagherani, N; Smoller, BR | 1 |
| Damsky, W; King, BA | 1 |
| Charles-Schoeman, C; Cohen, SB; Curtis, JR; DeMasi, R; Geier, J; Kwok, K; Lee, EB; Mariette, X; Nash, P; Riese, R; Tanaka, Y; Thirunavukkarasu, K; Wang, L; Winthrop, KL; Wollenhaupt, J | 1 |
| Alvarez-Moreno, C; Cardiel, MH; Castañeda, OM; Castelli, G; Citera, G; García, EG; Jaller, JJ; Kwok, K; Mysler, E; Ponce de Leon, D; Radominski, SC; Rillo, O; Rojo, R; Romero, FJ; Salinas, A | 1 |
| D'Haens, GR; De Jonge, WJ; De Vries, LCS; Wildenberg, ME | 1 |
| Ramot, Y; Shreberk-Hassidim, R; Zlotogorski, A | 1 |
| Abria, C; Raychaudhuri, SK; Raychaudhuri, SP | 1 |
| Fearon, U; Gao, W; McGarry, T; Veale, DJ | 1 |
| Alpert, C; Bays, N; Byford, A; Chakravarthy, K; Chiu, CS; Dandliker, PJ; Deshmukh, SV; Dinsmore, C; Dorosh, L; Elwood, F; Goldenblatt, P; Ivanovska, I; Kariv, I; Klappenbach, J; Kraybill, B; Lee, HH; Pan, BS; Piesvaux, J; Qu, Y; Rivkin, A; Scott, ME; Slipetz, D; Tang, H; Witter, DJ; Zielstorff, M | 1 |
| Han, Y; Mesplède, T; Quan, Y; Wainberg, MA; Xu, H | 1 |
| Chan, G; Colombel, JF; D'Haens, G; Feagan, BG; Healey, P; Higgins, PDR; Maller, E; Marren, A; Moscariello, M; Niezychowski, W; Panaccione, R; Panés, J; Sandborn, WJ; Sands, BE; Schreiber, S; Vermeire, S; Wang, W | 1 |
| Ferreira, R; Ferreira, SB; Jaller, AM; Jaller, JA; Jaller, JJ; Jaller-Char, JJ; Scheinberg, M | 1 |
| Winthrop, KL | 1 |
| Chen, L; Coe, J; Curtis, JR; Gal-Levy, R; Higginbotham, P; Nowell, WB; O'Hara, K; Sa'adon, R; Safford, M; Willig, J | 1 |
| Buchbinder, R; Hossain, A; Lopez-Olivo, MA; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Gomez-Reino, JJ; Maneiro, JR; Souto, A | 1 |
| Gharaibeh, M; Incerti, D; Jansen, JP; Kaur, P; MacEwan, JP; Mutebi, A; Peneva, D; Stolshek, B; Strand, V | 1 |
| Dougados, M; Miceli-Richard, C | 1 |
| Gupta, P; Hutmacher, MM; Ito, K; Krishnaswami, S; Mebus, C; Papp, K; Rottinghaus, ST; Tan, H; Valdez, H; Wolk, R | 1 |
| Passeron, T | 1 |
| Castelo-Soccio, L | 1 |
| Cernea, M; Gupta, AK; Lynde, CW | 1 |
| Bayart, CB; Bergfeld, WF; Hogan, S; Ibrahim, O; Piliang, M | 1 |
| Bijlsma, J; Burmester, G; Chatzidionysiou, K; Dougados, M; Emamikia, S; Landewé, R; Nam, J; Ramiro, S; Scholte, M; Smolen, J; van der Heijde, D; van Vollenhoven, R | 1 |
| Bamford, RN; Chen, J; Del Mistro, A; Epstein, AL; Jaffe, ES; Kadin, ME; Nakagawa, M; Nicolae, A; Ouyang, ST; Petrus, MN; Pittaluga, S; Raffeld, M; Waldmann, TA; Woessner, R; Xiao, W; Zhang, Y | 1 |
| Mitchell, TS; Moots, RJ; Wright, HL | 1 |
| Afrin, LB; Choe, L; Fox, RW; Glover, SC; Zito, SL | 1 |
| Shan, H; Xia, XH; Xiao, CJ | 1 |
| Handa, H; Hosogai, M; Kishi, S; Mitsui, T; Ogawa, Y; Todokoro, D; Yanagisawa, K; Yokohama, A | 1 |
| Elewski, B; Kaur, M; Lan, S; Merola, JF; Tallman, A; Tatulych, S | 1 |
| Dholakia, S; Fildes, JE; Friend, PJ | 1 |
| Amano, K; Iwata, K; Kubo, S; Nagano, S; Nagasawa, H; Suematsu, E; Tanaka, Y; Tohma, S; Yamaoka, K | 1 |
| Kosinski, M; Mebus, CA; Rendas-Baum, R; Singh, A; Wallenstein, GV; Wilkinson, BE | 1 |
| Amital, H; Gertel, S; Karmon, G; Mahagna, H; Watad, A | 1 |
| D'Haens, GR; Danese, S; Feagan, BG; Friedman, G; Healey, P; Lawendy, N; Mukherjee, A; Niezychowski, W; Panés, J; Reinisch, W; Sandborn, WJ; Sands, BE; Schreiber, S; Su, C; Vermeire, S; Woodworth, D; Yu, D; Zhang, H | 1 |
| Aramaki, T; Eguchi, K; Fukui, S; Hirai, Y; Horai, Y; Ichinose, K; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Nakamura, H; Nishino, A; Origuchi, T; Shimizu, T; Takatani, A; Tamai, M; Terada, K; Tsuji, S; Ueki, Y; Umeda, M | 1 |
| Ahadieh, S; Checchio, T; Gupta, P; Ito, K; Kaur, M; Krishnaswami, S; Mandema, J; Puig, L; Tallman, A; Tan, H; Valdez, H; Wolk, R | 1 |
| Buchbinder, R; Hossain, A; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Hirai, M; Kurebayashi, Y; Suzuki, M; Tse, S | 1 |
| Bosdelekidou, EE; Economopoulos, KP; Iliopoulou, SM; Kokkinidis, DG; Kousoulis, AA; Tassos, AG; Texakalidis, PT | 1 |
| Barrow, AD; Capuder, K; Cella, M; Colonna, M; Gilfillan, S; Lin, LL; Notarangelo, LD; Robinette, ML; Telliez, JB; Ulland, TK | 1 |
| Bradley, CA | 1 |
| Kim, BY; Kim, HS | 1 |
| Hang, T; Song, M; Wang, L; Wu, X; Zeng, X | 1 |
| Chen, J; Crook, T; Gu, J; Jin, H; Lee, MG; Li, R; Liu, Q; Ports, WC; Qi, C; Tsai, TF; Tu, C; Wang, G; Zhang, J; Zheng, M; Zhu, H | 1 |
| Aguilar-Pimentel, A; Alessandrini, F; Blank, S; Chaker, A; Fuchs, H; Gailus-Durner, V; Graessel, A; Gutermuth, J; Hrabě de Angelis, M; Ollert, M; Russkamp, D; Schmidt-Weber, CB | 1 |
| Avila, L; Lo Sicco, K; Shapiro, J; Strazzulla, LC | 1 |
| Wang, C; Wang, H; Wang, S; Wang, Z; Yun, T | 1 |
| Bayart, CB; Brichta, L; Craiglow, BG; DeNiro, KL; Sidbury, R | 1 |
| Abdel, MP; Brause, B; Chen, AF; Dasa, V; George, M; Gewurz-Singer, O; Giles, JT; Gililland, J; Goodman, M; Goodman, SM; Guyatt, G; Hurley-Rosenblatt, A; Johnson, B; Kirou, K; Lee, S; Losina, E; MacKenzie, R; Mandl, LA; Michaud, K; Mikuls, T; Miller, AS; Mont, MA; Russell, L; Sah, A; Sculco, P; Singh, JA; Sporer, S; Springer, B; Stryker, L; Turgunbaev, M; Yates, A | 2 |
| DeMasi, R; Fleischmann, R; Hall, S; Kivitz, AJ; Krishnaswami, S; Luo, Z; Menon, S; Mojcik, C; Moots, RJ; Mysler, E; Smolen, JS; Soma, K; Takiya, L; Tatulych, S; Zhang, R | 1 |
| Adışen, E; Aksakal, AB; Erduran, F | 1 |
| Barrasa, JI; Gratal, P; Herrero-Beaumont, G; Largo, R; Larrañaga-Vera, A; Pérez-Baos, S; Prieto-Potin, I | 1 |
| Chen, X; Ji, S; Jin, T; Li, R; Sun, Z; Wang, Y; Zhao, Y | 1 |
| Chen, DY; Chen, YH; Chen, YM; Hsieh, TY; Huang, WN; Lin, CT; Wu, YD | 1 |
| Onuora, S | 2 |
| Cohen, AD; Egeberg, A; Gupta, P; Ito, K; Kaur, M; Lebwohl, M; Mallbris, L; Rottinghaus, ST; Tan, H; Tyring, SK; Valdez, H; Weinberg, JM; Winthrop, KL | 1 |
| Abe, M; Ihn, H; Isogawa, N; Ito, K; Kawaguchi, I; Kobayashi, M; Nagaoka, M; Nishigori, C; Papp, KA; Tallman, AM; Tomochika, Y; Torii, H | 1 |
| Betts, KA; Curtis, JR; Douglas, K; Du, EX; Ganguli, A; Wells, AF | 1 |
| Harada, R; Horita, M; Kaneda, D; Machida, T; Nakahara, R; Nasu, Y; Nishida, K; Ozaki, T; Ozawa, M; Takeshita, A; Yoshida, A | 1 |
| Chen, Y; Gao, XM; Gong, FY; Gong, Z; Li, ZJ; Ma, SY; Zhou, Z | 1 |
| D'Haens, GR; De Vries, LCS; Hicks, KJ; Ludbrook, VJ | 1 |
| Harris, JE; King, BA; Liu, LY; Refat, MA; Strassner, JP | 1 |
| Faubion, WA; Papadakis, KA; Ramos, GP | 1 |
| Boland, BS; Vermeire, S | 1 |
| Cush, JJ | 1 |
| Biswas, P; Choy, EH; Hodge, JA; Mojcik, CF; Nduaka, CI; Needle, E; Passador, S; Rigby, WF; Soma, K; Winthrop, KL; Wouters, AG | 1 |
| Bananis, E; Chen, C; Curtis, JR; Fan, H; Hirose, T; Lindsey, S; Mendelsohn, AM; Nduaka, CI; Tanaka, Y; Valdez, H; Wang, L; Winthrop, KL; Yamaoka, K | 1 |
| Deenonpoe, R; Meephansan, J; Ponnikorn, S; Suchonwanit, P; Thummakriengkrai, J; Yingmema, W | 1 |
| Benigno, C; Bertolini, N; Caso, F; Caso, P; Chimenti, MS; Costa, L; Del Puente, A; Girolimetto, N; Peluso, R; Perricone, R; Sabbatino, V; Scarpa, R; Tasso, M | 1 |
| McHugh, J | 2 |
| Berstein, G; Correa-da Rosa, J; Fitz, LJ; Garcet, S; Kim, J; Krueger, JG; Lee, J; Lowes, MA; Suarez-Farinas, M; Tomalin, L; Valdez, H; Wolk, R | 1 |
| Biswas, P; Boy, MG; Chen, C; Kwok, K; Mariette, X | 1 |
| Chen, L; He, L; Lan, T; Pei, H; Tang, M; Zhang, C | 1 |
| Tsai, TF; Wang, TS | 1 |
| Canhão, H; Cascão, R; da Glória, VG; Finnilä, MAJ; Fonseca, JE; Lopes, IP; Saarakkala, S; Vidal, B; Zioupos, P | 1 |
| Bayliss, M; Bushmakin, AG; Cappelleri, JC; Friedman, G; Lindsay, JO; Maher, S; Panés, J; Rubin, DT; Sands, BE; Su, C; Vermeire, S; Yarlas, A; Zhang, H | 1 |
| Cho, S; Huh, CH; Kim, MW; Kwon, O; Lee, JS; Park, HS; Yoon, HS | 1 |
| Ceric-Dehdari, P; Meurer, M | 1 |
| Amano, K; Hatta, K; Kanazawa, T; Kume, K; Kuwaba, N; Ohta, H; Yamada, S | 1 |
| Heyes, C; Robertson, SJ; Ross, G; Varigos, GA; Vu, M | 1 |
| Chastek, B; Chen, CI; Kuznik, A; Proudfoot, C; Shinde, S; Wei, W | 1 |
| Azevedo, VF; Behrens, F; Blanco, R; Gladman, D; Hendrikx, T; Kanik, KS; Kaszuba, A; Kudlacz, E; Menon, S; Rigby, W; Wang, C | 1 |
| Avila-Zapata, F; Cieślak, D; FitzGerald, O; Graham, D; Hall, S; Hendrikx, T; Kanik, KS; Mease, P; Menon, S; Merola, JF; van der Heijde, D; Wang, C | 1 |
| Ball, DJ; Bartholomew, PM; Koza-Taylor, P; Nambiar, P; Papanikolaou, A; Radi, ZA; Vogel, WM; Wisialowski, T | 1 |
| Abramovits, W; Gardner, A; Kaur, M; Korman, N; Mukwaya, G; Rottinghaus, ST; Tan, H; Valdez, H; Winthrop, KL | 1 |
| Deleuran, B; Eggertsen, PP; Frøling, M; Mikkelsen, C; Stern, M; van de Looij, A | 1 |
| Azevedo, A; Torres, T | 1 |
| Chi, CC; Kuo, CM; Tung, TH; Wang, SH | 1 |
| Dhillon, S | 1 |
| Bananis, E; Burmester, GR; Charles-Schoeman, C; Connell, CA; Fan, H; Fleischmann, R; Kwok, K; Nash, P; van der Heijde, D; Zerbini, CAF | 1 |
| Hallur, G; Mullangi, R; Saini, NK; Sulochana, SP; Tamizharasan, N; Zainuddin, M | 1 |
| Mori, S; Ueki, Y; Yoshitama, T | 1 |
| Cardwell, LA; Cline, A; Feldman, SR | 1 |
| Bushmakin, AG; Cappelleri, JC; Luger, T; Mamolo, C; Ständer, S; Tallman, AM; Yosipovitch, G; Zielinski, MA | 1 |
| Fumery, M; Murad, MH; Sandborn, WJ; Singh, S | 1 |
| Bonovas, S; Danese, S; Lytras, T; Nikolopoulos, G; Peyrin-Biroulet, L | 2 |
| Berry, GJ; Goronzy, JJ; Tian, L; Watanabe, R; Weyand, CM; Zhang, H | 1 |
| Fujio, K; Hanata, N; Komai, T; Shoda, H | 1 |
| Contreras-Yáñez, I; Ortiz-Haro, AB; Pascual-Ramos, V; Pérez-Román, DI; Ruiz-Medrano, E | 1 |
| Brehm, JH; Cameron, C; Dupuy, FP; Gavegnano, C; Hurwitz, SJ; Kulpa, DA; Marconi, VC; Ribeiro, SP; Routy, JP; Sabbagh, L; Santos, S; Schinazi, RF; Sékaly, RP; Talla, A | 1 |
| Wu, C; Wu, K; Wu, Q; Zhao, J | 1 |
| King, BA; Liu, LY | 3 |
| Breault, DT; Carlone, DL; Deary, L; Ediger, T; Richmond, CA; Rickner, H; Shah, MS; Tovaglieri, A; Zhou, F | 1 |
| Barroso, NS; Furst, DE; Miller, EZ | 1 |
| An, Y; Kwok, K; Li, G; Li, X; Li, Z; Su, H; Wang, L; Wu, Q; Xu, J; Zheng, Y | 1 |
| Accossato, P; Choy, E; DeMasi, R; Kola, B; Lula, S; Nurmohamed, M | 1 |
| Kravvas, G; Runcie, H | 1 |
| Tsai, HH | 1 |
| Bokarewa, MI; Erlandsson, MC | 1 |
| Hazra, A; Martin, SW; Mould, DR; Mukherjee, A; Niezychowski, W; Smith, MK; Su, C | 1 |
| Heaton, H; Kim, SR; King, BA; Liu, LY | 1 |
| Dasic, G; Frajzyngier, V; Jones, T; Madsen, A; Rojo, R; Valdez, H | 1 |
| Ezzedine, K | 1 |
| Lacour, JP | 1 |
| Deverapalli, SC; Rosmarin, D | 1 |
| Bitterman, A; Borbon, J; Cerise, J; Chen, JC; Christiano, AM; Clynes, R; Jabbari, A; Mackay-Wiggan, J; Sansaricq, F; Ulerio, G | 1 |
| Ball, DJ; Bowman, CJ; Collinge, M; Nilson, AL; Radi, ZA; Vogel, WM | 1 |
| Sendo, T; Shimada, A; Yagi, K | 1 |
| Gladman, D; Mease, P | 1 |
| Aletaha, D; Kerschbaumer, A; Smolen, JS | 1 |
| Ergun, T; Salman, A; Sarac, G | 1 |
| Arbeit, R; Kanhoush, R; Noell, C | 1 |
| Lee, SH; Seo, GS | 1 |
| Hider, SL; Scott, DL; Scott, IC | 1 |
| Banovic, F; Blubaugh, A; Denley, T; Eguiluz-Hernandez, S; Elder, D; Rissi, D | 1 |
| Biswas, P; Brennan, TV; Bukowski, JF; Cheng, J; Clark, JD; Collinge, M; Hammond, C; Hazra, A; Hodge, JA; Jesson, MI; Lan, S; Lin, L; Mojcik, CF; Noveck, RJ; Staats, JS; Stempora, L; Weinhold, KJ; Wouters, A | 1 |
| Bonnel, D; Eriksson, AH; Legouffe, R; Mortensen, RW; Nielsen, KT; Pamelard, F; Stauber, J | 1 |
| Bermejo, I; Martyn-St James, M; Ren, S; Scott, DL; Stevenson, M; Uttley, L; Wong, R; Young, A | 1 |
| Abrahamowicz, M; Bernatsky, S; Curtis, JR; Guerra, SF; Machado, MAÁ; Moura, CS | 1 |
| Du, GH; Jian, LL; Li, CH; Liu, XY; Sun, L; Xu, LL; Yu, RH; Zhao, JX | 1 |
| Banon-Maneus, E; Brunet, M; Campistol, JM; Cucchiari, D; Diekmann, F; Hierro-Garcia, N; Lazo-Rodríguez, M; Moya-Rull, D; Oppenheimer, F; Piñeiro, GJ; Ramírez-Bajo, MJ; Revuelta, I; Rovira, J; Tubita, V; Ventura-Aguiar, P | 1 |
| Aftab, BT; Ferguson, ID; Hann, BC; Lam, C; Lin, YT; Liu, H; Liu, JO; Mariano, MC; Mitsiades, CS; Murnane, M; Smith, GA; Taunton, J; Wiita, AP; Wong, SW | 1 |
| Abe, N; Jodo, S; Kudo, T | 1 |
| Bananis, E; Bergman, MJ; Dikranian, A; Lee, EB; Strand, V; Takiya, L; Wilkinson, B; Yazici, Y; Zang, C | 1 |
| Cho, S; Huh, CH; Kwon, O; Lee, JS; Park, HS; Yoon, HS | 1 |
| Chapman, D; DeMasi, R; Fallon, L; Keystone, E; Lee, EB; van Vollenhoven, RF; Wilkinson, B; Zwillich, SH | 1 |
| Bonovas, S; D'Amico, F; Danese, S; Peyrin-Biroulet, L | 1 |
| Golan, MA; Rubin, DT; Weisshof, R; Yvellez, OV | 1 |
| Wang, Z; Wu, B; Zhang, Q | 1 |
| Baraliakos, X; Deodhar, A; Fleishaker, D; Hendrikx, T; Kanik, KS; Li, D; Maksymowych, WP; Sherlock, SP; van der Heijde, D | 1 |
| Bodycombe, D; Curtis, JR; Dyagilev, K; Kan, HJ; Kharrazi, H; Molta, CT; Saria, S; Schulam, P | 1 |
| Ilevsky, IDJ; Meshkov, AD; Moiseev, SV; Novikov, PI; Zhilyaev, EV | 1 |
| Pivarcsi, A; Sonkoly, E; Srivastava, A; Ståhle, M | 1 |
| Berstein, G; Fitz, L; Fraser, S; Lee, J; Mebus, CA; Quazi, A; Soderstrom, C; Valdez, H; Wolk, R; Zhang, W | 1 |
| Castelo-Soccio, L; Putterman, E | 1 |
| Bakos, N; Bissonnette, R; Gardner, AC; Harper, MK; Korman, NJ; Ports, WC; Tallman, A; Tan, H; Tsai, TF; Valdez, H; Valenzuela, F | 1 |
| Colombel, JF | 1 |
| Biniecka, M; Fearon, U; Gallagher, L; Low, C; McGarry, T; Orr, C; Veale, DJ; Wade, S | 1 |
| Bensen, W; Bird, P; El-Zorkany, B; Kaine, J; Manapat-Reyes, BH; Pascual-Ramos, V; Soma, K; Thirunavukkarasu, K; Witcombe, D; Zhang, R | 1 |
| Chan, G; Lawendy, N; Long, MD; Melmed, GY; Nduaka, CI; Pedersen, RD; Su, C; Thorpe, AJ; Vermeire, S; Winthrop, KL | 1 |
| Gupta, P; Ito, K; Krishnaswami, S; Langley, R; Ma, G; Rottinghaus, S; Strober, B; Tallman, A; Valdez, H; Wolk, R; Xie, R | 1 |
| Kotyla, PJ | 1 |
| Hu, WT; Lin, FQ; Xu, AE | 1 |
| Cho, H; Choy, EH; Hashizume, M; John, MR; O'Mahony, A | 1 |
| Bourret, JA; Claxton, L; Gerber, RA; Soonasra, A; Taylor, M | 1 |
| Hao, W; Li, C; Luo, Y; Yang, Q; Zhang, W; Zhao, Y | 1 |
| Yin, Y; Zhang, DY; Zhang, TT | 1 |
| Galdamez, J; Goldring, SR; Lele, SM; Liu, Y; Mikuls, TR; Purdue, PE; Soni, DM; Wang, D; Wang, X; Wei, X; Wu, J; Zhao, G | 1 |
| Bäumer, W; Ehling, S; Fukuyama, T; Wilzopolski, J | 1 |
| Claxton, L; Gerber, RA; Gruben, D; Moynagh, D; Singh, A; Taylor, M; Wallenstein, GV | 1 |
| Baumgart, DC; Clowse, MEB; Dubinsky, MC; Feldman, SR; Graham, D; Jones, TV; Lawendy, N; Mahadevan, U; Marren, A; Su, C; Zhang, H | 1 |
| Cheng, MW; Goh, C; Kehl, A; Worswick, S | 1 |
| Cheifetz, A; Danese, S; Friedman, GS; Hanauer, S; Higgins, PDR; Lawendy, N; Nduaka, CI; Panaccione, R; Quirk, D; Reinisch, W; Su, C; Woodworth, DA; Zhang, H | 1 |
| Castaños-Mollor, I; García-Rodríguez, C; Gómez, C; López, J; Parra-Izquierdo, I; San Román, JA; Sánchez Crespo, M | 1 |
| Aguirre-Valencia, D; Naranjo-Escobar, J; Navarro, EP; Posso-Osorio, I; Tobón, GJ | 1 |
| Atzeni, F; Gerratana, E; Marino, F; Masala, IF; Nucera, V; Sangari, D; Sarzi-Puttini, P; Talotta, R | 1 |
| Bay-Jensen, AC; Hägglund, P; Karsdal, MA; Kayed, A; Kjelgaard-Petersen, CF; Mobasheri, A; Sharma, N; Thudium, CS | 1 |
| Arai, S; Arima, M; Kurasawa, K; Maezawa, R; Namiki, Y; Owada, T; Takamura, Y; Tanaka, A | 1 |
| Bastian, Y; Castañeda-Delgado, JE; Castañeda-Sánchez, JJ; Castillo-Ortiz, JD; Enciso-Moreno, JA; Fernández-Ruiz, JC; González-Amaro, R; Monsivais-Urenda, AE; Ochoa-González, F; Ramos-Remus, C; Romo-García, MF; Sánchez-Corona, J | 1 |
| Akylbekova, EL; Brenol, CV; de Leon, DP; García, EG; Lomonte, ABV; Marcolino, FMD; Radominski, SC; Rojo, R; Zerbini, CAF | 1 |
| Abinun, M; Allenspach, EJ; Castro-Wagner, J; Cooper, MA; Cunningham-Rundles, C; Demirdag, YY; Eckstein, O; Forbes, LR; Freeman, AF; Gennery, A; Guillerman, RP; Holland, SM; Leiding, JW; Lilic, D; Milner, JD; Olbrich, P; Patel, NC; Plant, AS; Schussler, E; Slatter, M; Su, HC; Szabolcs, P; Torgerson, TR; Vogel, TP; Weinacht, KG; Zerbe, C | 1 |
| Suchonwanit, P; Triyangkulsri, K | 1 |
| Le Berre, C; Loeuille, D; Peyrin-Biroulet, L | 1 |
| Berekmeri, A; Helliwell, P; Mahmood, F; Wittmann, M | 1 |
| Brown, L; Skopit, S | 1 |
| Chen, C; Deng, C; Fan, H; Lamba, M; Lukic, T; Mojcik, C; Stock, T; Sugiyama, N; Tanaka, Y; Toyoizumi, S; Valdez, H; Yuasa, H; Zhang, R | 1 |
| Aschenbrenner, DS | 2 |
| Asano, T; Furuya, MY; Kawakami, A; Kobayashi, H; Koga, T; Kozuru, H; Migita, K; Ohira, H; Sato, S; Sekine, H; Sumichika, Y; Suzuki, E; Watanabe, H; Yatsuhashi, H | 1 |
| Dawwas, GK; Thai, TN | 1 |
| Bokhari, L; Sinclair, R | 1 |
| Bananis, E; Cohen, S; Connell, CA; Fan, H; Fleischmann, R; Haraoui, B; Kaine, J; Keystone, E; Kivitz, AJ; Takiya, L; van Vollenhoven, RF | 1 |
| Bachelez, H; Chouela, E; Frajzyngier, V; Gottlieb, AB; Gupta, P; Imafuku, S; Kaur, M; Puig, L; Strober, BE; Tan, H; Thaçi, D; Valdez, H; van de Kerkhof, PCM; Wolk, R | 1 |
| Dixit, A; Mallurwar, SR; Mullangi, R; Sulochana, SP; Zainuddin, M | 1 |
| Cho, S; Lee, JS; Park, HS; Yoon, HS | 1 |
| Armstrong, AW; Singh, S | 1 |
| Elman, SA; Merola, JF; Weinblatt, M | 1 |
| Huang, F; Luo, ZC | 1 |
| Bordone, LA; Christiano, AM; Khanna, T; Sallee, B; Yang, CC | 1 |
| Cho, S; Huh, CH; Kim, MW; Kwon, O; Lee, JS; Park, HS; Shin, JW | 1 |
| Christiano, AM; Clynes, R; Dai, Z; de Jong, A; Duvic, M; Hordinsky, M; Jabbari, A; Lee, D; Li, MM; Mackay-Wiggan, J; Norris, DA; Price, V; Xing, L | 1 |
| Chikugo, M; Harada, N; Iuchi, M; KIshi, J; Kuroda, M; Nishioka, Y; Sakaue, H; Sebe, M; Tsutsumi, R | 1 |
| Castro-Poceiro, J; Fernández-Clotet, A; Panés, J | 1 |
| Deenonpoe, R; Meephansan, J; Pongcharoensuk, T; Ponnikorn, S; Thummakriengkrai, J; Yingmema, W | 1 |
| Bernatsky, S; Chen, L; Curtis, JR; Winthrop, K; Xie, F; Yang, S; Yun, H | 1 |
| Lloyd-Lavery, A | 1 |
| Gru, AA; Junkins-Hopkins, JM; Williams, E | 1 |
| Finlay, JL; Li, C; Lin, J; Ma, L; Pierson, CR; Wei, J | 1 |
| Baron, J; Clarysse, K; Gutermuth, J; Huth, L; Kluwig, D; Kortekaas Krohn, I; Lüscher, B; Marquardt, Y; Pfaff, CM | 1 |
| Adorini, K; Brown, M; Habib, P; Joshua, F; McLean, A; Ng, B; Podgorski, M; Tjeuw, M | 1 |
| Coates, LC; Elaine Husni, M; FitzGerald, O; Helliwell, P; Hendrikx, T; Hsu, MA; Kanik, KS; Kudlacz, E; Nash, P; Soriano, ER; Wu, J | 1 |
| El Jurdi, K; Rubin, DT; Weisshof, R; Zmeter, N | 1 |
| Athanasiadou, E; Giouleme, O; Katsoula, A; Paschos, P; Salanti, G; Tsapas, A | 1 |
| Bananis, E; Charles-Schoeman, C | 1 |
| Boers, M | 1 |
| Herfarth, HH; Herfarth, N; Kochar, B; Mamie, C; Navarini, AA; Scharl, M | 1 |
| Adawi, M; Amital, H; Biln, NK; Blank, M; Bragazzi, NL; Gilburd, B; Katz, I; Langevitz, P; Lidar, M; Marotta, A; Perez, D; Shoenfeld, Y; Shovman, O; Watad, A | 1 |
| An, Y; Bao, CD; Chen, ZW; Gu, JR; Hwang, LJ; Kremer, J; Li, ZG; Liu, Y; Wang, L; Wu, QZ; Xu, HJ; Zhao, DB | 1 |
| Biswas, P; Choy, E; Clark, JD; Hazra, A; Hodge, J; Krishnaswami, S; Lazariciu, I; Lee, EB; Mojcik, C; Strengholt, S; Valdez, H; van Vollenhoven, R; Wang, L | 1 |
| Tahir, H | 1 |
| Aldrich, LB; Allen, JI; Berinstein, JA; Bishu, S; Higgins, PDR; Kinnucan, JAR; Regal, RE; Steiner, CA; Stidham, RW; Waljee, AK | 1 |
| Akiyama, T; Hashimoto, T; Sakai, K; Sanders, KM; Yosipovitch, G | 1 |
| Chan, G; D'Haens, GR; Friedman, GS; Jones, T; Lawendy, N; Moscariello, M; Panés, J; Pedersen, R; Sandborn, WJ; Sands, BE; Su, C | 1 |
| Coates, LC; Deal, C; Deodhar, A; Dubreuil, M; Dunham, J; Gladman, DD; Gottlieb, A; Guyatt, G; Husni, ME; Jonsson, AH; Kenny, S; Kwan-Morley, J; Lin, J; Magrey, M; Marchetta, P; Mease, PJ; Merola, JF; Miner, J; Nowell, WB; Ogdie, A; Orbai, AM; Reddy, SM; Reston, J; Ritchlin, CT; Scher, JU; Shah, AA; Siaton, B; Siegel, E; Siegel, M; Singh, JA; Smith, BJ; Sullivan, N; Turgunbaev, M; Turner, AS; Van Voorhees, AS; Walsh, JA | 1 |
| Choy, EH | 2 |
| Abudu, M; Gordon, SC; Ko, JM; Rosmarin, D; Zancanaro, P | 1 |
| Castañeda, S; Morell Baladrón, A; Serra López-Matencio, JM | 1 |
| Aragón, CC; Cañas, CA; Garcia-Robledo, JE; Nieto-Aristizabal, I; Posso-Osorio, I; Tobón, GJ | 2 |
| Desai, RJ; Kim, SC; Pawar, A; Weinblatt, ME | 1 |
| Ports, WC; Purohit, VS; Riley, S; Wang, C | 1 |
| Almutairi, N; Hussain, NH; Nour, TM | 1 |
| Damsky, W; Emeagwali, N; Galan, A; King, B; Thakral, D | 1 |
| Fleming, P | 1 |
| Caldera, F; Cross, RK; Hayney, MS | 1 |
| Chen, DY; Chen, HH; Chen, JP; Chen, YH; Chen, YM; Hsieh, TY; Huang, WN; Hung, WT; Liao, TL; Yang, SS | 1 |
| Aggarwal, R; Charlton, D; Moghadam-Kia, S; Oddis, CV | 1 |
| Ananthakrishnan, AN; Burke, KE | 1 |
| Cacciapaglia, F; Fornaro, M; Iannone, F; Lopalco, G; Venerito, V | 1 |
| Chen, CC; Dai, YX | 1 |
| Deng, W; Sun, L; Wu, Q; Zhang, Z | 1 |
| Click, B; Regueiro, M | 1 |
| Bertolo, MB; Brenol, CV; Castelar Pinheiro, GDR; Cruz, BA; de Albuquerque, CP; de Freitas, MVC; Duarte, ALBP; Giorgi, RDN; Gomides, APM; Kakehasi, AM; Laurindo, IMM; Louzada-Júnior, P; Mota, LMHD; Pereira, IA; Ubirajara Silva de Souza, MPG; Xavier, RM | 1 |
| Chan, G; D'Haens, GR; Higgins, PDR; Maller, E; Mele, L; Moscariello, M; Niezychowski, W; Panés, J; Su, C; Wang, W | 1 |
| Cardiel, MH; Cohen, S; Connell, CA; Fleischmann, R; Gruben, D; Keystone, E; Kremer, J; Nash, P; Song, YW; Strand, V; Tanaka, Y; Tegzová, D; van der Heijde, D; Wallenstein, G; Zerbini, CAF | 1 |
| D'Haens, GR; De Jonge, WJ; De Krijger, M; De Vries, LCS; Duarte, JM; Jongejan, A; Moerland, PD; Van Hamersveld, PHP; Van Leeuwen-Hilbers, FWM; Welting, O; Wildenberg, ME | 1 |
| Dressler, C; Eisert, L; Nast, A; Pham, PA; Werner, RN | 1 |
| Aşkın, Ö; Çelik, U; Engin, B; Erkan, E; Kutlubay, Z; Oba, Ç; Serdaroğlu, S | 1 |
| Cappelleri, JC; Covarrubias-Cobos, JA; de Vlam, K; Gladman, DD; Graham, D; Hendrikx, T; Hsu, MA; Mease, PJ; Strand, V; Wang, C | 1 |
| Cappelleri, JC; Chen, L; Covarrubias-Cobos, JA; de Vlam, K; Gladman, DD; Hendrikx, T; Hsu, MA; Kudlacz, E; Mease, PJ; Strand, V; Wu, J | 1 |
| Cuenca-Barrales, C; Linares-Gonzalez, L; Ródenas-Herranz, T; Ruiz-Villaverde, R | 1 |
| Alewine, C; Antignani, A; FitzGerald, D; Gadina, M; Hewitt, SM; Simon, N | 1 |
| Alegre-Del Rey, E; Camean-Castillo, M; Fenix-Caballero, S; Gimeno-Ballester, V; Rios-Sanchez, E; Vázquez-Real, M | 1 |
| Aharoni Golan, M; Cohen, RD; Dalal, S; El Jurdi, K; Ollech, JE; Pekow, J; Rubin, DT; Sakuraba, A; Sossenheimer, PH; Weisshof, R | 1 |
| Christophi, GP; Ciorba, MA; Deepak, P; Gregory, MH | 1 |
| De Silva, T; Le Marshall, K; Rischin, A | 1 |
| Armstrong, AW; Connor, C; Cordoro, KM; Davis, DMR; Elewski, BE; Elmets, CA; Gelfand, JM; Gordon, KB; Gottlieb, AB; Hariharan, V; Kaplan, DH; Kavanaugh, A; Kiselica, M; Kivelevitch, D; Korman, NJ; Kroshinsky, D; Lebwohl, M; Leonardi, CL; Lichten, J; Lim, HW; Mehta, NN; Menter, A; Paller, AS; Parra, SL; Pathy, AL; Prater, EF; Rupani, RN; Siegel, M; Stoff, B; Strober, BE; Wong, EB; Wu, JJ | 1 |
| Batu, ED; Sönmez, HE | 1 |
| Westhovens, R | 1 |
| Taylor, PC | 1 |
| Lee, YH; Song, GG | 5 |
| Fallon, L; FitzGerald, O; Gladman, DD; Graham, D; Kavanaugh, A; van der Heijde, D; Wang, C | 1 |
| Santos, LDN; Shapiro, J | 1 |
| Eichele, DD; Lele, SM; Wang, D; Wei, X; Wu, J; Yang, L; Zhang, F; Zhao, G | 1 |
| Agarwal, P; Frye, BC; May, AM; Rizzi, M; Thiel, J; Venhoff, N; Voll, RE; Wendel, S | 1 |
| Bouhnik, Y; Brunet-Possenti, F; Charpentier, C; Descamps, D; Descamps, V; Deschamps, L; Moins-Teisserenc, H | 1 |
| Cudzich-Madry, A; Fragiadaki, M; Huang, Z; Patera, F | 1 |
| Bird, P; Connell, CA; Hall, S; Kwok, K; Nash, P; Thirunavukkarasu, K; Witcombe, D | 1 |
| Deeks, ED; Paik, J | 1 |
| Chen, C; Kwok, K; Lee, EB; Liu, Y; Llamado, LJ; Luo, Y; Sugiyama, N; Tanaka, Y; Tsai, WC; Wang, L; Yamanaka, H; Yoo, HJ | 1 |
| Dina, Y; McKesey, J; Pandya, AG | 1 |
| Cao, C; Dulai, PS; Lasch, K; Osterman, MT; Riaz, F; Sandborn, WJ | 1 |
| Huang, Z; Lee, PY; Li, T; Yao, X; Zheng, S | 1 |
| Cohen, S; Curtis, JR; DeMasi, R; Kwok, K; Lazariciu, I; Lee, EB; Mojcik, C; Silverfield, J; Soma, K; Strengholt, S; Terry, K; Wang, L; Wollenhaupt, J | 1 |
| Eldik, H; Leung, N; Ramirez, MR; Sodha, P | 1 |
| Abe, Y; Hayashi, M; Hozumi, Y; Okamura, K; Suzuki, T | 1 |
| Cranwell, WC; De Cruz, R; Doolan, BJ; Varigos, GA | 1 |
| Atzeni, F; Bechman, K; Cope, AP; Galli, M; Galloway, JB; Norton, S; Subesinghe, S; Winthrop, KL | 1 |
| Aykara, I; Diller, M; Frommer, K; Hasseli, R; Hülser, ML; Müller-Ladner, U; Neumann, E; Rehart, S | 1 |
| Addison, KJ; Ledford, JG; Myrdal, PB; Vallorz, E; Younis, US | 1 |
| Gomez-Arteaga, A; Horwitz, S; Inghirami, G; Margolskee, E; van Besien, K; Wei, MT | 1 |
| Huang, S; Li, D; Li, T; Liang, L; Liu, J; Nong, L; Zhang, B; Zheng, Y | 1 |
| Cohen, L; Griller, N | 1 |
| Chen, CI; Fournier, M; Gal, P; Kiss, Z; Kuznik, A; Michaud, K; Muszbek, N; Proudfoot, C | 1 |
| Li, H; Li, M; Tian, X; Wang, Q; You, H; Zeng, X; Zhang, G; Zhang, S; Zhao, J | 1 |
| McKesey, J; Pandya, AG | 1 |
| Demidova, NV; Kirillova, IG; Markelova, EI; Misiyuk, AS; Novikova, DS; Popkova, TV; Udachkina, HV | 1 |
| Feng, Q; Guo, M; Qiu, Q; Tan, X | 1 |
| Dwadasi, S; Israel, A; Rubin, DT | 1 |
| Abdulganieva, DI; Fairushina, IF; Nasonov, EL | 1 |
| Chen, Z; Tian, F; Xu, T | 1 |
| Almanzar, G; Kienle, F; Maas, A; Prelog, M; Schmalzing, M; Tony, HP | 1 |
| Charles-Schoeman, C; DeMasi, R; Gladman, DD; Graham, D; Jones, T; McInnes, IB; Nurmohamed, M; Thiers, B; Veale, DJ; Wang, C; Wolk, R | 1 |
| Aguilar-Luque, M; Gay-Mimbrera, J; Gómez-Arias, PJ; Gómez-García, F; Hernandez, J; Isla-Tejera, B; Montilla, AM; Ruano, J; Velez García-Nieto, A; Viguera-Guerra, I | 1 |
| Gomides, AP; Mota, L; Neto, LL; Rocha Silva, C; Scheinberg, MA; Winthrop, K | 1 |
| Witte, T | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K | 1 |
| Bushmakin, AG; Callis Duffin, K; Cappelleri, JC; Mallbris, L; Mamolo, C | 1 |
| Chan, EWY; Li, X; Man, KK; Pathadka, S; Wong, ICK | 1 |
| Damsky, W; Galan, A; King, B; Leventhal, J; McGeary, MK; Thakral, D | 1 |
| Choong, K; Dyer, J; Morwood, K | 1 |
| Abud-Mendoza, C; Calabrese, LH; Fleischmann, R; Iikuni, N; Lee, SH; Lindsey, SM; Luo, Z; Soma, K; Takiya, L; Tatulych, S | 1 |
| Choi, SJ; Lee, YH; Song, GG | 1 |
| Kwon, O; Park, H; Yu, DA | 1 |
| Gilhar, A; Keren, A; Laufer Britva, R; Paus, R | 1 |
| Bauermann, P; Heiligenhaus, A; Heinz, C | 1 |
| Cheng, Z; Wan, M; Wang, Z; Wu, Q; Yang, X | 1 |
| Bonelli, M; Dalwigk, K; Hayer, S; Holinka, J; Karonitsch, T; Kiener, HP; Niederreiter, B; Olmos Calvo, I; Pap, T; Platzer, A; Sevelda, F; Smolen, JS; Steiner, G; Superti-Furga, G | 1 |
| Poddubnyy, D; Sieper, J | 1 |
| Aguirre-Félix, ÓG; Bueno-Arias, GM; Morales-Miranda, AY; Tovar-Franco, R | 1 |
| Chen, Z; Wang, X; Ye, S | 1 |
| Battat, R; Dulai, PS; Feagan, BG; Jairath, V; Ma, C; Parker, CE; Sandborn, WJ | 1 |
| Greiling, T; Hagstrom, E; Haynes, D; Topham, C | 1 |
| Sato, S; Suga, H | 1 |
| Deng, C; Kanik, KS; Menon, S; Nicholas, T; Wang, Q; Xie, R | 1 |
| Almon, RR; DuBois, DC; Jusko, WJ; Song, D; Yu, R | 1 |
| Chen, Y; Li, C; Maguire, RJ; McWilliams, JC; Mustakis, J; Peng, H; Samp, L; Tang, W; Wan, F; Yu, S | 1 |
| Antonelli, E; Bassotti, G; Torti, G | 1 |
| Byers, NL; Higgs, RE; Lee, J; Macias, WL; McInnes, IB; Na, S; Ortmann, RA; Rocha, G; Rooney, TP; Taylor, PC; Wehrman, T; Zhang, X; Zuckerman, SH | 1 |
| Huang, Z; Kane, S; Lissoos, T; Moran, K; Null, K | 1 |
| Biswas, P; Boy, MG; Charles-Schoeman, C; DeMasi, R; Hwang, LJ; McInnes, IB; Soma, K; Valdez, H | 1 |
| Morinobu, A; Nishimura, K; Saegusa, J; Sendo, S; Yamada, H | 1 |
| Mori, S; Ueki, Y | 1 |
| Bessette, L; Crooks, M; Fallon, L; Gold, D; Gruben, D; Haraoui, B; Jones, N; Pope, J; Woolcott, J | 1 |
| Chen, Y; Guo, X; Li, Q; Li, W; Peng, Y; Zhao, G; Zheng, J | 1 |
| Anderson, PO | 1 |
| Biehl, A; Bigham, R; Borenstein, D; Caplan, L; Deodhar, A; Dubreuil, M; Fang, MA; Gensler, LS; Haroon, N; Khan, MA; Louie, G; Majithia, V; Maksymowych, WP; Ng, B; Oristaglio, J; Pianin, M; Shah, AA; Sullivan, N; Turgunbaev, M; Turner, A; Wang, R; Ward, MM; Yu, D | 1 |
| Abdulrahim, H; Adebajo, AO; Sharlala, H | 1 |
| Krüger, K | 1 |
| Dassopoulos, T; Johnson, CM; Linzay, CD | 1 |
| Feng, S; Guo, L; Jiang, X; Liu, Y; Sun, B | 1 |
| Chen, KQ; Li, C; Liu, S; Sui, X; Tang, MW; Tian, XL; Xu, KF; Xu, WS | 1 |
| Khale, A; Khanjiwala, Z; Prabhu, A | 1 |
| Dolinger, MT; Dubinsky, MC; Phan, BL; Rolfes, P | 1 |
| Danese, S; Fan, H; Jones, TV; Koram, N; Lawendy, N; Modesto, I; Panés, J; Quirk, D; Reinisch, W; Sandborn, WJ; Sands, BE; Su, C | 2 |
| Allenbach, Y; Benveniste, O; Landon-Cardinal, O | 1 |
| Almeida de Jesus, A; Carrasco, R; Goldbach-Mansky, R; Hwang, S; Jung, L; Kim, H; Kuehn, HS; Rider, LG; Rosenzweig, S; Sabbagh, S | 1 |
| Frangos, J; Ganesan, AK; Guerra, R; Huang, V; Li, SJ; Mobasher, P | 1 |
| Akdogan, N; Atakan, N; Doğan, S; Ersoy-Evans, S | 1 |
| Feng, X; Han, P; Lei, Y; Tian, D; Wang, H; Xia, Y; Yan, W | 1 |
| Andrews, J; Bowes, MA; Chapman, D; Conaghan, PG; Guillard, G; Koenig, A; Stein, A; Troum, O; Wilkinson, B; Xie, Z; Østergaard, M | 1 |
| Kumar, N; Mishra, J; Simonsen, R | 1 |
| Abria, C; Chaudhari, AJ; Harmany, ZT; Kundu-Raychaudhuri, S; Raychaudhuri, S; Raychaudhuri, SP; Smith, CM | 1 |
| Armuzzi, A; Bressler, B; Chan, G; Colombel, JF; Danese, S; Lawendy, N; Lindsay, JO; Maller, E; Marren, A; Marshall, JK; Panés, J; Salese, L; Sandborn, WJ; Sands, BE; Su, C; Tsilkos, K; Zhang, H | 2 |
| AlMutairi, N; Nour, T | 1 |
| DeMasi, R; Fleischmann, R; Gruben, D; Iikuni, N; Moots, RJ; Mysler, E; Smolen, JS; Soma, K; Strand, V; Wallenstein, GV | 1 |
| Bhoyrul, B; John, JM; Kerkemeyer, KLS; Sinclair, R | 1 |
| Chu, FF; Doroshow, JH; Esworthy, RS; Gao, Q; Shen, B | 1 |
| Guo, X; Han, L; Jia, Y; Li, W; Peng, Y; Zhang, Z; Zhao, Y; Zheng, J | 1 |
| Bako, HY; Ibrahim, MA; Ibrahim, S; Isah, MS | 1 |
| D'Haens, G; Dulai, PS; Feagan, BG; Jairath, V; Ma, C; Narula, N; Peyrin-Biroulet, L; Sandborn, WJ; Singh, S; Vande Casteele, N; Vermeire, S | 1 |
| Atas, N; Babaoglu, H; Salman, R; Satis, H; Tufan, A; Varan, O | 1 |
| Asano, T; Fujita, Y; Fujiwara, T; Furuya, M; Gunji, N; Kobayashi, H; Matsumoto, H; Matsuoka, N; Migita, K; Ohira, H; Onizawa, M; Sato, S; Temmoku, J; Watanabe, H | 1 |
| Lei, Y; Li, Y; Lu, J; Shen, H; Xia, L; Yang, J; Yuan, L; Zhang, H | 1 |
| Hayashi, S; Itoh, I; Iwano, M; Kasuno, K; Kimura, H; Ojima, T; Shimizu, H; Takahashi, N; Yamamoto, C | 1 |
| Argyriou, K; Moran, GW; Phillips, F; Tsakiridou, E; Varyani, F | 1 |
| Kato, F; Kurosaka, D; Oto, Y; Takahashi, Y | 1 |
| Glover, S; Liu, X; Mendoza Alvarez, LB | 1 |
| Dowty, ME; Hegen, M; Jesson, MI; Katkade, V; Lin, TH; Martin, DA; Menon, S; Telliez, JB | 1 |
| Dash, RP; Veeravalli, V | 1 |
| Bonovas, S; Danese, S; Evripidou, D; Nikolopoulos, GK; Pantavou, K; Peyrin-Biroulet, L; Piovani, D; Yiallourou, AI | 1 |
| Chandran, U; Reps, J; Ryan, PB; Stang, PE | 1 |
| Chen, YC; Chen, YY; Lan, CE; Lin, SY; Yang, CC | 1 |
| Bonovas, S; Danese, S; Lasa, JS; Olivera, PA; Peyrin-Biroulet, L | 1 |
| Bertoldi, I; Orsolini, G; Rossini, M | 1 |
| Davies, SC; Hussein, IM; Jairath, V; Khanna, R; Nguyen, TM; Parker, CE | 1 |
| Chang, S; Hudesman, D | 1 |
| Brinkman, ACK; Burmester, GR; Buttgereit, F; Damerau, A; Diesing, K; Gaber, T; Hoff, P; Lang, A; Ohrndorf, S; Pfeiffenberger, M; Pienczikowski, J | 1 |
| Amiot, A | 1 |
| Estevez, AJ; Papagno, MJ; Vinicki, JP | 1 |
| Caso, F; Chimenti, MS; Costa, L; Del Puente, A; Giacomelli, R; Girolimetto, N; Navarini, L; Ruscitti, P; Scarpa, R | 1 |
| Cheng, X; Chi, H; Hu, Q; Jia, J; Liu, HL; Liu, T; Shi, H; Su, Y; Sun, Y; Teng, J; Wan, L; Wang, F; Wang, M; Wang, Z; Yang, C; Ye, J; Zhou, Z | 1 |
| Okano, S; Sako, M; Takazoe, M; Yoshimura, N | 1 |
| Lefevre, PLC; Vande Casteele, N | 1 |
| Biswas, P; Chen, C; Choy, EH; Needle, E; Rigby, WF; Soma, K; Valdez, H; Wang, L; Winthrop, KL; Wouters, A | 1 |
| Georgiou, S; Plachouri, KM | 1 |
| Bruscas Izu, C; García Latasa de Araníbar, FJ; Hörndler Argarate, C | 1 |
| Horita, T; Kuwabara, S; Matsumoto, S; Nakamura, H; Tanimura, S | 1 |
| Biemans, VBC; Bodelier, AGL; de Boer, NKH; de Vries, AC; Dijkstra, G; Hoekstra, J; Hoentjen, F; Horjus Talabur Horje, CS; Jansen, JM; Löwenberg, M; Oldenburg, B; Pierik, MJ; Römkens, TEH; Sleutjes, JAM; Srivastava, N; van Bodegraven, AA; van der Meulen-de Jong, AE; van der Woude, CJ; van Schaik, FDM; Weersma, RK; West, RL | 1 |
| Craiglow, BG; Olamiju, B | 1 |
| Boehncke, WH; Graham, D; Gratacós, J; Hsu, MA; Merola, JF; Nash, P; Papp, KA; Thaçi, D; Wang, C; Wu, J; Young, P | 1 |
| Damsky, W; King, B; Peterson, D | 1 |
| Chopey, IV; Chubirko, KI; Hnepa, YY; Kurakh, AV; Varvarynets, AV | 1 |
| Betts, KA; Du, EX; Pope, J; Qi, CZ; Sawant, R; Song, Y; Tang, P; Tundia, N | 1 |
| Balsa, A; Casado, MA; de Andrés-Nogales, F; Gómez, S; Martinez-Sesmero, JM; Montoro, M; Navarro, F; Oyagüez, I; Peral, C; Valderrama, M | 1 |
| Honda, M; Kondo, M; Kumakura, S; Moriyama, M; Murakawa, Y | 1 |
| Cao, Y; Huo, J; Li, C; Li, Y; Li, Z; Yu, M; Zhang, W; Zhang, Y | 1 |
| Benhong, Z; Jiexin, L; Peng, C; Yue, W | 1 |
| Clark-Snustad, K; Jacobs, J; Lee, S | 1 |
| Barsky, M; Battat, R; Boland, BS; D'Haens, G; Dulai, PS; Feagan, BG; Jairath, V; Ma, C; Mosli, M; Murad, MH; Narula, N; Nguyen, NH; Prokop, L; Sandborn, WJ; Singh, S; Vande Casteele, N | 1 |
| Ferreira, S; Michalany, N; Sabbagh, C; Scheinberg, M | 1 |
| Damião, AOMC; Kotze, PG; Teixeira, FV | 1 |
| Baldovino, S; Buccarano, N; Cecchi, I; Crosasso, P; Di Gregorio, F; Di Nunzio, P; Favuzzi, MD; Foddai, SG; Osella, S; Radin, M; Roccatello, D; Rossi, D; Rubini, E; Sciascia, S; Valeria, M | 1 |
| Hou, Y; Li, C; Li, L; Liu, J; Sun, L; Zeng, X; Zhang, F; Zhao, Y; Zheng, W | 1 |
| Bajocchi, G; Beltrami, M; Boiardi, L; Cassone, G; Catanoso, M; Cimino, L; Costantini, M; Croci, S; Di Lernia, V; Dolci, G; Galli, E; Giorgi Rossi, P; Girolimetto, N; Gradellini, F; Mancuso, P; Marata, AM; Massari, M; Muratore, F; Pipitone, N; Salvarani, C | 1 |
| Guo, X; Hu, Z; Li, W; Peng, Y; Zheng, J | 1 |
| Hoff, P; Mohr, J; Mössner, R; Wilsmann-Theis, D | 1 |
| Morinobu, A | 1 |
| Batist, G; Esfahani, K; Hudson, M | 1 |
| Ballerie, A; Batteux, F; Fardel, O; Jego, P; Jeljeli, M; Jouneau, S; Lecureur, V; Lelong, M; Lescoat, A; Morzadec, C; Piquet-Pellorce, C; Vernhet, L | 1 |
| Fukuyama, M; Hayashida, M; Hisamatsu, T; Kikuchi, O; Matsuura, M; Minowa, S; Mitsui, T; Miura, M; Miyoshi, J; Ohyama, M; Ozaki, R; Saito, D; Sakuraba, A; Tokunaga, S; Wada, H | 1 |
| Alikhan, M; Jogi, R; Nguyen, JK; Patel, AB; Schlichte, MJ | 1 |
| Biedermann, T; Boehmer, D; Eyerich, K; Lauffer, F; Pilz, AC; Seiringer, P | 1 |
| Jerjen, R; Meah, N; Sinclair, R; Trindade de Carvalho, L; Wall, D | 1 |
| Alayo, QA; Bader, G; Beniwal-Patel, P; Christophi, GP; Ciorba, MA; Cohen, BL; Colombel, JF; Deepak, P; Dimopoulos, C; Fenster, M; Gutierrez, A; Ha, C; Hirten, RP; Jacobs, M; Khatiwada, A; Lin, B; Patel, A; Pekow, J; Rubin, DT; Syal, G; Ungaro, RC; Weisshof, R; Yarur, A | 1 |
| Jerjen, R; Meah, N; Sinclair, R; Wall, D | 1 |
| Charles-Schoeman, C; Cohen, S; Connell, C; Curtis, JR; Fallon, L; Graham, D; Greenberg, J; Hauben, M; Hung, E; Jones, TV; Kanik, KS; Kremer, J; Madsen, A; Malley, W; Mease, P; Onofrei, A; Valdez, H; Wang, C; Woolcott, J; Yun, H | 1 |
| Chan, G; Ciorba, MA; Lawendy, N; Lichtenstein, GR; Nduaka, CI; Panés, J; Pedersen, RD; Quirk, D; Rogler, G; Su, C; Thorpe, AJ | 1 |
| Ibrahim, SSA; Salama, MA; Selima, E; Shehata, RR | 1 |
| Askin, O; Balci Ekmekci, O; Oba, MC; Serdaroglu, S | 1 |
| Feist, E; Hoff, P; Ohrndorf, S; Walther, M; Weinerth, J; Wesselmann, H | 1 |
| De Cruz, P; Raine, T; Verstockt, B | 1 |
| Kobak, S | 1 |
| Dutta Majumder, P; Kaushik, V; Shah, A | 1 |
| Moreker, MR | 1 |
| Biswas, J; Dutta Majumder, P; Kaushik, V; Pyare, R | 1 |
| Cardiel, MH; Castañeda, O; Chartrand, S; Citera, G; Fischer, A; Girard, T; Kwok, K; Madariaga, H; Mysler, E; Park, JK; Ponce de Leon, D; Richette, P; Rivas, JL; Strengholt, S; Thorat, AV; Wang, L | 1 |
| Lomborg, N; Lottenburger, T | 1 |
| Armuzzi, A; Colombel, JF; Farnier, M; Friedman, GS; Ha, C; Kwok, K; Quirk, D; Salese, L; Sands, BE; Su, C; Taub, PR | 1 |
| Palasik, BN; Wang, H | 1 |
| Jiménez-Gallo, D; Linares-Barrios, M; Navarro-Navarro, I; Rodríguez-Hernández, C; Rodríguez-Mateos, ME | 1 |
| Fujiwara, M; Ishikawa, Y; Kasuya, T; Kita, Y | 1 |
| Chen, Y; Dong, P; Guo, Q; Ma, A; Tian, L; Wang, L; Xiong, X | 1 |
| Dörner, T | 1 |
| Chen, DY; Chen, HH; Chen, JP; Chen, YH; Chen, YJ; Chen, YM; Hsieh, TY; Huang, WN; Liao, TL | 1 |
| Blachley, T; Chen, C; Cohen, SB; Dandreo, KJ; Dougados, M; Greenberg, JD; Gruben, D; Harnett, J; Lenihan, A; Litman, HJ; Lukic, T; Madsen, A; Rivas, JL; Smith, TW; Woolcott, J; Zhang, R | 1 |
| Maksimow, A; Stintzing, D; Wohlrab, J | 1 |
| Alten, R; Diehl, A; Germino, R; Kaine, J; Murray, CW; Shi, H; Strand, V; Wallenstein, G | 1 |
| Alayo, QA; Beniwal-Patel, P; Christophi, GP; Ciorba, MA; Cohen, BL; Colombel, JF; Deepak, P; Dimopoulos, C; Fenster, M; Gutierrez, A; Ha, C; Hirten, RP; Khatiwada, A; Patel, A; Pekow, J; Rubin, DT; Syal, G; Ungaro, RC; Wang, W; Yarur, A | 1 |
| Kadoba, K; Mukoyama, H; Murabe, H; Nishimura, K; Saito, R; Waki, D; Yokota, T | 1 |
| Dincer, D; Kose Ozkan, C; Tanacan, E | 1 |
| Geng, H; Jia, E; Wei, J; Xiao, M; Yan, G; Zhang, J | 1 |
| Crespo Cruz, A; Del Boz, J; Romero Gómez, C | 1 |
| Mukherjee, A; Nduaka, CI; Peyrin-Biroulet, L; Quirk, D; Sandborn, WJ; Sands, BE; Su, C; Wang, W | 1 |
| Biswas, P; Charles-Schoeman, C; Chen, C; Cohen, SB; Curtis, JR; Kwok, K; Lee, EB; Madsen, A; Mariette, X; Nash, P; Shapiro, A; Tanaka, Y; Wang, L; Winthrop, KL; Wollenhaupt, J | 1 |
| Hashimoto, M; Morinobu, A; Watanabe, R | 1 |
| Abboud, H; Al-Hashel, JY; Ismail, II; Massoud, F | 1 |
| Gómez Castro, S; González Fernández, CM; Gratacós Masmitjà, J; Rebollo Laserna, FJ | 1 |
| Desai, S; LaChance, A; Lo, K; Nambudiri, VE; Villa-Ruiz, C; Vleugels, RA | 1 |
| Amuro, H; Ebina, K; Hara, R; Hashimoto, M; Hirano, T; Hirao, M; Jinno, S; Katayama, M; Kumanogoh, A; Maeda, Y; Murata, K; Nakata, K; Okita, Y; Onishi, A; Son, Y; Takeuchi, T; Yamamoto, K; Yamamoto, W; Yoshikawa, A | 1 |
| Bhattoa, HP; Bodnár, N; Bodoki, L; Czókolyová, M; Domján, A; Gulyás, K; Hamar, A; Hodosi, K; Horváth, Á; Nagy, G; Panyi, G; Pethő, Z; Pusztai, A; Soós, B; Szamosi, S; Szántó, S; Szekanecz, É; Szekanecz, Z; Szűcs, G; Tajti, G; Végh, E | 1 |
| Guillo, L; Louis, E; Peyrin-Biroulet, L | 1 |
| Kamath, S | 1 |
| Castelo-Soccio, L; McKenzie, PL | 1 |
| Gunay, LM; Modesto, I; Mundayat, R; Peyrin-Biroulet, L; Salese, L; Sandborn, WJ; Sands, BE; Sharara, AI; Su, C | 1 |
| Gong, Y; Qi, F; Zhang, J; Zhou, S; Zhu, B | 1 |
| Neumann, K; Terheyden, P; Thaçi, D | 1 |
| Ng, AC | 1 |
| Chang, Y; Chen, J; Christiano, AM; Dai, Z | 1 |
| Lee, YH; Sung, YK | 1 |
| Li, Y; Sun, Y; Wei, S; Zhang, L; Zong, S | 1 |
| Bhoyrul, B; Kerkemeyer, KLS; Sinclair, RD | 1 |
| Jena, A; Mishra, S; Sachan, A; Sharma, V; Singh, AK; Singh, H | 1 |
| Alba, C; Olivares, D; Taxonera, C | 1 |
| Bokhari, L; Lai, VWY; Sinclair, R | 1 |
| Domdey, A; Hawerkamp, HC; Homey, B; Meller, S; Oláh, P; Radau, L; Sewerin, P | 1 |
| Farraye, FA; Judd, DT; Kotze, PG; Lawendy, N; Moore, GT; Mundayat, R; Qazi, T; Sharma, PP | 1 |
| Sheng Ding, N; Singh, S; Tassone, D | 1 |
| Abaalkhail, S; Gilvaz, VJ; Mody, E | 1 |
| Honap, S; Irving, PM; Pavlidis, P | 1 |
| Aramaki, T; Eguchi, K; Endo, Y; Fujikawa, K; Ichinose, K; Igawa, T; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Kurushima, S; Michitsuji, T; Mizokami, A; Nakamura, H; Nishihata, S; Okada, A; Okamoto, M; Origuchi, T; Sato, S; Shimizu, T; Sumiyoshi, R; Suzuki, T; Tamai, M; Tsuji, Y; Ueki, Y | 1 |
| Barbich, T; Cerda, OL; Citera, G; Schneeberger, EE | 1 |
| Connell, W; Kamm, MA; Lo, SW; Lust, M; Wright, EK | 1 |
| Biemans, VBC; Hoentjen, F; Pierik, MJ; Straatmijer, T | 1 |
| Alesse, E; Berardicurti, O; Ciccia, F; Cipriani, P; Di Benedetto, P; Di Francesco, B; Di Vito Nolfi, M; Dolo, V; Giacomelli, R; Grazia, N; Guggino, G; Maurizi, A; Navarini, L; Panzera, N; Rucci, N; Ruscitti, P; Teti, AM; Zazzeroni, F | 1 |
| Fleischmann, R; Hirose, T; Iikuni, N; Paulissen, J; Shi, H; Smolen, JS; Soma, K; Takeuchi, T | 1 |
| Hanauer, SB; Tetangco, EP | 1 |
| Yee, AMF | 1 |
| Bedaj, M; Benson, RA; Bonilha, CS; Garside, P; McInnes, IB | 1 |
| Bhandari, S; Bhattarai, S; Bista, B; Dhungana, A; Poudel, N; Shrestha, GS; Shrestha, M; Vaidya, B | 1 |
| Iwasawa, M; Juji, T; Maenohara, Y; Matsumoto, T; Nakamura, I; Omata, Y; Takahashi, H; Tanaka, S; Uchio, A | 1 |
| Feng, Y; Shi, Y; Xie, Y; Zhang, G | 1 |
| Danese, S; Jones, TV; Koram, N; Kwok, KK; Modesto, I; Ng, SC; Rubin, DT; Vermeire, S | 1 |
| Bensimon, A; Bergman, M; Clewell, J; Orvis, E; Tundia, N; Yang, M | 1 |
| AlAnazi, R; AlHarithy, R; AlHayaza, G; AlIssa, A; AlKhalifah, A; AlMarzoug, A; AlOrainy, M; AlSheikh, A; AlTawil, L | 1 |
| Altwegg, R; Charpy, F; Debourdeau, A | 1 |
| Kim, JW; Kim, SY | 1 |
| Dunnick, CA; Kibbie, J; Kines, K; Norris, D | 1 |
| Damião, AOMC; Danese, S; Dotan, I; Guo, X; Hart, A; Judd, DT; Lawendy, N; Loftus, EV; Modesto, I; Panés, J; Sandborn, WJ; Su, C; Wang, W | 1 |
| Armuzzi, A; Danese, S; Irving, PM; Lawendy, N; Liguori, G; Mundayat, R; Sandborn, WJ; Sharara, AI; Woolcott, JC | 1 |
| Benton, S; Farah, R; Freese, R; Hordinsky, M | 1 |
| Desai, RJ; Khosrow-Khavar, F; Kim, SC; Lee, H; Lee, SB | 1 |
| Cs, G; Es, SS; M, G; Murugesan, H; Nasreen, HS; Ravi, S; Santhanam, S | 1 |
| Askling, J; Barbulescu, A; Chatzidionysiou, K; Forsblad-d'Elia, H; Frisell, T; Kastbom, A; Lindström, U; Turesson, C | 1 |
| Bacci, ED; Bushmakin, AG; Cappelleri, JC; Coates, LC; Fallon, L; Gladman, DD; Helliwell, PS; Wu, J | 1 |
| Bessette, L; Kinch, CD; Kwok, K; Lukic, T; Mysler, E; On, PV; van Vollenhoven, RF | 1 |
| Abreu, MT; Chaparro, M; Lawendy, N; Lazariciu, I; Mundayat, R; Panaccione, R; Salese, L; Sands, BE; Woolcott, JC | 1 |
| Abello, M; Amador, L; Castillo, D; Gutierrez-Ardila, MV; Guzman, R; Izquierdo, J; Lukic, T; Madariaga, H; Otero, W; Ponce de Leon, D; Reyes, J; Velez, P | 1 |
| Albayda, J; Castillo, R | 1 |
| Ju, T; Labib, A; Vander Does, A; Yosipovitch, G | 1 |
| Agarwal, I; Das, A; Panda, M | 1 |
| Cook, JA; D'Haens, GR; Modesto, I; Mukherjee, A; Nicholas, T; Sandborn, WJ; Su, C; Tsuchiwata, S | 1 |
| Bartlett, SJ; Bingham, CO; Cella, D; Gold, DA; Gruben, D; Murray, C; van Vollenhoven, R | 1 |
| Bilgin, E; Duran, E; Ertenli, İ; Kalyoncu, U; Kiraz, S; Ünaldı, E | 1 |
| Llevat, N; Montoro, M; Román Ivorra, JA | 1 |
| Bordone, LA; Fan, W; Lavian, J; Lee, EY; Youssef, S | 1 |
| Arbrile, M; Baldovino, S; Barinotti, A; Buccarano, N; Cecchi, I; Crosasso, P; Di Gregorio, F; Di Nunzio, P; Favuzzi, MD; Menegatti, E; Milone, V; Osella, S; Radin, M; Roccatello, D; Rossi, D; Sciascia, S | 1 |
| Álvaro-Gracia, JM; Curtis, JR; Dikranian, AH; Gonzalez-Gay, MA; Paulissen, J; Shi, H; Stockert, L; Takiya, L; Tatulych, S; Wellborne, F | 1 |
| Arias-Santiago, S; Cantudo-Cuenca, MR; Diaz-Calvillo, P; Molina-Leyva, A; Rodriguez-Pozo, JA; Sanchez-Diaz, M; Tercedor-Sánchez, J | 1 |
| Amin, S; Khenat, A; Malandkar, M; Phatak, S | 1 |
| Cappelleri, JC; Dina, O; Fallon, L; Fleishaker, D; Magrey, M; Navarro-Compán, V; Strand, V; Van den Bosch, F; Wang, C; Wang, L; Wei, JC; Wu, J | 1 |
| Choquette, D; Galos, C; Gruben, D; Haraoui, B; Keystone, EC; Khraishi, M; Kinch, C; Lisnevskaia, L; Roy, P; Sampalis, JS; Teo, M; Vaillancourt, J; Woolcott, JC | 1 |
| Arai, S; Hibi, T; Hisamatsu, T; Hoshi, M; Kim, HJ; Matsuoka, K; Shi, N; Tabira, J; Toyoizumi, S; Woo, JS; Ye, BD; Yuasa, H | 1 |
| Ahuja, V; Jena, A; Kakadiya, R; Mishra, S; Sharma, V | 1 |
| Geng, SL; Gong, T; Ji, C; Su, HH | 1 |
| Landewé, R; Ramiro, S; van der Heijde, D | 1 |
| Leng, X; Sun, B; Yang, H; Zeng, X; Zhang, W; Zhou, J; Zhou, S | 1 |
| Balanescu, AR; Bhatt, DL; Chen, AS; Citera, G; Connell, CA; Gold, D; Pascual-Ramos, V; Pope, JE; Sawyerr, G; Schulze-Koops, H; Shapiro, AB | 1 |
| Fox, DA; Gudjonsson, JE; Huang, S; Kahlenberg, JM; Khanna, D; Khanna, PP; Lafyatis, R; Nagaraja, V; Padilla, C; Tabib, T; Tsoi, LC; Young, A | 1 |
| Dubinsky, MC; Irving, PM; Leung, Y | 1 |
| Jung, JY; Kim, HA; Kim, JW; Lee, E; Suh, CH | 1 |
| Isomäki, P; Kuuliala, A; Kuuliala, K; Leirisalo-Repo, M; Palmroth, M; Peltomaa, R; Silvennoinen, O; Valli, A; Vidqvist, KL; Virtanen, A | 1 |
| D'Haens, GR; Guo, X; Kulisek, N; Lawendy, N; Modesto, I; Mundayat, R; Ng, SC; Panaccione, R; Panés, J; Sandborn, WJ; Sands, BE; Su, C; Vranic, I | 1 |
| Abdulla, N; Al-Obaidli, A; Ali-Alam, M; Husein-ElAhmed, H; Steinhoff, M | 1 |
| Barough, MS; Behrangi, E; Goodarzi, A; Hejazi, P; Khoramdad, M; Koltapeh, MP | 1 |
| Eason, C; Elston, D; Plante, J; Robinson, I; Santa Lucia, G | 1 |
| Biedermann, L; Dubinsky, MC; Fellmann, M; Gardiner, S; Hur, P; Mundayat, R; Panés, J; Rubin, DT; Vermeire, S | 1 |
| Huang, ZS; Liu, QP; Wei, JC; Xu, Q | 1 |
| Charles-Schoeman, C; Hyde, C; Martin, DA; Paciga, SA; Sahin, B; Szekanecz, Z; Vranic, I; Wang, Z; Weitz, JI | 1 |
| Jeon, JY; Jo, JY; Ju, JH; Lee, EB; Sung, YK; Yoo, HJ | 1 |
| Perche, P; Pichardo, R; Purvis, C | 1 |
| Bertolini, N; Caso, F; Costa, L; Del Puente, A; Luppino, JME; Mostacciuolo, E; Passavanti, S; Peluso, R; Santelli, F; Scarpa, R; Tasso, M | 1 |
| Bhatt, DL; Chen, YH; Connell, CA; Curtis, JR; Gómez-Reino, JJ; Gunay, LM; Menon, S; Sugiyama, N; Vranic, I; Wang, C; Wu, J; Yamaoka, K | 1 |
| Bhatt, DL; Buch, MH; Charles-Schoeman, C; Connell, CA; Dougados, M; Giles, JT; Koch, GG; Kwok, K; Menon, S; Rivas, JL; Szekanecz, Z; Vranic, I; Wang, C; Wu, J; Yndestad, A; Ytterberg, SR | 1 |
| Ashraf, A; Bharali, P; Tiwari, A | 1 |
| Ahmed, HM; Chan, G; Cohen, BL; Lichtenstein, GR; Modesto, I; Peyrin-Biroulet, L; Salese, L; Su, C; Wang, W | 1 |
| Allegretti, JR; Connelly, SB; Gecse, KB; Lawendy, N; Lee, SD; Paulissen, J; Steinwurz, F | 1 |
| Bingham, CO; Brault, Y; Dougados, M; Fallon, L; Kessouri, M; Roychoudhury, S; Taylor, PC; Wang, L | 1 |
| Ding, NS; Gilmore, R; Tassone, D | 1 |
| Cheng, X; Dai, SM; Du, F; Hu, Q; Jiang, L; Liu, H; Lu, LJ; Ma, L; Shi, H; Su, Y; Tao, YL; Teng, J; Wang, M; Xue, Y; Yang, C; Ye, J; Zhao, D | 1 |
| Abolghasemi, S; Mardani, M; Mohammadshahi, J; Teimourpour, R | 1 |
| Barton, A; Bluett, J; Church, S; Hyrich, KL; Ogungbenro, K; Unwin, RD | 1 |
| Armağan, B; Dağlı, PA; Erden, A; Güven, SC; Küçükşahin, O; Omma, A; Özin, YÖ; Yürekli, ÖT | 1 |
| Choe, JY; Jeon, JY; Kim, SK; Lee, SH; Sun, J; Yoo, HJ | 1 |
| Atsumi, T; Bracher, M; Brooks, D; Davies, J; Fleischmann, RM; Goode, C; Gupta, A; McInnes, IB; Mukherjee, S; O'Shea, C; Saurigny, D; Schifano, LA; Shelton, C; Smith, JE; Strand, V; Takeuchi, T; Taylor, PC; van der Heijde, D; Wang, M; Wang, R; Watts, S; Weinblatt, ME | 1 |
| Ciurea, A; Distler, O; Frank Bertoncelj, M; Jo, H; Killeen, T; Kwok, K; Ospelt, C; Wang, L | 1 |
| Deng, S; Huang, J; Li, J; Liu, F; Liu, Y; Rao, S; Shi, W; Tang, Y | 1 |
226 review(s) available for pyrroles and tofacitinib
| Article | Year |
|---|---|
JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
Topics: Animals; Drug Design; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Janus Kinase 3; Lymphocytes; Organ Transplantation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Severe Combined Immunodeficiency; Transplantation Immunology; Transplantation, Homologous | 2004 |
JAK protein kinase inhibitors.
Topics: Animals; Drug Design; Enzyme Inhibitors; Forecasting; Gene Expression Regulation; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Mannich Bases; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; TYK2 Kinase | 2005 |
[Rheumatoid arthritis].
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Autoantibodies; Cytokines; Humans; Immunoconjugates; Janus Kinase 3; Peptides, Cyclic; Piperidines; Pyrimidines; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2009 |
[Targeted therapies including monoclonal antibodies for connective tissue diseases].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; B-Lymphocytes; Connective Tissue Diseases; Etanercept; Humans; Immunoglobulin G; Infliximab; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2009 |
CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
Topics: Animals; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation, Preclinical; Graft Rejection; Humans; Immunosuppressive Agents; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2009 |
JAK3: a two-faced player in hematological disorders.
Topics: Animals; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Interleukin Receptor Common gamma Subunit; Janus Kinase 3; Lymphocytes; Mice; Piperidines; Pyrimidines; Pyrroles; Receptors, Cytokine; Signal Transduction | 2009 |
Novel immunosuppressive agents in kidney transplantation.
Topics: Abatacept; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cyclosporine; Everolimus; Graft Rejection; Graft Survival; Humans; Immunoconjugates; Immunosuppressive Agents; Kidney Transplantation; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Recombinant Fusion Proteins; Sirolimus | 2010 |
Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile.
Topics: Abatacept; Cardiovascular Diseases; Clinical Trials as Topic; Graft Rejection; Humans; Immunoconjugates; Immunosuppression Therapy; Immunosuppressive Agents; Janus Kinase 3; Kidney Transplantation; Piperidines; Pyrimidines; Pyrroles | 2010 |
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Health Status; Humans; Janus Kinase 3; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2010 |
Treating inflammation with the Janus kinase inhibitor CP-690,550.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Graft Rejection; Humans; Immunosuppressive Agents; Inflammation; Isoenzymes; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors | 2011 |
Tofacitinib.
Topics: Animals; Clinical Trials as Topic; Drugs, Investigational; Humans; Immunosuppressive Agents; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles | 2010 |
Current landscape for T-cell targeting in autoimmunity and transplantation.
Topics: Autoimmune Diseases; Calcineurin Inhibitors; Cell Differentiation; Cell Proliferation; Cytokines; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Janus Kinase 3; Organ Transplantation; Piperidines; Protein Kinase C; Pyrimidines; Pyrroles; Quinazolines; Receptors, Cytokine; T-Lymphocytes; Transplantation Immunology; Transplantation Tolerance | 2011 |
Targeting JAK3 in kidney transplantation: current status and future options.
Topics: Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Janus Kinase 3; Kidney Transplantation; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2011 |
Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinases; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Syk Kinase; Treatment Outcome | 2011 |
[Recent progress in the treatment of rheumatoid arthritis].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Denosumab; Etanercept; Humans; Immunoglobulin G; Infliximab; Interleukin-6; Methotrexate; Molecular Targeted Therapy; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; Receptors, Tumor Necrosis Factor; Reference Standards; Remission Induction; Tumor Necrosis Factor-alpha | 2012 |
Novel small-molecular therapeutics for rheumatoid arthritis.
Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Molecular Targeted Therapy; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles | 2012 |
Tofacitinib for the treatment of rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
Are calcineurin inhibitors-free regimens ready for prime time?
Topics: Abatacept; Calcineurin Inhibitors; Drug Therapy, Combination; Graft Rejection; Graft Survival; Humans; Immunoconjugates; Immunosuppressive Agents; Kidney Diseases; Piperidines; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2012 |
JAK inhibitors in psoriasis: a promising new treatment modality.
Topics: Animals; Cytokines; Humans; Janus Kinases; Nitriles; Piperidines; Psoriasis; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index | 2012 |
New drug therapies on the horizon for IBD.
Topics: Animals; Antibodies, Monoclonal; Cell Adhesion Molecules; Humans; Immunization; Inflammatory Bowel Diseases; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha | 2012 |
[Janus kinase inhibitors as a new therapeutic principle].
Topics: Arthritis, Rheumatoid; Colitis, Ulcerative; Enzyme Inhibitors; Humans; Janus Kinases; Nitriles; Piperidines; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction | 2012 |
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
Kinase inhibitors for the treatment of rheumatoid arthritis.
Topics: Aminopyridines; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Treatment Outcome | 2012 |
Tofacitinib (Xeljanz) for rheumatoid arthritis.
Topics: Animals; Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic | 2013 |
IBD in 2012: Pathogenesis and management of IBD--thinking outside the box.
Topics: Antibodies, Monoclonal, Humanized; Genetic Loci; Humans; Inflammatory Bowel Diseases; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy.
Topics: Arthritis, Rheumatoid; Disease Management; Enzyme Inhibitors; Genetic Predisposition to Disease; HLA Antigens; Humans; Piperidines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles | 2013 |
Novel targets for inflammatory bowel disease therapeutics.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Adhesion Molecules; Certolizumab Pegol; Colitis, Ulcerative; Crohn Disease; Humans; Immunoglobulin Fab Fragments; Infliximab; Natalizumab; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Tumor Necrosis Factor-alpha; Ustekinumab | 2013 |
Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis.
Topics: Administration, Oral; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forecasting; Germany; Humans; Janus Kinases; Male; Maximum Tolerated Dose; Molecular Targeted Therapy; Morpholines; Oxazines; Piperidines; Prognosis; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2013 |
Targeting kinases: a new approach to treating inflammatory rheumatic diseases.
Topics: Animals; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinase 3; Mitogen-Activated Protein Kinases; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Rheumatic Diseases; Syk Kinase | 2013 |
A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Cytochrome P-450 CYP3A; Humans; Janus Kinase 1; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2013 |
Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inflammatory Bowel Diseases; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; United States; United States Food and Drug Administration | 2013 |
Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Topics: Animals; Humans; Inflammatory Bowel Diseases; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors | 2013 |
Tofacitinib in kidney transplantation.
Topics: Animals; Clinical Trials as Topic; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Janus Kinase 3; Kidney Transplantation; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors | 2013 |
Tofacitinab in renal transplantation.
Topics: Graft Rejection; Humans; Immunosuppressive Agents; Infections; Kidney Transplantation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors | 2013 |
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Inflammation; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Tofacitinib for treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
[JAK inhibitor].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2013 |
Jakpot! New small molecules in autoimmune and inflammatory diseases.
Topics: Animals; Autoimmune Diseases; Cytokines; Humans; Immunosuppressive Agents; Inflammation; Janus Kinases; Mice; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction | 2014 |
Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma.
Topics: Animals; Benzazepines; Carcinogenicity Tests; Disease Models, Animal; Humans; Hydromorphone; Lipoma; Mutagenicity Tests; Neoplasms; Phentolamine; Piperidines; Pyrimidines; Pyrroles; Quinoxalines; Rats; Risk Assessment; Varenicline | 2013 |
Therapeutic targeting of the Jak/STAT pathway.
Topics: Animals; Autoimmune Diseases; Cytokines; Disease Models, Animal; Humans; Janus Kinases; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors | 2014 |
Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Humans; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Failure | 2013 |
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aryl Hydrocarbon Hydroxylases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders.
Topics: Alopecia Areata; Animals; Antibodies, Monoclonal; Autoimmune Diseases; Humans; Interleukin-15; Leukemia-Lymphoma, Adult T-Cell; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Interleukin-15; Signal Transduction | 2013 |
Janus kinases: an ideal target for the treatment of autoimmune diseases.
Topics: Animals; Autoimmune Diseases; Cytokines; Humans; Janus Kinases; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors | 2013 |
Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis.
Topics: Acute Disease; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2014 |
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Methotrexate; Piperidines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Autoimmune Diseases; Clinical Trials as Topic; Cytokines; Humans; Inflammation; Inflammatory Bowel Diseases; Janus Kinases; Piperidines; Protein Conformation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2014 |
Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Design; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Pyrroles; Signal Transduction | 2014 |
[New therapies for rheumatoid arthritis].
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Therapeutic potential of tyrosine kinase 2 in autoimmunity.
Topics: Adaptive Immunity; Autoimmune Diseases; Autoimmunity; Dendritic Cells; Drug Design; Genetic Predisposition to Disease; Humans; Immunity, Cellular; Lymphocyte Subsets; Macrophages; Molecular Targeted Therapy; Neutrophils; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; TYK2 Kinase | 2014 |
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
In the pipeline for psoriasis: upcoming psoriasis treatments.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Certolizumab Pegol; Etanercept; Humans; Immunoglobulin Fab Fragments; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Interleukin-12 Subunit p40; Janus Kinases; Nitriles; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Interleukin-17; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha; Ustekinumab | 2014 |
[Tofacitinib].
Topics: Administration, Oral; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Drug Approval; Europe; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
Topics: Biological Products; Humans; Incidence; Latent Tuberculosis; Piperidines; Pyrimidines; Pyrroles; Risk; Tuberculosis | 2014 |
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
Topics: Clinical Trials as Topic; Gene Expression Regulation; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Molecular Targeted Therapy; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Treatment Outcome | 2014 |
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Infections; Longitudinal Studies; Male; Methotrexate; Middle Aged; Piperidines; Prevalence; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2014 |
Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Update on Janus kinase antagonists in inflammatory bowel disease.
Topics: Animals; Dyslipidemias; Humans; Inflammatory Bowel Diseases; Janus Kinases; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2014 |
[Pharmacology profile and clinical findings of tofacitinib citrate (Xeljanz® tablet 5 mg)].
Topics: Administration, Oral; Animals; Humans; Mice; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rheumatic Diseases | 2014 |
Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Janus Kinases; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Therapeutic development in psoriasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Humans; Immunologic Factors; Interleukin-23; Phosphodiesterase Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide; Treatment Outcome | 2014 |
Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Biological Products; Chronic Disease; Female; Humans; Lipids; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylarthritis; Treatment Outcome | 2015 |
Current and future oral systemic therapies for psoriasis.
Topics: Acitretin; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Cyclosporine; Fumarates; Humans; Hydroxyurea; Immunosuppressive Agents; Isoxazoles; Keratolytic Agents; Leflunomide; Methotrexate; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Thioguanine | 2015 |
Current and emerging biologics for ulcerative colitis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Factors; Cell Adhesion Molecules; Colitis, Ulcerative; Humans; Infliximab; Janus Kinases; Piperidines; Pyrimidines; Pyrroles | 2015 |
Tofacitinib for the treatment of moderate-to-severe psoriasis.
Topics: Animals; Clinical Trials as Topic; Disease Progression; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; STAT Transcription Factors | 2015 |
New systemic therapies for psoriasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Factors; Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide | 2015 |
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Humans; Incidence; Janus Kinase 3; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult | 2016 |
Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Current State of Immunosuppression: Past, Present, and Future.
Topics: Abatacept; Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Azathioprine; Bone Marrow Transplantation; Calcineurin Inhibitors; Cyclosporine; Disease Models, Animal; Everolimus; Heart Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Transplantation; Lung Transplantation; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Tacrolimus | 2015 |
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
Topics: Arthritis, Rheumatoid; Humans; Inflammation; Janus Kinase 1; Janus Kinase 3; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT1 Transcription Factor; Translational Research, Biomedical; Tumor Necrosis Factor-alpha | 2015 |
Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Thalidomide | 2015 |
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Immunocompromised Host; Immunosuppressive Agents; Incidence; Janus Kinase 3; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Assessment; Tuberculosis | 2016 |
Pharmacology Update on Chronic Obstructive Pulmonary Disease, Rheumatoid Arthritis, and Major Depression.
Topics: Anti-Anxiety Agents; Arthritis, Rheumatoid; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Depressive Disorder; Fluticasone; Humans; Nursing Process; Piperazines; Piperidines; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrimidines; Pyrroles; Sulfides; United States; Vortioxetine | 2015 |
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Topics: Adaptive Immunity; Animals; Cytokines; Humans; Immunity, Innate; Inflammatory Bowel Diseases; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2016 |
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Communicable Diseases; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled tri
Topics: Abatacept; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Drug Substitution; Humans; Network Meta-Analysis; Odds Ratio; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab; Treatment Failure; Tumor Necrosis Factor-alpha | 2016 |
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
Topics: Chronic Disease; Clinical Trials as Topic; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2016 |
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles | 2016 |
Interleukin 21 as a new possible player in pemphigus: Is it a suitable target?
Topics: Animals; Antibodies, Monoclonal; Humans; Immunity, Cellular; Interleukins; Molecular Targeted Therapy; Pemphigus; Piperidines; Pyrimidines; Pyrroles | 2016 |
An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
Topics: Abatacept; Animals; Calcineurin Inhibitors; Drug Therapy, Combination; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Molecular Targeted Therapy; Organ Transplantation; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Risk Assessment; Risk Factors; Signal Transduction; Time Factors; Treatment Outcome | 2016 |
Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lipids; Piperidines; Pyrimidines; Pyrroles; Rheumatology | 2016 |
Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Herpes Zoster; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocyte Subsets | 2015 |
Tofacitinib in ulcerative colitis.
Topics: Animals; Arthritis, Rheumatoid; Autoimmunity; Colitis, Ulcerative; Cytokines; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2016 |
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Etanercept; Humans; Infliximab; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab | 2016 |
Tofacitinib for the treatment of ulcerative colitis.
Topics: Administration, Oral; Animals; Colitis, Ulcerative; Humans; Intestinal Mucosa; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Signal Transduction; STAT Transcription Factors | 2016 |
Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Heterocyclic Compounds, 2-Ring; Humans; Janus Kinase 1; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Valine | 2016 |
Tofacitinib for the treatment of psoriasis.
Topics: Biomarkers; Drug Administration Schedule; Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2016 |
[Guidelines for the management of rheumatoid arthritis].
Topics: Abatacept; Algorithms; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Substitution; Drug Therapy, Combination; Humans; Japan; Methotrexate; Piperidines; Practice Guidelines as Topic; Pyrimidines; Pyrroles | 2016 |
[Tofacitinib for the treatment of rheumatoid arthritis].
Topics: Administration, Ophthalmic; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Drug Discovery; Humans; Janus Kinases; Lymphocytes; Molecular Targeted Therapy; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides; Treatment Outcome | 2016 |
Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Follow-Up Studies; Herpes Zoster; Humans; Incidence; Janus Kinases; Japan; Molecular Targeted Therapy; Piperidines; Product Surveillance, Postmarketing; Pyrimidines; Pyrroles | 2016 |
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2016 |
Next-Generation Therapeutics for Inflammatory Bowel Disease.
Topics: Antibodies, Monoclonal, Humanized; Biological Products; Cell Adhesion Molecules; Gastrointestinal Agents; Humans; Immunoglobulins; Indans; Inflammatory Bowel Diseases; Mucoproteins; Oligonucleotides; Oxadiazoles; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Ustekinumab | 2016 |
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2016 |
Recent trends and future directions for the medical treatment of ulcerative colitis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Budesonide; Calcineurin Inhibitors; Colitis, Ulcerative; Drug Therapy, Combination; Drugs, Chinese Herbal; Forecasting; Gastrointestinal Agents; Glucocorticoids; Humans; Phenylalanine; Piperidines; Pyrimidines; Pyrroles; Quinazolinones; Tumor Necrosis Factor-alpha | 2016 |
Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cytokines; Humans; Inflammatory Bowel Diseases; Interleukin-23; Janus Kinases; Lysophospholipids; Molecular Targeted Therapy; Oligonucleotides; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Smad7 Protein; Sphingosine; Th17 Cells; Transforming Growth Factor beta; Ustekinumab | 2017 |
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Disease Progression; Etanercept; Humans; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Failure | 2016 |
New targets in psoriatic arthritis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Cyclophosphamide; Etanercept; Humans; Infliximab; Methotrexate; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Sulfasalazine; Thalidomide; Ustekinumab | 2016 |
Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Humans; Male; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha | 2016 |
Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist.
Topics: Abatacept; Antirheumatic Agents; Contraindications; Drug Interactions; Herpes Zoster Vaccine; Humans; Immunocompromised Host; Immunogenicity, Vaccine; Influenza Vaccines; Methotrexate; Piperidines; Pneumococcal Vaccines; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatologists; Rituximab; Vaccines; Vaccines, Attenuated; Yellow Fever Vaccine | 2017 |
Malignancy and Janus Kinase Inhibition.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Incidence; Janus Kinases; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms | 2017 |
Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges?
Topics: Graft Rejection; Humans; Immunosuppression Therapy; Interleukin Receptor Common gamma Subunit; Janus Kinase 3; Kidney Transplantation; Molecular Targeted Therapy; Monitoring, Physiologic; Piperidines; Pyrimidines; Pyrroles; Signal Transduction | 2017 |
Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Etanercept; Humans; Network Meta-Analysis; Piperidines; Poisson Distribution; Pyrimidines; Pyrroles; Regression Analysis; Risk; Rituximab | 2017 |
Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Topics: Alopecia Areata; Azetidines; Dermatitis, Atopic; Humans; Janus Kinase Inhibitors; Janus Kinases; Nitriles; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Skin Diseases; Sulfonamides; Vitiligo | 2017 |
Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Topics: Administration, Oral; Alopecia Areata; Dermatitis, Atopic; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Signal Transduction; Skin Diseases; Vitiligo | 2017 |
Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Forkhead Transcription Factors; Gene Expression Regulation; Humans; Immunologic Factors; Inflammation; Interleukin-17; Nuclear Receptor Subfamily 1, Group F, Member 3; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; T-Lymphocytes, Regulatory; Th17 Cells; Ustekinumab | 2017 |
JAK inhibitors in dermatology: The promise of a new drug class.
Topics: Alopecia Areata; Anti-Inflammatory Agents; Azetidines; Clinical Trials as Topic; Dermatitis, Atopic; Dermatologic Agents; Humans; Janus Kinases; Molecular Targeted Therapy; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Skin Diseases; Sulfonamides; Vitiligo | 2017 |
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Topics: Animals; Cytokines; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Mutation; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors | 2017 |
JAK inhibition in inflammatory bowel disease.
Topics: Animals; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Inflammatory Bowel Diseases; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Assessment; Signal Transduction; STAT Transcription Factors | 2017 |
Janus kinase inhibitors in dermatology: A systematic review.
Topics: Alopecia Areata; Anti-Inflammatory Agents; Antineoplastic Agents; Azetidines; Dermatologic Agents; Drug Eruptions; Humans; Janus Kinases; Molecular Targeted Therapy; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Skin Diseases; Sulfonamides | 2017 |
The emerging safety profile of JAK inhibitors in rheumatic disease.
Topics: Azetidines; Humans; Infections; Janus Kinases; Neoplasms; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rheumatic Diseases; Signal Transduction; Sulfonamides | 2017 |
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Disease Progression; Humans; Methotrexate; Neoplasms; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Failure | 2017 |
Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Humans; Neoplasms; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Risk | 2017 |
Medical and Maintenance Treatments for Vitiligo.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; alpha-MSH; Anti-Bacterial Agents; Calcineurin Inhibitors; Dinoprostone; Humans; Immunosuppressive Agents; Low-Level Light Therapy; Methotrexate; Minocycline; Oxytocics; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Ultraviolet Therapy; Vitamin D; Vitiligo | 2017 |
Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Topics: Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Glucocorticoids; Humans; Methotrexate; Piperidines; Practice Guidelines as Topic; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2017 |
The use of kinase inhibitors in solid organ transplantation.
Topics: Aminopyridines; Humans; Immunosuppressive Agents; Indoles; Morpholines; Organ Transplantation; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Syk Kinase | 2017 |
Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.
Topics: Dose-Response Relationship, Drug; Humans; Models, Statistical; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Topics: Abatacept; Adalimumab; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Etanercept; Humans; Infliximab; Methotrexate; Methylprednisolone; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab | 2017 |
Emerging treatments for ulcerative colitis: a systematic review.
Topics: Andrographis paniculata; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Induction Chemotherapy; Mesalamine; Piperidines; Plant Extracts; Pyrimidines; Pyrroles; Remission Induction | 2017 |
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Elective Surgical Procedures; Glucocorticoids; Humans; Lupus Erythematosus, Systemic; Perioperative Care; Piperidines; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology; Spondylarthritis; Spondylitis, Ankylosing; Surgeons; United States | 2017 |
Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |
A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Janus Kinase Inhibitors; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Targeting Specific Immunologic Pathways in Crohn's Disease.
Topics: Antibodies, Monoclonal, Humanized; Cell Adhesion Molecules; Cell Movement; Crohn Disease; Endothelium, Vascular; Gastrointestinal Agents; Humans; Immunologic Factors; Integrins; Interleukin-12; Interleukin-12 Subunit p40; Interleukin-23; Janus Kinase Inhibitors; Janus Kinases; Leukocytes; Natalizumab; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; Th1 Cells; Th17 Cells; Ustekinumab | 2017 |
Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Topics: B-Lymphocytes; Colitis, Ulcerative; Crohn Disease; Humans; Indans; Janus Kinase 1; Janus Kinase Inhibitors; Oligonucleotides; Oxadiazoles; Piperidines; Pyridines; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; Smad7 Protein; T-Lymphocytes; Triazoles | 2017 |
Two new drugs for rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azetidines; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2017 |
Small molecule therapy for managing moderate to severe psoriatic arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Humans; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Small Molecule Libraries; Thalidomide; Treatment Outcome | 2017 |
Tofacitinib in psoriatic arthritis.
Topics: Animals; Arthritis, Psoriatic; Clinical Trials as Topic; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2017 |
[Systemic treatment of vitiligo : Balance and current developments].
Topics: alpha-MSH; Animals; Biomarkers; Combined Modality Therapy; Disease Models, Animal; Humans; Immunosuppressive Agents; Interferon-alpha; Janus Kinases; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Ultraviolet Therapy; Vitiligo | 2017 |
Tofacitinib in the treatment of active rheumatoid arthritis in adults.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Pyrimidines; Pyrroles | 2018 |
[Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Humans; Janus Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2017 |
Tofacitinib: A New Oral Therapy for Psoriasis.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2018 |
Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Topics: Dermatologic Agents; Humans; Janus Kinase Inhibitors; Piperidines; Placebos; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2018 |
Tofacitinib: A Review in Rheumatoid Arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Janus Kinases; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2017 |
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide | 2017 |
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Biological Factors; Biological Products; Colitis, Ulcerative; Drug Therapy; Humans; Infliximab; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2018 |
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
Topics: Adult; Biological Products; Biological Therapy; Colitis, Ulcerative; Double-Blind Method; Humans; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index | 2018 |
Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
Topics: Administration, Topical; Adolescent; Adult; Algorithms; Alopecia Areata; Autoimmune Diseases; Clinical Trials as Topic; Female; Humans; Janus Kinase Inhibitors; Male; Piperidines; Pyrimidines; Pyrroles | 2018 |
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.
Topics: Animals; Antirheumatic Agents; Biological Products; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Rheumatic Diseases; Risk Factors | 2018 |
[What's new in dermatological therapy?]
Topics: Adalimumab; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dermatologic Agents; Dermatology; Erlotinib Hydrochloride; Herpes Zoster Vaccine; Humans; Interleukin 1 Receptor Antagonist Protein; Isotretinoin; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Diseases; Trimethoprim, Sulfamethoxazole Drug Combination | 2016 |
Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
Topics: Alopecia Areata; Humans; Janus Kinase Inhibitors; Male; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Failure; Young Adult | 2017 |
[Emerging Therapies: What Are Promising in the Near Future?]
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Colitis, Ulcerative; Crohn Disease; Gastrointestinal Agents; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Ustekinumab | 2018 |
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Humans; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Thromboembolism | 2018 |
Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Costs; Drug Resistance; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Technology Assessment, Biomedical | 2018 |
Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis.
Topics: Algorithms; Colitis, Ulcerative; Humans; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index | 2018 |
The use of tofacitinib in the treatment of inflammatory bowel disease.
Topics: Humans; Inflammatory Bowel Diseases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2018 |
Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.
Topics: Antiviral Agents; Colitis, Ulcerative; Disease Management; Herpes Zoster; Herpesvirus 3, Human; Humans; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Prognosis; Pyrimidines; Pyrroles | 2018 |
Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Humans; Janus Kinase Inhibitors; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Topics: Animals; Azetidines; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rheumatic Fever; Sulfonamides | 2018 |
[Research progress of JAK-3 kinase and its inhibitors].
Topics: Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Humans; Janus Kinase 1; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2018 |
Role of janus kinase inhibitors in the treatment of alopecia areata.
Topics: Alopecia Areata; Animals; Humans; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Pyrimidines; Pyrroles | 2018 |
Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Clinical Trials as Topic; Drug Approval; Humans; Janus Kinases; Nasopharyngitis; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2018 |
An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
Topics: Alopecia Areata; Child; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Steroids; Treatment Outcome | 2018 |
Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Humans; Network Meta-Analysis; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2019 |
Oral small molecules for psoriasis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Humans; Patient Selection; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide; Thiazoles | 2018 |
Targeted therapies for psoriatic arthritis: an update for the dermatologist.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Psoriatic; Dermatologic Agents; Dermatology; Humans; Interleukin-17; Interleukin-23; Janus Kinase Inhibitors; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Thalidomide; Tumor Necrosis Factor-alpha | 2018 |
Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
Topics: Autoimmune Diseases; Dose-Response Relationship, Drug; Humans; Janus Kinase Inhibitors; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Tofacitinib for the treatment of ulcerative colitis.
Topics: Animals; Colitis, Ulcerative; Drug-Related Side Effects and Adverse Reactions; Expert Testimony; Humans; Janus Kinases; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Signal Transduction; STAT Transcription Factors; Treatment Outcome | 2018 |
Emerging Therapies for Inflammatory Bowel Disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Female; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2018 |
Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Infliximab; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index | 2018 |
Therapies in ankylosing spondylitis-from clinical trials to clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Health Services Needs and Demand; Humans; Piperidines; Pyrimidines; Pyrroles; Spondylitis, Ankylosing; Translational Research, Biomedical; Ustekinumab | 2018 |
Clinical significance of Janus Kinase inhibitor selectivity.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Humans; Inflammation; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2019 |
JAK-STAT inhibitors for the treatment of immunomediated diseases.
Topics: Autoimmune Diseases; Azetidines; Humans; Immunologic Factors; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; STAT Transcription Factors; Sulfonamides | 2019 |
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Factors; Drug Therapy, Combination; Etanercept; Humans; Infliximab; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab; Treatment Outcome | 2019 |
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Asia, Eastern; Drug Therapy, Combination; Herpes Zoster; Herpesvirus 3, Human; Humans; Mycobacterium tuberculosis; Piperidines; Prevalence; Pyrimidines; Pyrroles; Recurrence; Risk; Tuberculosis; Virus Activation | 2019 |
Managing Risks with Biologics.
Topics: Antibodies, Monoclonal, Humanized; Biological Products; Demyelinating Diseases; Deprescriptions; Drug Substitution; Gastrointestinal Agents; Humans; Infections; Inflammatory Bowel Diseases; Lymphoma; Melanoma; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk; Risk Assessment; Skin Neoplasms; Tumor Necrosis Factor-alpha; Ustekinumab | 2019 |
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Confidence Intervals; Humans; Infliximab; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Time Factors; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Ustekinumab | 2019 |
Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients.
Topics: Arthritis, Rheumatoid; Biological Products; Humans; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic | 2019 |
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Biosimilar Pharmaceuticals; Certolizumab Pegol; Dermatologic Agents; Drug Therapy, Combination; Etanercept; Evidence-Based Medicine; Humans; Infliximab; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Ustekinumab | 2019 |
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine | 2019 |
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome | 2019 |
Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Bayes Theorem; Humans; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2019 |
What's New in Hair Loss.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Alopecia Areata; Azetidines; Humans; Janus Kinase Inhibitors; Nitriles; Piperidines; Platelet-Rich Plasma; Purines; Pyrazoles; Pyrimidines; Pyrroles; Retinoids; Sulfonamides | 2019 |
Tofacitinib: A Review in Psoriatic Arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Psoriatic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2019 |
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Infections; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2019 |
Tofacitinib for the treatment of rheumatoid arthritis: an update.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2019 |
JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Proliferation; Humans; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Niacinamide; Piperidines; Pyrimidines; Pyrroles | 2019 |
The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?
Topics: Adalimumab; Antibodies, Monoclonal; Biosimilar Pharmaceuticals; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Infliximab; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2019 |
The use of Tofacitinib in the treatment of inflammatory bowel disease.
Topics: Humans; Inflammatory Bowel Diseases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors | 2019 |
Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.
Topics: Chronic Disease; Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
Topics: Arthritis, Psoriatic; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Humans; Incidence; Lipids; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Topics: Humans; Janus Kinase Inhibitors; Janus Kinases; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Skin Diseases; STAT Transcription Factors | 2019 |
[JAK Inhibitors in Rheumatology].
Topics: Arthritis, Rheumatoid; Azetidines; Germany; Humans; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2019 |
Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Janus kinase inhibitors: An innovative treatment for alopecia areata.
Topics: Administration, Oral; Alopecia Areata; Azetidines; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Janus Kinase Inhibitors; Janus Kinases; Middle Aged; Nitriles; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides; T-Lymphocytes, Cytotoxic; Treatment Outcome | 2019 |
Current Unmet Needs in Spondyloarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Delayed Diagnosis; Humans; Interleukin-17; Interleukin-23; Janus Kinase Inhibitors; Magnetic Resonance Imaging; Molecular Targeted Therapy; Piperidines; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Referral and Consultation; Spondylarthropathies; Tumor Necrosis Factor Inhibitors; Ustekinumab | 2019 |
Innovations in Oral Therapies for Inflammatory Bowel Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Discovery; Heterocyclic Compounds, 3-Ring; Humans; Indans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Mesalamine; Oxadiazoles; Phosphodiesterase Inhibitors; Piperidines; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Lysosphingolipid; Triazoles | 2019 |
Novel topical and systemic therapies in atopic dermatitis.
Topics: Acrylamides; Administration, Topical; Antibodies, Monoclonal, Humanized; Biological Products; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Dermatitis, Atopic; Humans; Immunotherapy; Interleukin-13; Janus Kinase Inhibitors; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Pyridines; Pyrimidines; Pyrroles; Resorcinols; Stilbenes; TRPV Cation Channels | 2019 |
Stereoelectronic Effects in Ligand Design: Enantioselective Rhodium-Catalyzed Hydrogenation of Aliphatic Cyclic Tetrasubstituted Enamides and Concise Synthesis of (R)-Tofacitinib.
Topics: Catalysis; Hydrogenation; Ligands; Piperidines; Pyrimidines; Pyrroles; Rhodium; Stereoisomerism | 2019 |
Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.
Topics: Administration, Oral; Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Piperidines; Pyrimidines; Pyrroles; Quality of Life | 2019 |
An evaluation of tofacitinib for the treatment of psoriatic arthritis.
Topics: Arthritis, Psoriatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Half-Life; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
[Role of janus kinase inhibitors in the treatment of rheumatic diseases].
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome | 2019 |
Maneuvering Clinical Pathways for Ulcerative Colitis.
Topics: Antibodies, Monoclonal, Humanized; Colitis, Ulcerative; Critical Pathways; Gastrointestinal Agents; Humans; Piperidines; Practice Guidelines as Topic; Prognosis; Pyrimidines; Pyrroles; Risk Assessment; Treatment Outcome | 2019 |
Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.
Topics: Alopecia Areata; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Assessment | 2020 |
In brief: Risk of pulmonary thromboembolism and death with tofacitinib.
Topics: Drug Labeling; Humans; Piperidines; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome | 2019 |
Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Fatigue; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2019 |
Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Methotrexate; Network Meta-Analysis; Piperidines; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2020 |
Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data.
Topics: Administration, Oral; Colitis, Ulcerative; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
Topics: Biological Factors; Biomarkers; Clinical Trials as Topic; Colitis, Ulcerative; Drug Therapy, Combination; Humans; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2019 |
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Topics: Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Placebos; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfonamides; Survival Analysis; Treatment Outcome; Triazoles | 2020 |
Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Bone and Bones; Bone Remodeling; Humans; Immune System; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors | 2020 |
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Topics: Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Maintenance Chemotherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic | 2020 |
First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician.
Topics: Antibodies, Monoclonal, Humanized; Biological Products; Clinical Trials as Topic; Comparative Effectiveness Research; Humans; Inflammatory Bowel Diseases; Piperidines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2020 |
Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
Topics: Administration, Oral; Antirheumatic Agents; Arthritis, Psoriatic; Azetidines; Humans; Janus Kinases; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Thalidomide; Treatment Outcome | 2020 |
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Topics: Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2020 |
JAK inhibitors in chronic plaque psoriasis: What is known so far.
Topics: Adamantane; Azetidines; Humans; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Nitriles; Piperidines; Prospective Studies; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2020 |
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Methotrexate; Network Meta-Analysis; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides | 2020 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2021 |
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism | 2020 |
A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Topics: Adult; Arthritis, Rheumatoid; Female; Hidradenitis Suppurativa; Humans; Janus Kinase Inhibitors; Keratoacanthoma; Melanoma; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Psoriasis; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Vitiligo | 2020 |
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Cost-Benefit Analysis; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Treatment Outcome | 2020 |
Relative efficacy and safety of tofacitinib for treating psoriasis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Humans; Network Meta-Analysis; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Biological Therapies for Atopic Dermatitis: A Systematic Review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azetidines; Biological Products; Carbamates; Clinical Trials as Topic; Dermatitis, Atopic; Dermatologic Agents; Heterocyclic Compounds, 3-Ring; Humans; Nitriles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2021 |
Comparison of the efficacy and safety of tofacitinib and mavrilimumab in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Topics: Adamantane; Colitis; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Niacinamide; Piperidines; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2021 |
Tofacitinib in paediatric dermatoses: a narrative review.
Topics: Alopecia Areata; Child; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2022 |
Real-world evidence of tofacitinib in rheumatoid arthritis patients in Spain.
Topics: Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Spain; Treatment Outcome | 2022 |
Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective.
Topics: Aged; Biosimilar Pharmaceuticals; Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2022 |
Review article: guide to tofacitinib dosing in patients with ulcerative colitis.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Recurrence | 2022 |
Efficacy and safety of tofacitinib for treatment of alopecia areata in children: A systematic review and meta-analysis.
Topics: Alopecia Areata; Child; Humans; Piperidines; Pyrroles | 2022 |
Tofacitinib experience in patients with enteropathic arthritis.
Topics: Colitis, Ulcerative; Gastrointestinal Diseases; Humans; Inflammatory Bowel Diseases; Janus Kinases; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Spondylarthritis; STAT Transcription Factors | 2023 |
158 trial(s) available for pyrroles and tofacitinib
| Article | Year |
|---|---|
Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Graft Survival; Humans; Janus Kinase 3; Kidney Transplantation; Lymphocytes; Male; Middle Aged; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Transplantation, Homologous | 2008 |
The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients.
Topics: Cell Proliferation; Cells, Cultured; Female; Gene Expression Regulation; Health; Humans; Immune System; Interferon-gamma; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Janus Kinase 3; Kidney Transplantation; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes; Transplantation, Homologous | 2009 |
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.
Topics: Adult; Biopsy; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Middle Aged; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2009 |
Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers.
Topics: Administration, Oral; Adult; Double-Blind Method; Glomerular Filtration Rate; Humans; Immunosuppressive Agents; Iohexol; Janus Kinase 3; Kidney; Kidney Function Tests; Male; Middle Aged; p-Aminohippuric Acid; Piperidines; Placebos; Pyrimidines; Pyrroles; Renal Plasma Flow, Effective | 2009 |
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
Topics: Arthritis, Rheumatoid; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; International Cooperation; Janus Kinases; Male; Middle Aged; Nausea; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2009 |
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Janus Kinase 3; Male; Middle Aged; Pain; Pain Measurement; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recovery of Function; Treatment Outcome | 2010 |
Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Biopsy; Calcineurin Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Humans; Immunosuppressive Agents; Janus Kinases; Kaplan-Meier Estimate; Kidney; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Piperidines; Pyrimidines; Pyrroles; Tacrolimus; Transplantation, Homologous; Young Adult | 2009 |
Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients.
Topics: Animals; Blotting, Western; Cell Division; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Immunosuppressive Agents; Janus Kinase 3; Kidney Transplantation; Killer Cells, Natural; Monitoring, Physiologic; Mycophenolic Acid; Piperidines; Placebos; Prednisolone; Primates; Pyrimidines; Pyrroles; Rodentia; Safety; STAT5 Transcription Factor; T-Lymphocytes | 2009 |
A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Neutropenia; Piperidines; Pyrimidines; Pyrroles; Time Factors | 2010 |
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2010 |
The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells.
Topics: CD4-Positive T-Lymphocytes; Female; Humans; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Kidney Transplantation; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; STAT5 Transcription Factor; T-Lymphocytes; T-Lymphocytes, Regulatory | 2010 |
Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients.
Topics: Adult; Area Under Curve; Dose-Response Relationship, Drug; Drug Therapy, Combination; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Models, Biological; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Tacrolimus | 2010 |
A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participants.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Humans; Janus Kinase 3; Long QT Syndrome; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Systole; Young Adult | 2011 |
Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Topics: Adult; Antibodies, Monoclonal; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunomodulation; Janus Kinase 3; Longitudinal Studies; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2011 |
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Topics: Adalimumab; Administration, Oral; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Substitution; Drug Tolerance; Female; Health Status; Humans; Injections, Subcutaneous; Janus Kinase 3; Joints; Male; Methotrexate; Middle Aged; Pilot Projects; Piperidines; Pyrimidines; Pyrroles; Recovery of Function | 2012 |
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Topics: Adult; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Female; GABA Modulators; Half-Life; Humans; Janus Kinases; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Young Adult | 2012 |
In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Isoenzymes; Janus Kinase 3; Mice; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2012 |
Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Topics: Cyclosporine; Double-Blind Method; Dry Eye Syndromes; Female; Humans; Janus Kinase 3; Male; Middle Aged; Ophthalmic Solutions; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Surveys and Questionnaires; Tears; Treatment Outcome | 2012 |
Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
Topics: Administration, Topical; Conjunctiva; Cyclosporine; Cytokines; Dry Eye Syndromes; Female; Flow Cytometry; HLA-DR1 Antigen; Humans; Janus Kinase 3; Male; Middle Aged; Ophthalmic Solutions; Piperidines; Pyrimidines; Pyrroles; Tears | 2012 |
Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.
Topics: Adult; Female; Humans; Immunosuppressive Agents; Janus Kinase 3; Kidney Transplantation; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2012 |
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
Topics: Activities of Daily Living; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Janus Kinase 3; Least-Squares Analysis; Leukocyte Count; Male; Middle Aged; Neutrophils; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2012 |
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Janus Kinase 3; Least-Squares Analysis; Leukocyte Count; Lipoproteins; Male; Methotrexate; Middle Aged; Neutrophils; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Topics: Administration, Oral; Adult; Colitis, Ulcerative; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinases; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction | 2012 |
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Topics: Administration, Oral; Adult; Chronic Disease; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinase 3; Male; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Topics: Antibodies, Monoclonal; Basiliximab; Cyclosporine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Interleukin-15; Interleukin-2; Interleukin-7; Janus Kinases; Kidney Transplantation; Lymphocyte Activation; Lymphocyte Count; Lymphocytes; Netherlands; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Interleukin-2; Recombinant Fusion Proteins; Signal Transduction; STAT5 Transcription Factor; Tacrolimus; Time Factors; Treatment Outcome | 2012 |
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Topics: Adult; Double-Blind Method; Female; Humans; Janus Kinase 3; Male; Middle Aged; Patient Outcome Assessment; Patient Satisfaction; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2014 |
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Janus Kinases; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Pain Measurement; Piperidines; Pyrimidines; Pyrroles; Recurrence; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Resistance; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Motor Activity; Piperidines; Pyrimidines; Pyrroles; Radiography; Treatment Outcome | 2013 |
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Topics: Administration, Cutaneous; Adult; Aged; Chronic Disease; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ointments; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2013 |
Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.
Topics: Double-Blind Method; Factor Analysis, Statistical; Humans; Pain Measurement; Physicians; Piperidines; Protein Kinase Inhibitors; Psoriasis; Psychometrics; Pyrimidines; Pyrroles; Quality of Life; Reproducibility of Results; Severity of Illness Index | 2013 |
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
Topics: Adolescent; Adult; Aged; Basophils; Blood Cell Count; Chronic Disease; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Hematocrit; Hemoglobins; Humans; Killer Cells, Natural; Leukocytes; Male; Middle Aged; Monocytes; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Young Adult | 2013 |
Tofacitinib prevents radiographic progression in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiography; Severity of Illness Index; Treatment Outcome | 2013 |
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2013 |
Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.
Topics: Animals; Arthritis, Experimental; Double-Blind Method; Drug Evaluation, Preclinical; Humans; Janus Kinase 1; Janus Kinase 3; Male; Mice; Mice, Inbred DBA; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pruritus; Psoriasis; Psychometrics; Pyrimidines; Pyrroles; Reproducibility of Results; Treatment Outcome | 2015 |
Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
Topics: Adult; Aged; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Cell Proliferation; Double-Blind Method; Female; Humans; In Vitro Techniques; Infections; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Severity of Illness Index; Treatment Outcome | 2014 |
A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
Topics: Adult; Animals; Blood Chemical Analysis; C-Reactive Protein; Crohn Disease; Feces; Female; Humans; Janus Kinases; Leukocyte L1 Antigen Complex; Male; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2014 |
Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; C-Reactive Protein; Double-Blind Method; Down-Regulation; Female; Humans; Interleukin-6; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Serum Amyloid A Protein | 2014 |
Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses.
Topics: Double-Blind Method; Humans; Piperidines; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2015 |
Tofacitinib versus methotrexate in rheumatoid arthritis.
Topics: Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Herpes Zoster; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Inflammation; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Self Report; Treatment Outcome | 2015 |
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chemokines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 1; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RNA, Messenger; Signal Transduction; STAT Transcription Factors; Synovial Membrane; Treatment Outcome | 2015 |
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Chronic Disease; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Outcome Assessment; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Retreatment; Treatment Outcome; Young Adult | 2015 |
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Biomarkers; Cholesterol; Female; Healthy Volunteers; Humans; Hungary; Lipoproteins; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2015 |
Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Follow-Up Studies; Humans; Janus Kinase 3; Japan; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2015 |
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Topics: Colitis, Ulcerative; Colonoscopy; Humans; Patient Preference; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Remission Induction; Self Report; Severity of Illness Index | 2015 |
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza Vaccines; Influenza, Human; Male; Methotrexate; Middle Aged; Piperidines; Pneumococcal Infections; Pneumococcal Vaccines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2016 |
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2015 |
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
Topics: Adult; C-Reactive Protein; Cytomegalovirus; DNA, Viral; Dose-Response Relationship, Drug; Female; Herpesvirus 4, Human; Humans; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Viral Load | 2015 |
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Receptors, Tumor Necrosis Factor; Treatment Outcome | 2015 |
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2015 |
Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.
Topics: Adult; Aged; Female; Humans; Male; Medication Adherence; Middle Aged; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Research Design; Self Care; Severity of Illness Index | 2015 |
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
Topics: Administration, Oral; Adult; Area Under Curve; Biomarkers; Colitis, Ulcerative; Colonoscopy; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Feces; Female; Follow-Up Studies; Humans; Leukocyte L1 Antigen Complex; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; ROC Curve; Severity of Illness Index; Treatment Outcome; Young Adult | 2016 |
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Self Report; Surveys and Questionnaires; Treatment Outcome | 2015 |
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Japan; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2016 |
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Arthritis, Psoriatic; Double-Blind Method; Female; Herpes Zoster; Humans; Japan; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Male; Methotrexate; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index; Treatment Outcome | 2016 |
Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.
Topics: Adult; Cross-Over Studies; Delayed-Action Preparations; Diet, High-Fat; Dietary Fats; Drug Administration Schedule; Drug Compounding; Food-Drug Interactions; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitati
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Bone Marrow; Bone Marrow Diseases; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Hand; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Synovitis; Treatment Outcome; Wrist Joint | 2016 |
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Biopsy; Double-Blind Method; Drug Administration Schedule; Female; Humans; Keratinocytes; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Signal Transduction; Skin; Treatment Outcome; Young Adult | 2016 |
Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Double-Blind Method; Drug Administration Schedule; Female; Half-Life; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; New Jersey; Piperidines; Pyrimidines; Pyrroles; Texas; Young Adult | 2015 |
The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
Topics: Administration, Oral; Adult; Area Under Curve; Biotransformation; Cytochrome P-450 CYP2C19; Female; Florida; Genotype; Humans; Janus Kinase Inhibitors; Liver; Liver Diseases; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index | 2014 |
Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.
Topics: Administration, Oral; Adult; Area Under Curve; Belgium; Drug Interactions; Female; Healthy Volunteers; HEK293 Cells; Humans; Janus Kinase Inhibitors; Kidney Tubules; Male; Metformin; Middle Aged; Organic Cation Transporter 2; Piperidines; Pyrimidines; Pyrroles; Renal Elimination; Transfection; Young Adult | 2014 |
Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Asian People; China; Drug Administration Schedule; Female; Half-Life; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Male; Metabolic Clearance Rate; Models, Biological; Piperidines; Pyrimidines; Pyrroles; Young Adult | 2015 |
Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.
Topics: Adult; Area Under Curve; Contraceptives, Oral, Combined; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Half-Life; Humans; Levonorgestrel; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2016 |
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
Topics: Aged; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2016 |
Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Double-Blind Method; Female; Humans; Male; Patient Satisfaction; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Surveys and Questionnaires; Treatment Outcome | 2016 |
Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
Topics: Chronic Disease; Dermatologic Agents; Etanercept; Humans; Patient Satisfaction; Piperidines; Placebos; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Substitution; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
Topics: Adolescent; Adult; Dermatitis, Atopic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ointments; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2016 |
Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Topics: Administration, Oral; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Psoriasis; Pyrimidines; Pyrroles; ROC Curve; Severity of Illness Index; Treatment Outcome | 2017 |
Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recovery of Function; Remission Induction; Time Factors; Treatment Outcome | 2017 |
Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
Topics: Chronic Disease; Dermatologic Agents; Double-Blind Method; Humans; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index | 2017 |
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
Topics: Adult; Female; Humans; Male; Middle Aged; Pain; Patient Satisfaction; Piperidines; Protein Kinase Inhibitors; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index | 2016 |
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinases; Male; Middle Aged; Ointments; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Young Adult | 2016 |
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Regression Analysis; Surveys and Questionnaires; Treatment Outcome | 2017 |
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Spondylitis, Ankylosing; Treatment Outcome | 2017 |
Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Dermatologic Agents; Humans; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Topics: Adult; C-Reactive Protein; Crohn Disease; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Severity of Illness Index | 2017 |
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.
Topics: Administration, Oral; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Models, Biological; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Nail Diseases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2017 |
Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cost of Illness; Double-Blind Method; Drug Therapy, Combination; Female; Health Expenditures; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Return to Work; Risk Factors; Treatment Outcome | 2017 |
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Topics: Adult; Chi-Square Distribution; Colitis, Ulcerative; Double-Blind Method; Female; Humans; Induction Chemotherapy; Janus Kinases; Maintenance Chemotherapy; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction | 2017 |
Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in Japanese.
Topics: Adult; Asian People; Cross-Over Studies; Female; Healthy Volunteers; Humans; Male; Middle Aged; Models, Theoretical; Pharmacogenomic Variants; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; White People; Young Adult | 2017 |
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Asian People; China; Double-Blind Method; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Republic of Korea; Severity of Illness Index; Taiwan; Treatment Outcome | 2017 |
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Topics: Adalimumab; Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2017 |
Serum Human Beta-Defensin-2 Is a Possible Biomarker for Monitoring Response to JAK Inhibitor in Psoriasis Patients.
Topics: Adult; Aged; beta-Defensins; Biomarkers; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; ROC Curve; Severity of Illness Index | 2017 |
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
Topics: Adult; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2017 |
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
Topics: Aged; Antibodies, Viral; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Enzyme-Linked Immunospot Assay; Female; Herpes Zoster; Herpes Zoster Vaccine; Herpesvirus 3, Human; Humans; Immunogenicity, Vaccine; Immunoglobulin G; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes | 2017 |
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
Topics: Adult; Aged; Cardiovascular Diseases; Cytokines; Etanercept; Female; Humans; Inflammation; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Proteomics; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome; Young Adult | 2018 |
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Topics: Adult; Colitis, Ulcerative; Double-Blind Method; Female; Humans; Induction Chemotherapy; Janus Kinase Inhibitors; Maintenance Chemotherapy; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Surveys and Questionnaires; Time Factors | 2018 |
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Topics: Administration, Oral; Adult; Alanine Transaminase; Antirheumatic Agents; Arthritis, Psoriatic; Aspartate Aminotransferases; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Failure; Tumor Necrosis Factor-alpha | 2017 |
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Topics: Adalimumab; Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Psoriatic; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2017 |
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2018 |
Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; China; Disability Evaluation; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Health Status; Humans; Male; Middle Aged; Pain Measurement; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Recovery of Function; Time Factors; Treatment Outcome; Young Adult | 2018 |
Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Topics: Adult; Aged; Anti-Inflammatory Agents; Colitis, Ulcerative; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastrointestinal Agents; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Models, Biological; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Severity of Illness Index; Treatment Outcome; Young Adult | 2018 |
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Topics: Adult; Alopecia Areata; Autoimmune Diseases; Biopsy; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Hair Follicle; Humans; Janus Kinase Inhibitors; Janus Kinases; Male; Middle Aged; Nitriles; Photography; Pilot Projects; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome; Young Adult | 2018 |
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Leukocytes; Lymphocyte Count; Male; Middle Aged; Phenotype; Piperidines; Pyrimidines; Pyrroles; T-Lymphocytes | 2018 |
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2018 |
Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.
Topics: Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Probability; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2019 |
Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients.
Topics: Adult; Disease Progression; Double-Blind Method; Female; Humans; Janus Kinase 3; Magnetic Resonance Imaging; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Spondylitis, Ankylosing; Thoracic Vertebrae; Treatment Outcome | 2018 |
Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
Topics: Double-Blind Method; Etanercept; Female; Humans; Immunosuppressive Agents; Interleukin-17; Linear Models; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Remission Induction; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2018 |
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
Topics: Administration, Oral; Adult; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome | 2018 |
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Colitis, Ulcerative; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; United States; Young Adult | 2018 |
Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Alopecia Areata; Female; Follow-Up Studies; Hair Follicle; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2018 |
Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; MicroRNAs; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Recurrence | 2018 |
Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Brazil; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Topics: Administration, Cutaneous; Alopecia; Clobetasol; Double-Blind Method; Glucocorticoids; Hair; Humans; Janus Kinase Inhibitors; Nitriles; Ointments; Pilot Projects; Piperidines; Prospective Studies; Pyrazoles; Pyrimidines; Pyrroles | 2018 |
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2018 |
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Psoriatic; Drug Delivery Systems; Female; Humans; Injections, Subcutaneous; Janus Kinase Inhibitors; Longitudinal Studies; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Asian People; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Surveys and Questionnaires; Young Adult | 2018 |
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
Topics: Adult; Aged; Colitis, Ulcerative; Colonoscopy; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome | 2019 |
Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning.
Topics: Adult; Dermatitis, Atopic; Double-Blind Method; Humans; Models, Biological; Ointments; Pediatrics; Piperidines; Pyrimidines; Pyrroles | 2019 |
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Topics: Administration, Oral; Adolescent; Adult; Alopecia; Alopecia Areata; Female; Hair; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Recurrence; Severity of Illness Index; Time Factors; Young Adult | 2019 |
Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
Topics: Adult; Crohn Disease; Female; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Psoriatic; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
Topics: Arthritis, Psoriatic; Biomarkers; Female; Humans; Male; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2019 |
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Psoriatic; C-Reactive Protein; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome | 2019 |
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Citrullinated Protein Antibodies; Arthritis, Rheumatoid; Biomarkers; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatoid Factor; Risk Factors; Treatment Outcome; Young Adult | 2019 |
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Herpes Zoster; Humans; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2019 |
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Herpes Zoster; Herpes Zoster Vaccine; Humans; Incidence; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2020 |
Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.
Topics: Adult; Autoantibodies; Dermatomyositis; Drug Therapy, Combination; Female; Glucocorticoids; Historically Controlled Study; Humans; Interferon-Induced Helicase, IFIH1; Janus Kinase Inhibitors; Lung Diseases, Interstitial; Male; Methylprednisolone; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2019 |
Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
.
Topics: Adolescent; Adult; Aged; Arthritis, Psoriatic; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Young Adult | 2019 |
Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Piperidines; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
Topics: Adult; Colitis, Ulcerative; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2020 |
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
Topics: Adalimumab; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2019 |
A pilot study of tofacitinib for refractory Behçet's syndrome.
Topics: Adult; Behcet Syndrome; Female; Humans; Male; Middle Aged; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2020 |
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Fatigue; Humans; Pain; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2022 |
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Topics: Adult; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2022 |
Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics.
Topics: Alopecia Areata; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
Topics: Adalimumab; Antirheumatic Agents; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Topics: Child; Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Remission Induction | 2022 |
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2022 |
An Evaluation of Efficacy and Safety of Tofacitinib, A JAK Inhibitor in the Management of Hospitalized Patients with Mild to Moderate COVID-19 - An Open-Label Randomized Controlled Study.
Topics: Adult; COVID-19; Humans; Immunomodulating Agents; Janus Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RNA, Viral; SARS-CoV-2; Treatment Outcome | 2022 |
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Treatment Outcome; United States | 2022 |
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Remission Induction | 2022 |
The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Fatigue; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Sleep; Treatment Outcome | 2022 |
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
Topics: Adult; Arthritis, Rheumatoid; Body Mass Index; Humans; Piperidines; Pyrimidines; Pyrroles | 2022 |
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antirheumatic Agents; Fatigue; Humans; Pain; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Spondylitis, Ankylosing; Treatment Outcome | 2022 |
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
Topics: Analgesics, Opioid; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Female; Humans; Lung Diseases; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha | 2022 |
Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.
Topics: Biomarkers; Endothelial Cells; Fibroblasts; Humans; Keratinocytes; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Scleroderma, Systemic; Treatment Outcome | 2022 |
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Topics: Colitis, Ulcerative; Herpes Zoster; Humans; Janus Kinase Inhibitors; Opportunistic Infections; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Treatment Outcome | 2023 |
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Humans; Prospective Studies; Proteomics; Pyrroles; Tumor Necrosis Factor Inhibitors; Venous Thromboembolism | 2022 |
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lung Neoplasms; Pyrroles; Risk Factors; Skin Neoplasms; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2023 |
Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2023 |
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.
Topics: Adalimumab; Arthritis, Psoriatic; Arthritis, Rheumatoid; Bayes Theorem; C-Reactive Protein; Humans; Inflammation; Pyrroles; Treatment Outcome | 2022 |
Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Humans; Piperidines; Pyrroles; Quality of Life; Treatment Outcome | 2023 |
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Double-Blind Method; Humans; Methotrexate; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
536 other study(ies) available for pyrroles and tofacitinib
| Article | Year |
|---|---|
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
Topics: Animals; Enzyme Inhibitors; Gene Expression Regulation; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Immunosuppressive Agents; Interleukin-2; Janus Kinase 3; Kidney Transplantation; Lymphocyte Activation; Lymphocyte Count; Lymphocyte Culture Test, Mixed; Lymphocyte Subsets; Macaca fascicularis; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Myocardium; Piperidines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Transplantation, Heterotopic; Transplantation, Homologous; Tumor Cells, Cultured | 2003 |
The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing.
Topics: Administration, Oral; Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Enzyme Inhibitors; Female; Graft Rejection; Graft Survival; Humans; Immune Tolerance; Immunosuppression Therapy; Interleukin-15; Janus Kinase 3; Killer Cells, Natural; Lectins, C-Type; Macaca fascicularis; Male; Piperidines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles | 2004 |
Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.
Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Drug Tolerance; Flow Cytometry; Graft Rejection; Graft Survival; Immunosuppression Therapy; Immunosuppressive Agents; Intracellular Signaling Peptides and Proteins; Janus Kinase 3; Kidney; Kidney Transplantation; Leukocyte Count; Lymphocytes; Macaca fascicularis; Piperidines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Time Factors; Transplantation, Homologous | 2005 |
Quantitative analysis of the immunosuppressant CP-690,550 in whole blood by column-switching high-performance liquid chromatography and mass spectrometry detection.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Monitoring; Immunosuppressive Agents; Janus Kinase 3; Macaca fascicularis; Male; Piperidines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2005 |
Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts.
Topics: Animals; Cell Proliferation; Immune System; Interferon-gamma; Interleukin-2; Janus Kinase 3; Kidney Transplantation; Killer Cells, Natural; Leukocyte Count; Lymphocyte Activation; Macaca fascicularis; Male; Piperidines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; T-Lymphocytes | 2005 |
Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates.
Topics: Animals; Graft Survival; Janus Kinase 3; Kidney Transplantation; Macaca fascicularis; Models, Animal; Mycophenolic Acid; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles | 2005 |
Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy.
Topics: Animals; Aorta; Arteriosclerosis; Chemokine CCL5; Hyperplasia; Interferon-gamma; Janus Kinase 3; Killer Cells, Natural; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Inbred ACI; Rats, Inbred Lew; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Transplantation, Homologous; Tunica Intima | 2006 |
Arthritis clinical trial results revealed.
Topics: Acetates; Antirheumatic Agents; Arthritis, Rheumatoid; Chondroitin Sulfates; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Osteoarthritis; Piperidines; Pyrimidines; Pyrroles | 2007 |
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cartilage, Articular; Collagen; Dose-Response Relationship, Drug; Enzyme Inhibitors; Interleukin-6; Janus Kinase 3; Male; Mice; Mice, Inbred DBA; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Inbred Lew | 2008 |
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; B-Lymphocytes; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Dose-Response Relationship, Drug; Eosinophils; Female; Flow Cytometry; Histocompatibility Antigens Class II; In Vitro Techniques; Interleukin-4; Janus Kinase 3; Mice; Mice, Inbred BALB C; Mice, Knockout; Ovalbumin; Piperidines; Pulmonary Eosinophilia; Pyrimidines; Pyrroles; Receptors, IgE; Th2 Cells | 2008 |
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Topics: Animals; Apoptosis; Blotting, Western; Bone Marrow; Cell Cycle; Cell Nucleus; Cell Proliferation; Cells, Cultured; Erythroid Precursor Cells; Erythropoietin; Flow Cytometry; Humans; Immunoprecipitation; Janus Kinase 2; Membrane Potential, Mitochondrial; Mice; Mutation; Phosphorylation; Piperidines; Polycythemia Vera; Protein Kinase Inhibitors; Protein Transport; Pyrimidines; Pyrroles; Receptors, Erythropoietin; Signal Transduction; STAT3 Transcription Factor | 2008 |
Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).
Topics: Chemistry, Pharmaceutical; Drug Design; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Janus Kinase 2; Kinetics; Models, Chemical; Models, Molecular; Molecular Conformation; Monte Carlo Method; Piperidines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Stereoisomerism | 2008 |
A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.
Topics: Binding Sites; Butadienes; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; ETS Translocation Variant 6 Protein; Genes, Reporter; High-Throughput Screening Assays; Humans; Immunosuppressive Agents; Janus Kinase 2; Janus Kinase 3; MAP Kinase Kinase Kinases; Nitriles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-ets; Pyrimidines; Pyrroles; Recombinant Fusion Proteins; Repressor Proteins; Reproducibility of Results; Response Elements; STAT5 Transcription Factor; Transfection; Tyrphostins | 2010 |
Kinase inhibitors attract attention as oral rheumatoid arthritis drugs.
Topics: Administration, Oral; Aminopyridines; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Humans; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles | 2010 |
Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.
Topics: Benzimidazoles; Binding Sites; Calorimetry; Enzyme Inhibitors; Humans; Janus Kinase 3; Kinetics; Models, Molecular; Piperidines; Protein Binding; Protein Structure, Tertiary; Pyridones; Pyrimidines; Pyrroles; TYK2 Kinase | 2010 |
CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.
Topics: Animals; Bone Marrow Cells; CD4-Positive T-Lymphocytes; Cell Differentiation; Cytokines; Dendritic Cells; Graft vs Host Disease; Interferon-gamma; Interleukin-2; Janus Kinase 3; Lymphocyte Activation; Lymphocyte Depletion; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; STAT3 Transcription Factor | 2010 |
Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model.
Topics: Animals; Antibodies, Monoclonal; Brain Ischemia; Disease Models, Animal; Humans; Immunologic Memory; Interleukin-12; Interleukin-17; Interleukin-23; Janus Kinase 3; Male; Mice; Mice, Inbred C57BL; Piperidines; Pyrimidines; Pyrroles; T-Lymphocytes | 2010 |
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
Topics: Animals; Autoimmune Diseases; Blood Proteins; Caco-2 Cells; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Cyclohexane Monoterpenes; Dogs; Female; Fibroblasts; Graft Rejection; Humans; In Vitro Techniques; Janus Kinases; Lymphocyte Activation; Macaca fascicularis; Male; Models, Molecular; Monoterpenes; Piperidines; Protein Binding; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; T-Lymphocytes; Tissue Distribution | 2010 |
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.
Topics: Adult; Animals; Cell Line, Tumor; Cell Proliferation; Cytokines; Enzyme Activation; Humans; In Vitro Techniques; Interleukin-15; Janus Kinase 3; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Experimental; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Paraparesis, Tropical Spastic; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; STAT5 Transcription Factor; T-Lymphocytes | 2011 |
Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
Topics: Cell Line; Cell Membrane Permeability; Crystallography, X-Ray; Humans; Immunosuppressive Agents; Indoles; Janus Kinase 1; Janus Kinase 3; Maleimides; Models, Molecular; Molecular Structure; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; STAT5 Transcription Factor; Structure-Activity Relationship | 2011 |
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
Topics: Adaptive Immunity; Animals; Arthritis, Experimental; Avian Proteins; Cells, Cultured; Chickens; Collagen Type II; Humans; Immunity, Innate; Janus Kinase 3; MAP Kinase Signaling System; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2011 |
Estimating transformations for repeated measures modeling of continuous bounded outcome data.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Janus Kinase 3; Models, Statistical; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2011 |
CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Benzimidazoles; Cells, Cultured; Culture Media, Conditioned; Drug Interactions; Fibroblasts; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Oncostatin M; p38 Mitogen-Activated Protein Kinases; Piperidines; Pyridones; Pyrimidines; Pyrroles; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; STAT5 Transcription Factor; Synovial Membrane | 2011 |
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Drug Industry; Humans; Immunosuppression Therapy; Janus Kinases; Piperidines; Pyrimidines; Pyrroles; Receptors, Cytokine; Signal Transduction | 2011 |
A case study of model-based Bayesian dose response estimation.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Humans; Longitudinal Studies; Nonlinear Dynamics; Piperidines; Pyrimidines; Pyrroles | 2011 |
Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium.
Topics: Acute-Phase Reaction; Arthritis, Rheumatoid; Cells, Cultured; Enzyme Inhibitors; Humans; Interleukin-6; Janus Kinase 2; Janus Kinase 3; Janus Kinases; Piperidines; Pyrimidines; Pyrroles; RNA, Messenger; Serum Amyloid A Protein; Signal Transduction; STAT3 Transcription Factor; Synovial Membrane | 2011 |
Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production.
Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; CD3 Complex; CD4-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Humans; Immunosuppression Therapy; Janus Kinase 3; Lymphocyte Activation; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; Receptors, Antigen, T-Cell; Signal Transduction; STAT Transcription Factors | 2011 |
IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Chronic Disease; Enzyme Inhibitors; Fibroblasts; Gene Expression; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Joints; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Osteoclasts; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; Signal Transduction; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha | 2011 |
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Autocrine Communication; Cells, Cultured; Chemokines; Drug Evaluation, Preclinical; Fibroblasts; Humans; Interferon Type I; Interleukin-6; Janus Kinase 3; Mice; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; STAT1 Transcription Factor; STAT3 Transcription Factor; Synovial Membrane; Tumor Necrosis Factor-alpha | 2012 |
The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
Topics: Animals; Cartilage, Articular; CD4-Positive T-Lymphocytes; Cell Proliferation; Humans; Interferon-gamma; Interleukin-17; Janus Kinase 3; Mice; Monocytes; Piperidines; Pyrimidines; Pyrroles; Synovial Membrane; Synovitis | 2012 |
Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Crotonates; Dihydroorotate Dehydrogenase; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Gastrointestinal Tract; Half-Life; Hydroxybutyrates; Hypercholesterolemia; Immunosuppressive Agents; Janus Kinases; Joints; Leukocyte Disorders; Male; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; p38 Mitogen-Activated Protein Kinases; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Splenomegaly; Toluidines; Weight Loss | 2012 |
Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.
Topics: Animals; Cell Differentiation; Encephalomyelitis, Autoimmune, Experimental; HEK293 Cells; Humans; Janus Kinase 3; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Smad2 Protein; STAT1 Transcription Factor; STAT3 Transcription Factor; STAT5 Transcription Factor; Th1 Cells; Th17 Cells; Th2 Cells | 2012 |
EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Catechin; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor | 2012 |
Risk of tuberculosis reactivation with tofacitinib (CP-690550).
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Immunologic Factors; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Piperidines; Pyrimidines; Pyrroles; Tuberculosis | 2012 |
[Anti-rheumatic effect of JAK-inhibitors].
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Mice; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2012 |
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Enzyme Activation; Female; Humans; Janus Kinase 3; Lymphoma, T-Cell; Male; Middle Aged; Mutation; Natural Killer T-Cells; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; RNA Interference; STAT5 Transcription Factor | 2012 |
[Janus kinase inhibitors].
Topics: Antirheumatic Agents; Drug Delivery Systems; Humans; Janus Kinases; Piperidines; Pyrimidines; Pyrroles; Rheumatic Diseases | 2012 |
Kinase inhibition--a new approach to the treatment of rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Enzyme Inhibitors; Female; Humans; Janus Kinase 3; Male; Piperidines; Pyrimidines; Pyrroles | 2012 |
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
Topics: Animals; Arthritis, Experimental; Bone Resorption; Cell Differentiation; Cells, Cultured; Disease Models, Animal; Female; Humans; Janus Kinases; Macrophages; Monocytes; Osteoclasts; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RANK Ligand; Rats; Rats, Inbred Lew; Signal Transduction; T-Lymphocytes | 2012 |
Tofacitinib for the treatment of moderate to severe rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Interactions; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index | 2012 |
Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.
Topics: Animals; Arthritis, Rheumatoid; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Humans; In Vitro Techniques; Inflammation; Interleukin-6; Janus Kinases; Macrophages; Mice; Mice, Inbred C57BL; NF-kappa B; NFATC Transcription Factors; Nitriles; Piperidines; Proto-Oncogene Proteins c-jun; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; STAT1 Transcription Factor; Synovial Membrane; Tumor Necrosis Factor-alpha | 2012 |
FDA approves tofacitinib for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Approval; Humans; Piperidines; Pyrimidines; Pyrroles; United States; United States Food and Drug Administration | 2012 |
Therapeutics: Silencing psoriasis.
Topics: Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Dermatologic Agents; Humans; Interleukin-17; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Recombinant Fusion Proteins; Thalidomide; Ustekinumab | 2012 |
Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease.
Topics: Animals; Celiac Disease; Disease Models, Animal; Female; Humans; Immunophenotyping; Interleukin-15; Intestine, Small; Janus Kinases; Killer Cells, Natural; Lymphocyte Subsets; Mice; Mice, Transgenic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Spleen; Time Factors | 2013 |
Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling.
Topics: Abatacept; Adult; Cytokines; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Humans; Immunoconjugates; Immunosuppressive Agents; In Vitro Techniques; Middle Aged; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Sirolimus; T-Lymphocytes; Tacrolimus; Th1 Cells; Th2 Cells; Transcriptome | 2013 |
Kinase inhibition in rheumatoid arthritis: a big advance?
Topics: Arthritis, Rheumatoid; Female; Humans; Janus Kinases; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market.
Topics: Arthritis, Rheumatoid; Drug Costs; Drug Industry; Humans; Janus Kinases; National Institutes of Health (U.S.); Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; United States | 2013 |
RA gets first oral agent to compete with biologics.
Topics: Administration, Oral; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical Trials, Phase III as Topic; Drug Approval; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Therapeutic Equivalency; United States; United States Food and Drug Administration | 2013 |
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Line; Cell Survival; Cells, Cultured; Humans; Interleukin-10; Janus Kinase 3; Leukocytes, Mononuclear; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Piperidines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles; RNA Interference; Signal Transduction; STAT1 Transcription Factor; TYK2 Kinase; Tyrphostins | 2013 |
Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Dermatitis, Allergic Contact; Ear; Female; Hyperplasia; Janus Kinases; Oxazolone; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Skin | 2013 |
Tofacitinib and other kinase inhibitors in the treatment of psoriasis.
Topics: Humans; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2013 |
Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells.
Topics: Cell Movement; Cell Proliferation; Cells, Cultured; Concanavalin A; Enzyme Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Janus Kinases; Macrophage Colony-Stimulating Factor; Matrix Metalloproteinase 1; Mesenchymal Stem Cells; Neovascularization, Physiologic; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Toll-Like Receptor 2; Toll-Like Receptor 6; Transcription, Genetic; TYK2 Kinase; Tyrphostins | 2013 |
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 3; Lymphoma, Extranodal NK-T-Cell; Male; Mice; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
New drugs 2013, part 2.
Topics: Acetanilides; Adrenergic beta-Agonists; Anti-Asthmatic Agents; Anti-Retroviral Agents; Bronchodilator Agents; Citrates; Crotonates; Drug Approval; Humans; Hydroxybutyrates; Immunosuppressive Agents; Laxatives; Nitriles; Organometallic Compounds; Peptides; Picolines; Piperidines; Pyrimidines; Pyrroles; Quinolones; Receptors, Guanylate Cyclase-Coupled; Thiazoles; Toluidines; Tropanes | 2013 |
Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma.
Topics: Abatacept; B-Lymphocytes; Calcineurin Inhibitors; Cell- and Tissue-Based Therapy; Delayed Graft Function; Graft Rejection; Histocompatibility Testing; Humans; Immune Tolerance; Immunoconjugates; Immunosuppression Therapy; Janus Kinase 3; Kidney Transplantation; Organ Transplantation; Piperidines; Protein Kinase C; Pyrimidines; Pyrroles; T-Lymphocytes | 2013 |
Systemics to topicals in psoriasis: the unfilled need.
Topics: Dermatologic Agents; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2013 |
Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Rα.
Topics: Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Humans; Insulin-Secreting Cells; Interleukin-15; Interleukin-15 Receptor alpha Subunit; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Transgenic; Piperidines; Pyrimidines; Pyrroles; Signal Transduction | 2013 |
Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Topics: Arthritis, Rheumatoid; Fibroblasts; Humans; Janus Kinases; Oncostatin M; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Synovial Fluid; Synovial Membrane | 2013 |
The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Topics: B7-1 Antigen; B7-2 Antigen; Cell Differentiation; Dendritic Cells; Humans; Interleukin-1beta; Interleukin-6; Janus Kinase 3; Lymphocyte Activation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2014 |
Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2013 |
Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Half-Life; Humans; Janus Kinases; Kidney Diseases; Kidney Failure, Chronic; Liver; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Renal Dialysis | 2014 |
Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib.
Topics: Administration, Oral; Animals; Bone Marrow; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Chemokines; Cytokines; Dermatitis; Gene Expression Regulation; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-2; Keratinocytes; Mice; Mice, Inbred C57BL; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages.
Topics: Animals; Cell Line; Cyclooxygenase 2; Dinoprostone; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Hydroxyprostaglandin Dehydrogenases; Interleukin-10; Interleukin-6; Intramolecular Oxidoreductases; Janus Kinases; Macrophages; Matrix Metalloproteinase 9; Mice; Models, Biological; Piperidines; Prostaglandin-E Synthases; Pyrimidines; Pyrroles | 2014 |
Effects of sulfasalazine and tofacitinib on the protein profile of articular chondrocytes.
Topics: Aged; Cartilage, Articular; Chondrocytes; Female; Humans; Interleukin-1beta; Male; Piperidines; Pyrimidines; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulfasalazine | 2014 |
Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity.
Topics: Adaptive Immunity; Administration, Topical; Animals; CD11b Antigen; Cell Movement; Cytokines; Disease Models, Animal; Dry Eye Syndromes; Female; Flow Cytometry; Gene Expression Regulation; Janus Kinase 3; Keratitis; Leukocyte Common Antigens; Leukocytes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Ophthalmic Solutions; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Chemokine | 2014 |
Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
Topics: Drug Design; HeLa Cells; Humans; Janus Kinase 3; Models, Molecular; Molecular Probes; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors | 2014 |
Fate of lymphocytes after withdrawal of tofacitinib treatment.
Topics: Antigens, CD; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Drug Administration Schedule; Humans; Janus Kinase 3; Killer Cells, Natural; Lymphocyte Activation; Lymphocyte Count; Phytohemagglutinins; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.
Topics: Animals; Cells, Cultured; HIV Infections; HIV-1; Humans; Janus Kinase 1; Janus Kinase 2; Lymphocytes; Macaca mulatta; Macrophages; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Virus Replication | 2014 |
Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo.
Topics: Animals; Bone Resorption; Cell Differentiation; Cells, Cultured; Interleukin-6; Macrophages; Mice; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Osteoprotegerin; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Pyrimidines; Pyrroles; RANK Ligand; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha | 2014 |
The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Feces; Female; Humans; Janus Kinases; Liver; Magnetic Resonance Spectroscopy; Male; Metabolic Clearance Rate; Microsomes, Liver; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Tandem Mass Spectrometry | 2014 |
Inhibition of TAK1 and/or JAK can rescue impaired chondrogenic differentiation of human mesenchymal stem cells in osteoarthritis-like conditions.
Topics: Adult; Cartilage, Articular; Cell Differentiation; Chondrogenesis; Fetus; Humans; Janus Kinases; MAP Kinase Kinase Kinases; Mesenchymal Stem Cells; Osteoarthritis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Zearalenone | 2014 |
In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection.
Topics: Animals; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chronic Disease; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Janus Kinase 3; Killer Cells, Natural; Macaca mulatta; Piperidines; Pyrimidines; Pyrroles; Simian Acquired Immunodeficiency Syndrome; Viral Load | 2014 |
[A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chronic Disease; Drug Approval; Humans; Inflammation; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Switzerland | 2014 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, Type A; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Depression; Dermatitis, Atopic; Food Hypersensitivity; Humans; Immunologic Factors; Ivermectin; Phosphodiesterase Inhibitors; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinoxalines; Skin Diseases; Societies, Medical; Thalidomide; Triazoles; United States | 2014 |
Recent trends in orthopedic surgery aiming to improve quality of life for those with rheumatoid arthritis: data from a large observational cohort.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cohort Studies; Databases, Factual; Female; Humans; Japan; Joints; Male; Orthopedic Procedures; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Tacrolimus | 2014 |
A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 3; Lymphoma, Large B-Cell, Diffuse; Mediastinal Neoplasms; Molecular Targeted Therapy; Mutation; Piperidines; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Stem Cell Transplantation; Transplantation, Homologous; Vincristine | 2014 |
Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.
Topics: ADP Ribose Transferases; Animals; Antibody Formation; B-Lymphocytes; Bacterial Toxins; Exotoxins; Female; Germinal Center; Hemocyanins; Immunoglobulin G; Immunoglobulin M; Immunotoxins; Janus Kinases; Mice; Mice, Inbred BALB C; Piperidines; Protein Kinase Inhibitors; Pseudomonas aeruginosa Exotoxin A; Pyrimidines; Pyrroles; Virulence Factors | 2014 |
Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
Topics: Adult; Alopecia; Dose-Response Relationship, Drug; Humans; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Herpes Zoster; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2014 |
Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.
Topics: Apoenzymes; Carbazoles; Crystallography, X-Ray; Furans; Humans; Ligands; Piperidines; Protein Conformation; Protein Kinase C; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.
Topics: Binding Sites; Hydrogen Bonding; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2014 |
Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro.
Topics: B-Lymphocytes; Cell Differentiation; Humans; Immunoglobulin Class Switching; In Vitro Techniques; Janus Kinase 3; Lymphocyte Activation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Cyclohexylamines; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrroles; RNA, Small Interfering; Signal Transduction; Structure-Activity Relationship; Thiazoles | 2015 |
JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Topics: Acute Disease; Animals; Cell Transformation, Neoplastic; Disease Models, Animal; Enzyme Activation; Janus Kinase 1; Janus Kinase 3; Leukemia, T-Cell; Male; Mice; Mice, Inbred BALB C; Mutation; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; T-Lymphocytes | 2014 |
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles | 2014 |
Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.
Topics: Drug Design; Humans; Janus Kinase 3; Models, Molecular; Molecular Conformation; Molecular Structure; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2014 |
A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study.
Topics: Animals; Chromatography, High Pressure Liquid; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2015 |
White-to-brown metabolic conversion of human adipocytes by JAK inhibition.
Topics: Adipocytes, Brown; Adipocytes, White; Animals; Bone Morphogenetic Protein 7; Cell Differentiation; Cells, Cultured; Gene Expression Profiling; Hedgehog Proteins; Humans; Interferon-gamma; Ion Channels; Janus Kinase 1; Janus Kinase 3; Male; Mice; Mice, Inbred C57BL; Mitochondria; Mitochondrial Proteins; Obesity; Oxazines; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; STAT1 Transcription Factor; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha; Uncoupling Protein 1; Veratrum Alkaloids | 2015 |
Effects of tofacitinib on nucleic acid metabolism in human articular chondrocytes.
Topics: Aged; Aged, 80 and over; AMP Deaminase; Blotting, Western; Cells, Cultured; Chondrocytes; Female; Gene Expression Regulation; Humans; Janus Kinase 3; Male; Nucleic Acids; Osteoarthritis, Knee; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA | 2015 |
Rheumatoid arthritis in 2014: Exciting times for RA research.
Topics: Animals; Arthritis, Rheumatoid; Disease Models, Animal; Humans; Inflammation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes, Regulatory | 2015 |
Detection of Xeljanz enantiomers in diethyl amine active pharmaceutical ingredients and tablets.
Topics: Chromatography, High Pressure Liquid; Diethylamines; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Stereoisomerism; Tablets | 2015 |
Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice.
Topics: Animals; Arthritis, Experimental; CD4-Positive T-Lymphocytes; Cell Differentiation; Dendritic Cells; Female; Mice; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2015 |
Development and validation of a RP-HPLC method for the quantitation of tofacitinib in rat plasma and its application to a pharmacokinetic study.
Topics: Animals; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Stability; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley | 2015 |
Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients.
Topics: Adult; Biopsy; Cyclosporine; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Graft Rejection; Humans; Immunosuppressive Agents; Kidney; Kidney Transplantation; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors | 2015 |
Super-enhancers delineate disease-associated regulatory nodes in T cells.
Topics: Animals; Arthritis, Rheumatoid; Basic-Leucine Zipper Transcription Factors; Cell Differentiation; Cell Lineage; Enhancer Elements, Genetic; Gene Expression Regulation; Genetic Predisposition to Disease; Janus Kinase 3; Mice; Mice, Inbred C57BL; p300-CBP Transcription Factors; Piperidines; Pyrimidines; Pyrroles; RNA, Untranslated; T-Lymphocytes, Helper-Inducer; Transcription, Genetic | 2015 |
Tofacitinib, a novel JAK3 inhibitor, as a potential cause of distal symmetric polyneuropathy.
Topics: Adult; Humans; Male; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2016 |
Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells.
Topics: Acetamides; Adalimumab; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dasatinib; Dose-Response Relationship, Drug; Humans; Inflammation Mediators; Interleukin-6; Interleukin-8; Macrophages; Monocytes; Naphthalenes; Oxazines; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; RNA, Small Interfering; Signal Transduction; Synovial Membrane; Tumor Necrosis Factor-alpha; Urea | 2015 |
JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis.
Topics: Actins; Animals; Apoptosis; Bone Marrow Transplantation; Cells, Cultured; Collagen Type I; Extracellular Matrix Proteins; Fibroblasts; Fibronectins; Fibrosis; Interleukin-13; Interleukin-4; Janus Kinase 3; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Myofibroblasts; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT6 Transcription Factor; Ureteral Obstruction | 2015 |
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Topics: Administration, Oral; Female; Humans; Janus Kinase 1; Janus Kinase 3; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Pigmentation; Treatment Outcome; Vitiligo | 2015 |
Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Antipruritics; Cytokines; Dermatitis, Allergic Contact; Disease Models, Animal; Female; Inflammation; Janus Kinases; Lymph Nodes; Mice; Mice, Inbred BALB C; Piperidines; Pruritus; Pyrimidines; Pyrroles; Skin; Sulfonamides | 2015 |
Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
Topics: Administration, Oral; Aggression; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Behavior, Animal; Brain; Dermatitis, Atopic; Disease Models, Animal; Female; Janus Kinases; Male; Mice, Inbred BALB C; Piperidines; Protein Kinase Inhibitors; Pruritus; Pyrimidines; Pyrroles; Stress, Psychological; Sulfonamides; Toluene 2,4-Diisocyanate | 2015 |
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.
Topics: Administration, Oral; Adolescent; Adult; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2015 |
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
Topics: Adult; Arthritis, Rheumatoid; Cost-Benefit Analysis; Female; Humans; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Republic of Korea; Severity of Illness Index; Surveys and Questionnaires | 2015 |
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Topics: Cell Line, Tumor; Genes, Tumor Suppressor; Humans; Janus Kinase 3; Lymphoma, T-Cell, Cutaneous; MicroRNAs; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Skin Neoplasms; STAT3 Transcription Factor; STAT5 Transcription Factor; Transfection | 2015 |
Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis.
Topics: Aged; Cryptococcosis; Humans; Lung Diseases; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2015 |
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.
Topics: bcl-X Protein; Cell Cycle; Cell Line, Tumor; Cyclin D1; Down-Regulation; Gene Expression; Humans; Imidazoles; Janus Kinases; Leukemia, Myeloid, Acute; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyrimidines; Pyrroles; Pyrrolidines; Sulfonamides | 2015 |
Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
Topics: Adult; Arthritis, Psoriatic; Cell Movement; Cells, Cultured; Female; Fibroblasts; Humans; Inflammation Mediators; Janus Kinase 3; Male; Middle Aged; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Synovial Membrane; Synovitis; Tissue Culture Techniques | 2016 |
Suppress for Success: A JAK Inhibitor for Adjunct Therapy of Tuberculosis.
Topics: Animals; Female; Humans; Piperidines; Pyrimidines; Pyrroles; Tuberculosis | 2015 |
Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis.
Topics: Animals; Cytokines; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred BALB C; Piperidines; Pyrimidines; Pyrroles; Tuberculosis | 2015 |
Binding of Janus kinase inhibitor tofacitinib with human serum albumin: multi-technique approach.
Topics: Calorimetry, Differential Scanning; Circular Dichroism; Humans; Hydrogen-Ion Concentration; Janus Kinases; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Serum Albumin; Spectrometry, Fluorescence; Structure-Activity Relationship; Thermodynamics | 2016 |
Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia.
Topics: Humans; Leukemia, Large Granular Lymphocytic; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Salvage Therapy; STAT3 Transcription Factor | 2015 |
Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome.
Topics: Animals; Body Weight; Caco-2 Cells; Cytokines; Diet, High-Fat; Disease Models, Animal; Genetic Predisposition to Disease; Glucose Tolerance Test; Humans; Immunity, Innate; Inflammation; Insulin; Janus Kinase 3; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Obesity; Organ Size; Piperidines; Pyrimidines; Pyrroles; Risk Factors; Signal Transduction; Toll-Like Receptors | 2015 |
Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).
Topics: Animals; Autoimmune Lymphoproliferative Syndrome; Disease Models, Animal; fas Receptor; Humans; Immunoglobulins; Janus Kinase 3; Mice; Mice, Inbred C57BL; Mice, Inbred MRL lpr; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2015 |
Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis.
Topics: Adult; Alopecia; Female; Humans; Janus Kinases; Male; Nail Diseases; Nails; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Appendectomy; Azathioprine; Colitis, Ulcerative; Cyclosporine; Drug Resistance; Drug Therapy, Combination; Fecal Microbiota Transplantation; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Infliximab; Leukapheresis; Mercaptopurine; Mesalamine; Methotrexate; New Zealand; Pediatrics; Piperidines; Proctocolectomy, Restorative; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Severity of Illness Index; Tacrolimus; Tumor Necrosis Factor-alpha | 2015 |
Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cyclohexylamines; Disease Models, Animal; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Immunophenotyping; Intracellular Signaling Peptides and Proteins; Janus Kinases; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Syk Kinase | 2015 |
Anti-inflammatory effect of topical administration of tofacitinib on corneal inflammation.
Topics: Administration, Topical; Animals; Cells, Cultured; Cornea; Corneal Neovascularization; Disease Models, Animal; Janus Kinase 3; Keratitis; Male; Mice; Mice, Inbred BALB C; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.
Topics: Cell Line, Tumor; Coculture Techniques; Enterotoxins; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin Receptor Common gamma Subunit; Interleukin-17; Lymphocyte Activation; Male; Neoplasm Proteins; Piperidines; Pyrimidines; Pyrroles; Sezary Syndrome; STAT3 Transcription Factor; T-Lymphocytes | 2016 |
Interaction of new kinase inhibitors cabozantinib and tofacitinib with human serum alpha-1 acid glycoprotein. A comprehensive spectroscopic and molecular Docking approach.
Topics: Anilides; Humans; Molecular Docking Simulation; Orosomucoid; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Pyrroles; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thermodynamics | 2016 |
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Janus Kinases; Male; Middle Aged; Patient Safety; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2016 |
Interspecies scaling of urinary excretory amounts of nine drugs belonging to different therapeutic areas with diverse chemical structures - accurate prediction of the human urinary excretory amounts.
Topics: Animals; Benzodiazepines; Carbamates; Carbazoles; Cephapirin; Humans; Indoles; Labetalol; Nevirapine; Olanzapine; Pharmaceutical Preparations; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Species Specificity; Voriconazole | 2017 |
Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Costs; Female; Humans; Male; Medication Adherence; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies | 2016 |
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Simplex; Herpes Zoster; Herpesviridae Infections; Humans; Incidence; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrimidines; Pyrroles; Risk Factors; Sex Factors | 2016 |
Elucidating the Mechanism of Tofacitinib Oxidative Decyanation.
Topics: Cytochrome P-450 Enzyme System; Humans; In Vitro Techniques; Microsomes, Liver; Oxidation-Reduction; Oxygen; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
Topics: Adult; Alopecia Areata; Biomarkers; Female; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin | 2016 |
Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment.
Topics: Administration, Oral; Adult; Dermatomyositis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple; Female; Follow-Up Studies; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sampling Studies; Severity of Illness Index; Treatment Outcome | 2016 |
Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes.
Topics: Antimetabolites, Antineoplastic; Cells, Cultured; Cytokines; Humans; Lymphocyte Activation; Lymphocytes; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Topics: Abatacept; Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Databases, Factual; Diverticulitis; Esophageal Perforation; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Incidence; Intestinal Perforation; Male; Medicare; Middle Aged; Peptic Ulcer; Piperidines; Prednisone; Proportional Hazards Models; Pyrimidines; Pyrroles; Risk Factors; Rituximab; Tumor Necrosis Factor-alpha; United States | 2016 |
Targeting the IFN-γ/CXCL10 pathway in lichen planus.
Topics: Chemokine CXCL10; Chemokine CXCL9; Enzyme Inhibitors; Humans; Inflammation; Interferon-gamma; Lichen Planus; Models, Theoretical; Piperidines; Promoter Regions, Genetic; Pyrimidines; Pyrroles; Signal Transduction; Skin; Treatment Outcome | 2016 |
JAK3-STAT pathway blocking benefits in experimental lupus nephritis.
Topics: Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Gene Expression Profiling; Janus Kinase 3; Lupus Nephritis; Mice; Mice, Inbred NZB; Piperidines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Transcriptome | 2016 |
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infant, Newborn; Methotrexate; Piperidines; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult | 2016 |
Efficacy of tofacitinib in treatment of alopecia universalis in two patients.
Topics: Adult; Alopecia; Humans; Male; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
Topics: Adolescent; Alopecia; Alopecia Areata; Arthritis, Psoriatic; Female; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retreatment | 2017 |
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.
Topics: Animals; Female; Lupus Erythematosus, Systemic; Mice; Mice, Inbred MRL lpr; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Vascular Diseases | 2017 |
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Topics: Arthritis, Rheumatoid; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Heart Failure; Humans; Hyperlipidemias; Hypertension; Incidence; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2016 |
The European League Against Rheumatism (EULAR) - 17th Annual European Congress of Rheumatology (June 8-11, 2016 - London, UK).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Humans; Piperidines; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology | 2016 |
Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Risk Assessment | 2017 |
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.
Topics: Adult; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Metabolic Syndrome; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides | 2016 |
Small Molecules for Psoriasis.
Topics: Acitretin; Administration, Oral; Dermatologic Agents; Evidence-Based Medicine; Humans; Piperidines; Psoriasis; PUVA Therapy; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Update on TNF Inhibitors.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Cardiovascular Diseases; Certolizumab Pegol; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dermatologic Agents; Etanercept; Humans; Infliximab; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha; Ustekinumab | 2016 |
Insights into kinetic mechanism of Janus kinase 3 and its inhibition by tofacitinib.
Topics: Adenosine Triphosphatases; Animals; Catalysis; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Insecta; Janus Kinase 3; Kinetics; Mutation; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sf9 Cells; Signal Transduction; Solvents; Viscosity | 2016 |
Tofacitinib for polyarteritis nodosa: a tailored therapy.
Topics: Adult; Biopsy, Needle; Computed Tomography Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Male; Molecular Targeted Therapy; Piperidines; Polyarteritis Nodosa; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Severity of Illness Index; STAT3 Transcription Factor; Time Factors; Treatment Outcome | 2016 |
Familial chilblain lupus due to a gain-of-function mutation in STING.
Topics: Adult; Blotting, Western; Chilblains; Family; Female; Greece; Humans; Interferon Type I; Interferon-beta; Lupus Erythematosus, Cutaneous; Male; Membrane Proteins; Microscopic Angioscopy; Molecular Docking Simulation; Mutation; Pedigree; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Skin | 2017 |
Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).
Topics: Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Piperidines; Protein Kinase C; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2016 |
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Humans; Models, Economic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; United States | 2016 |
A case of refractory dermatomyositis responsive to tofacitinib.
Topics: Azathioprine; Dermatomyositis; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Methotrexate; Middle Aged; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Retreatment; Treatment Failure; Treatment Outcome | 2017 |
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Topics: Adult; Aged; Alopecia Areata; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; United States; Young Adult | 2016 |
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
Topics: Adenoma; Animals; Hyperplasia; Leydig Cells; Male; Piperidines; Prolactin; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Signal Transduction; Testis | 2017 |
Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients.
Topics: Adult; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Case-Control Studies; CD3 Complex; Cells, Cultured; Class I Phosphatidylinositol 3-Kinases; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Inflammation Mediators; Interferon-gamma; Interleukin-13; Interleukin-17; Janus Kinase Inhibitors; Janus Kinases; Lung; Lymphocyte Activation; Male; Middle Aged; Molecular Targeted Therapy; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; T-Lymphocytes | 2016 |
Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Janus Kinase Inhibitors; Middle Aged; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
JAK inhibitors: A broadening approach in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biosimilar Pharmaceuticals; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Topics: Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Epstein-Barr Virus Infections; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Janus Kinase 3; Killer Cells, Natural; Lymphocyte Activation; Lymphoma, T-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT5 Transcription Factor; T-Lymphocytes; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors.
Topics: Amines; Cell Line; Humans; Janus Kinase 2; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2017 |
Impact of tofacitinib treatment on human B-cells in vitro and in vivo.
Topics: Antibody Formation; Arthritis, Rheumatoid; B-Lymphocytes; Cells, Cultured; Cytidine Deaminase; Humans; Immunoglobulin Class Switching; Immunomodulation; Interleukin Receptor Common gamma Subunit; Lymphocyte Activation; Lymphocyte Count; Piperidines; Plasma Cells; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2017 |
Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Topics: Adolescent; Alopecia; Alopecia Areata; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2017 |
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Topics: Adolescent; Adult; Aged; Alopecia; Alopecia Areata; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2017 |
Reversal of Alopecia Universalis by Tofacitinib: A Case Report.
Topics: Adult; Alopecia; Female; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Male; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2016 |
Next generation of small molecules in inflammatory bowel disease.
Topics: Administration, Oral; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Humans; Immunologic Factors; Indans; Inflammatory Bowel Diseases; Oxadiazoles; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Delayed-Action Preparations; Drug Administration Schedule; Drug Approval; Humans; Janus Kinases; Male; Metabolic Clearance Rate; Models, Animal; Models, Biological; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats, Sprague-Dawley; Therapeutic Equivalency; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Potential Involvement of the IL-6/JAK/STAT3 Pathway in the Pathogenesis of Intervertebral Disc Degeneration.
Topics: Adult; Aged; Animals; Annulus Fibrosus; Disease Models, Animal; Female; Humans; Interleukin-6; Intervertebral Disc Degeneration; Janus Kinases; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein | 2017 |
Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
Topics: Abatacept; Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Databases, Factual; Etanercept; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; United States | 2016 |
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
Topics: Adult; Aged; Female; Humans; Hypereosinophilic Syndrome; Janus Kinase Inhibitors; Male; Middle Aged; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Skin Diseases | 2017 |
Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor.
Topics: Animals; Bone Marrow Cells; Cell Differentiation; Colony-Forming Units Assay; Fibroblast Growth Factors; Fibroblasts; Gene Expression Regulation; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred CBA; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Tyrphostins | 2016 |
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction | 2017 |
Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Biosimilar Pharmaceuticals; Colitis, Ulcerative; Gastrointestinal Agents; Glucocorticoids; Humans; Immunosuppressive Agents; Infliximab; Integrins; Janus Kinases; Mercaptopurine; Mesalamine; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Tumor Necrosis Factor-alpha | 2016 |
JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa.
Topics: Apoptosis; Cell Line, Tumor; Dendritic Cells; Dose-Response Relationship, Drug; Gene Expression Regulation; Hepacivirus; Humans; Interferon-alpha; Interleukin-3; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles; STAT Transcription Factors; Virus Replication | 2017 |
Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro.
Topics: Apoptosis; B-Lymphocytes; CD40 Ligand; Cell Proliferation; Cells, Cultured; Humans; Immunosuppressive Agents; Interleukin-10; Interleukin-2; Interleukins; Janus Kinase 3; Leukocytes, Mononuclear; Lymphocyte Activation; Piperidines; Protein Kinase C; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sirolimus | 2016 |
A biophysical and computational study unraveling the molecular interaction mechanism of a new Janus kinase inhibitor Tofacitinib with bovine serum albumin.
Topics: Animals; Binding Sites; Biophysical Phenomena; Cattle; Circular Dichroism; Dynamic Light Scattering; Hydrogen Bonding; Janus Kinase Inhibitors; Models, Molecular; Molecular Docking Simulation; Piperidines; Protein Binding; Pyrimidines; Pyrroles; Serum Albumin, Bovine; Spectrometry, Fluorescence; Thermodynamics | 2017 |
Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Cell Count; Clinical Trials, Phase III as Topic; Fatigue; Female; Hemoglobins; Humans; Longitudinal Studies; Lymphocyte Count; Male; Middle Aged; Neutrophils; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173.
Topics: Child; Humans; Male; Membrane Proteins; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Vascular Diseases | 2017 |
Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance.
Topics: Animals; CD4 Lymphocyte Count; Cells, Cultured; Dendritic Cells; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Immune Tolerance; Immunotherapy, Adoptive; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells | 2016 |
Rheumatoid arthritis: TAK-ing the road to suppress inflammation in synovial fibroblasts.
Topics: Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Cytokines; Fibroblasts; Humans; Lactones; MAP Kinase Kinase Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Resorcinols; Synovial Membrane | 2017 |
Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
Topics: Animals; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Inflammation; Janus Kinases; Lipopolysaccharides; Lung; Male; Neutrophils; Phosphorylation; Piperidines; Pneumonia; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; STAT3 Transcription Factor | 2017 |
Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques.
Topics: Binding Sites; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Janus Kinase 3; Molecular Docking Simulation; Molecular Dynamics Simulation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quantitative Structure-Activity Relationship; Thermodynamics | 2017 |
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Herpes Zoster; Humans; Immunocompromised Host; Incidence; Infections; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Tuberculosis; Young Adult | 2017 |
Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Janus Kinase Inhibitors; Latin America; Long Term Adverse Effects; Male; Middle Aged; Patient Safety; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis.
Topics: Arthritis, Psoriatic; Humans; Inflammation; Interleukin-17; Interleukin-23; Janus Kinases; Piperidines; Pyrimidines; Pyrroles | 2017 |
Response to: 'Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis' by Raychaudhuri
Topics: Arthritis, Psoriatic; Humans; Inflammation; Interleukin-17; Interleukin-23; Janus Kinases; Piperidines; Pyrimidines; Pyrroles | 2017 |
Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Topics: Animals; Arthritis, Experimental; Autoimmune Diseases; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Isoenzymes; Janus Kinase 1; Janus Kinase 3; Monitoring, Immunologic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats | 2017 |
JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1.
Topics: Binding Sites; CD4 Antigens; CD4-Positive T-Lymphocytes; env Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Interleukin-2; Janus Kinases; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Pyrrolidines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Tetradecanoylphorbol Acetate; TOR Serine-Threonine Kinases; Virus Internalization; Virus Replication | 2017 |
Recovery of nail dystrophy potential new therapeutic indication of tofacitinib.
Topics: Adult; Alopecia; Female; Humans; Male; Nail Diseases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Comparative Effectiveness Research; Direct-to-Consumer Advertising; Herpes Zoster; Humans; Intestinal Perforation; Natural Language Processing; Piperidines; Pyrimidines; Pyrroles; Social Media | 2017 |
Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
Topics: Abatacept; Adalimumab; Age Factors; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Cost-Benefit Analysis; Drug Therapy, Combination; Etanercept; Humans; Infliximab; Models, Economic; Piperidines; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Severity of Illness Index; Sex Factors; Time Factors; Tumor Necrosis Factor-alpha; United States | 2017 |
Tracking JAKs in spondyloarthritis: rationale and expectations.
Topics: Humans; Motivation; Piperidines; Pyrimidines; Pyrroles; Spondylarthritis; Spondylitis, Ankylosing | 2017 |
Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis.
Topics: Administration, Oral; Adolescent; Alopecia; Child; Dermatologic Agents; Humans; Janus Kinase 1; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2017 |
Treatment of Alopecia Areata With Tofacitinib.
Topics: Adult; Alopecia Areata; Female; Follow-Up Studies; Hair; Humans; Male; Middle Aged; Piperidines; Polyps; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Scalp; Treatment Outcome; Young Adult | 2017 |
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Topics: Anaplastic Lymphoma Kinase; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokine Receptor gp130; Cytokines; Humans; Janus Kinase 1; Lymphoma, Large-Cell, Anaplastic; Mice; Nitriles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Cytokine; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Azetidines; Case-Control Studies; Cell Movement; Cells, Cultured; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-8; Janus Kinases; Male; Middle Aged; Neutrophils; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Reactive Oxygen Species; Respiratory Burst; Sulfonamides; Tetradecanoylphorbol Acetate; United Kingdom | 2017 |
Successful targeted treatment of mast cell activation syndrome with tofacitinib.
Topics: Adult; Biomarkers; Female; Humans; Mastocytosis; Middle Aged; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Symptom Assessment; Treatment Outcome | 2017 |
Facilitation of liver cancer SMCC7721 cell aging by sirtuin 4 via inhibiting JAK2/STAT3 signal pathway.
Topics: Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Doxorubicin; Humans; Janus Kinase 2; Liver Neoplasms; Mitochondrial Proteins; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; Sirtuins; STAT3 Transcription Factor; Tumor Suppressor Protein p53 | 2017 |
Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy.
Topics: Aged; Antiviral Agents; Arthritis, Rheumatoid; Cytomegalovirus Retinitis; Ganciclovir; Humans; Immunosuppressive Agents; Intravitreal Injections; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Uveitis | 2017 |
Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome; Withholding Treatment | 2017 |
Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; C-Reactive Protein; CD4-Positive T-Lymphocytes; Foot; Foot Joints; Forelimb; Hindlimb; Interferon-gamma; Interleukin-1beta; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spleen | 2017 |
Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2017 |
Jak3 deficiency blocks innate lymphoid cell development.
Topics: Animals; Arthritis, Rheumatoid; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cells, Cultured; Humans; Immunity, Innate; Interferon-gamma; Janus Kinase 3; Killer Cells, Natural; Mice; Mice, Mutant Strains; Mutation; Phenotype; Piperidines; Pyrimidines; Pyrroles; Severe Combined Immunodeficiency | 2018 |
IBD: Tofacitinib effective in ulcerative colitis.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2017 |
Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment.
Topics: Adult; Alopecia; Female; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Identification of related substances in tofacitinib citrate by LC-MS techniques for synthetic process optimization.
Topics: Chromatography, Liquid; Drug Stability; Piperidines; Pyrimidines; Pyrroles; Tandem Mass Spectrometry | 2017 |
Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma.
Topics: Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cell Differentiation; Cytokines; Desensitization, Immunologic; Disease Models, Animal; Humans; Janus Kinases; Mice; Mice, Inbred C57BL; Ovalbumin; Piperidines; Pyrimidines; Pyrroles | 2017 |
Image Gallery: Treatment of refractory alopecia universalis with oral tofacitinib citrate and adjunct intralesional triamcinolone injections.
Topics: Administration, Oral; Alopecia; Drug Therapy, Combination; Glucocorticoids; Humans; Injections, Intralesional; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Triamcinolone; Young Adult | 2017 |
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Diet, Atherogenic; Dose-Response Relationship, Drug; Foam Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2017 |
Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
Topics: Administration, Cutaneous; Adolescent; Alopecia Areata; Child, Preschool; Female; Humans; Janus Kinases; Male; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Skin Cream | 2017 |
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biological Products; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Orthopedics; Perioperative Care; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology; Societies, Medical; Spondylitis, Ankylosing; United States | 2017 |
Excellent response to tofacitinib treatment in a patient with alopecia universalis.
Topics: Alopecia; Female; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2017 |
Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.
Topics: Animals; Arthritis, Rheumatoid; Cholesterol; Diet, High-Fat; Dose-Response Relationship, Drug; Inflammation; Lipids; Macrophages; Male; Piperidines; Pyrimidines; Pyrroles; Rabbits; Structure-Activity Relationship | 2017 |
Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study.
Topics: Adult; Arthritis, Rheumatoid; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Taiwan; Virus Activation | 2018 |
Rheumatoid arthritis: JAK-ing up inadequate RA therapy.
Topics: Adalimumab; Arthritis, Rheumatoid; Double-Blind Method; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2017 |
Herpes zoster in psoriasis patients treated with tofacitinib.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Asian People; Biological Products; Etanercept; Female; Herpes Zoster; Hospitalization; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Piperidines; Proportional Hazards Models; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Young Adult | 2017 |
Inhibitory effect of JAK inhibitor on mechanical stress-induced protease expression by human articular chondrocytes.
Topics: ADAMTS4 Protein; ADAMTS5 Protein; Aggrecans; Cartilage, Articular; Cells, Cultured; Chondrocytes; Collagen Type II; Core Binding Factor Alpha 1 Subunit; Cytokines; Humans; Janus Kinase Inhibitors; Matrix Metalloproteinase 13; Mitogen-Activated Protein Kinases; Piperidines; Pyrimidines; Pyrroles; STAT3 Transcription Factor; Stress, Mechanical; Transcription Factor RelA | 2017 |
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis.
Topics: Administration, Oral; Adult; Animals; Arthritis, Rheumatoid; Candida albicans; Candidiasis; Disease Susceptibility; Female; Humans; Mice, Inbred BALB C; Neutrophil Activation; Neutrophils; Phagocytosis; Piperidines; Pyrimidines; Pyrroles; Risk Factors | 2017 |
GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis.
Topics: Adult; Azetidines; C-Reactive Protein; Clinical Trials as Topic; Colitis, Ulcerative; Humans; Janus Kinase 1; Leukocyte L1 Antigen Complex; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Triazoles | 2017 |
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Topics: Adult; Aged; Autoimmunity; Chemokine CXCL10; Chemokine CXCL9; Combined Modality Therapy; Female; Humans; Janus Kinase 1; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Severity of Illness Index; Skin Pigmentation; Ultraviolet Therapy; Vitiligo | 2017 |
Editorial: Herpes Zoster: Fear the Infection, Value the Solution.
Topics: Arthritis, Rheumatoid; Fear; Herpes Zoster; Humans; Piperidines; Pyrimidines; Pyrroles; Vaccination | 2017 |
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Clinical Trials as Topic; Databases, Factual; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucocorticoids; Herpes Zoster; Humans; Incidence; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Multivariate Analysis; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors | 2017 |
Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction.
Topics: Administration, Topical; Alopecia; Animals; Hair; Janus Kinase 3; Male; Mice; Mice, Inbred C57BL; Minoxidil; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Vascular Endothelial Growth Factor A | 2017 |
Rheumatoid arthritis: Reducing the risk of herpes zoster.
Topics: Arthritis, Rheumatoid; Herpes Zoster; Humans; Piperidines; Pyrimidines; Pyrroles; Vaccination | 2017 |
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.
Topics: Adult; Aged; Arthritis, Rheumatoid; Case-Control Studies; Female; Humans; Janus Kinase 3; Lymphoma; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2018 |
Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Inhibitory Concentration 50; Janus Kinase 3; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley | 2017 |
Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model.
Topics: Adjuvants, Immunologic; Animals; Arthritis; Bone and Bones; Bone Remodeling; Bone Resorption; Disease Models, Animal; Female; Osteocalcin; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Treatment Outcome; X-Ray Microtomography | 2018 |
Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series.
Topics: Administration, Oral; Adolescent; Adult; Alopecia Areata; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Republic of Korea; Retrospective Studies; Severity of Illness Index; Young Adult | 2017 |
Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol; Cohort Studies; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Single-Blind Method; Surveys and Questionnaires; Ultrasonography; Up-Regulation | 2017 |
Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
Topics: Adult; Alopecia Areata; Dermatitis, Atopic; Humans; Janus Kinase Inhibitors; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Th2 Cells; Treatment Outcome; Vitiligo | 2017 |
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Topics: Abatacept; Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Databases, Factual; Etanercept; Female; Humans; Infliximab; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Tumor Necrosis Factor-alpha | 2017 |
NICE issues positive recommendation for XELJANZ®▼(tofacitinib citrate) as a new treatment option for adults with severe rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Approval; Humans; Piperidines; Pyrimidines; Pyrroles; United Kingdom | 2017 |
Cellular and functional actions of tofacitinib related to the pathophysiology of hibernoma development.
Topics: Adipose Tissue, Brown; Animals; Blood Pressure; Cell Proliferation; Female; Heart Rate; Janus Kinase Inhibitors; Lipoma; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; STAT Transcription Factors; Trans-Activators | 2017 |
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment.
Topics: Adult; Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunity, Cellular; Male; Middle Aged; Piperidines; Pneumococcal Vaccines; Prospective Studies; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Sensitivity and Specificity; Severity of Illness Index; T-Lymphocytes; Tetanus Toxoid; Vaccination; Vaccines, Conjugate; Young Adult | 2018 |
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
Topics: Adult; Alopecia Areata; Female; Hair; Humans; Male; Middle Aged; Ointments; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2018 |
Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life.
Topics: Adult; Alopecia Areata; Emotions; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Young Adult | 2018 |
LC-ESI-MS/MS determination of defactinib, a novel FAK inhibitor in mice plasma and its application to a pharmacokinetic study in mice.
Topics: Animals; Area Under Curve; Benzamides; Carbon Isotopes; Chromatography, High Pressure Liquid; Drug Stability; Focal Adhesion Kinase 1; Limit of Detection; Liquid-Liquid Extraction; Male; Mice; Mice, Inbred BALB C; Nitrogen Isotopes; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry | 2018 |
Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.
Topics: Antipruritics; Clinical Trials, Phase III as Topic; Humans; Piperidines; Predictive Value of Tests; Pruritus; Psoriasis; Psychometrics; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Topics: Adaptive Immunity; Adoptive Transfer; Aged; Animals; Cell Proliferation; Cytokines; Disease Models, Animal; Female; Gene Expression Regulation; Giant Cell Arteritis; Heterografts; Humans; Immunity, Innate; Immunologic Memory; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Janus Kinases; Lymphocyte Activation; Male; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Middle Aged; Neointima; Neovascularization, Pathologic; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; T-Lymphocytes; Temporal Arteries; Vascular Remodeling | 2018 |
Spondyloarthropathies: Tofacitinib shows promise in PsA trials.
Topics: Arthritis, Psoriatic; Humans; Piperidines; Pyrimidines; Pyrroles; Spondylarthropathies | 2017 |
Epidemiology: Arthritis more common than expected.
Topics: Arthritis; Arthritis, Psoriatic; Humans; Piperidines; Pyrimidines; Pyrroles | 2017 |
Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis.
Topics: Arthritis; Female; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Scleroderma, Systemic | 2018 |
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Ethics, Research; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Remission Induction; Research Design; Research Subjects; Time Factors; Treatment Outcome; Vulnerable Populations | 2018 |
Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; HIV Infections; HIV-1; Humans; Janus Kinase Inhibitors; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Virus Latency; Virus Replication | 2017 |
[Inhibitory effect and mechanism of tofacitinib on the secretion of cytokines by T cells in human peripheral blood].
Topics: CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Humans; Interferon-gamma; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT1 Transcription Factor; STAT3 Transcription Factor; STAT4 Transcription Factor; Tumor Necrosis Factor-alpha | 2017 |
JAK/STAT-1 Signaling Is Required for Reserve Intestinal Stem Cell Activation during Intestinal Regeneration Following Acute Inflammation.
Topics: Acute Disease; Animals; Apoptosis; Cytokines; Enteritis; Inflammation; Intestinal Mucosa; Intestine, Small; Janus Kinases; Mice; Mice, Transgenic; Piperidines; Pyrimidines; Pyrroles; Regeneration; Signal Transduction; STAT1 Transcription Factor; Stem Cells | 2018 |
A Case Series on Patients on Tofacitinib in Combination With a Biologic.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Janus Kinase 3; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2018 |
Reply to: "Tofacitinib for the treatment of severe alopecia areata and variants".
Topics: Alopecia Areata; Humans; Piperidines; Pyrimidines; Pyrroles | 2018 |
Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.
Topics: Biological Products; Biological Therapy; Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2018 |
Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
Topics: Biological Products; Biological Therapy; Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2018 |
Bone remodelling: locus minori or unappreciated potential of tofacitinib?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bone Remodeling; Double-Blind Method; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.
Topics: Adult; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Pigmentation; Ultraviolet Therapy; Vitiligo | 2018 |
Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Feasibility Studies; Female; Humans; Incidence; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Pancreatic Neoplasms; Pharmacovigilance; Piperidines; Product Surveillance, Postmarketing; Pyrimidines; Pyrroles | 2018 |
[Current and upcoming treatments of adult atopic dermatitis].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Ustekinumab | 2017 |
The use of JAK inhibitors in the treatment of progressive systemic sclerosis.
Topics: Adult; Humans; Janus Kinase Inhibitors; Male; Piperidines; Pyrimidines; Pyrroles; Scleroderma, Systemic | 2018 |
Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats - Comparison of juvenile and adult responses.
Topics: Administration, Oral; Aging; Animals; Antigens; Erythrocyte Count; Female; Hematocrit; Hemocyanins; Hemoglobins; Janus Kinase Inhibitors; Leukocyte Count; Leukocytes; Lymphoma, B-Cell; Macaca fascicularis; Male; Organ Size; Piperidines; Pyrimidines; Pyrroles; Rats, Sprague-Dawley; Spleen; Thymus Gland; Toxicity Tests, Chronic | 2018 |
Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Humans; Imatinib Mesylate; Janus Kinase 3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperidines; Pyrimidines; Pyrroles; Signal Transduction | 2018 |
Tofacitinib for Psoriatic Arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Tofacitinib for Psoriatic Arthritis.
Topics: Arthritis, Psoriatic; Piperidines; Pyrimidines; Pyrroles | 2018 |
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Topics: Arthritis, Rheumatoid; Chronic Disease; Female; Herpes Zoster; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin; Skin Ulcer | 2018 |
The anti-inflammatory effect of topical tofacitinib on immediate and late-phase cutaneous allergic reactions in dogs: a placebo-controlled pilot study.
Topics: Animals; Anti-Inflammatory Agents; Dermatitis, Atopic; Dog Diseases; Dogs; Hypersensitivity, Delayed; Hypersensitivity, Immediate; Inflammation; Pilot Projects; Piperidines; Pyrimidines; Pyrroles | 2018 |
MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles.
Topics: Acetamides; Administration, Topical; Aminopyridines; Benzamides; Cyclopropanes; Drug Discovery; Humans; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Skin; Skin Absorption; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2018 |
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Infections; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2018 |
Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
Topics: Animals; Arthritis, Rheumatoid; Bone Resorption; Cyclic S-Oxides; Gene Expression Regulation; Genes, fos; Humans; Janus Kinases; Macrophages; Mice; NF-kappa B; NFATC Transcription Factors; Osteogenesis; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; RAW 264.7 Cells; Signal Transduction; STAT3 Transcription Factor | 2018 |
Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.
Topics: Animals; Chronic Disease; Complement C4b; Disease Models, Animal; Disease Progression; Graft Rejection; Graft Survival; Humans; Immunity, Cellular; Immunity, Humoral; Immunosuppressive Agents; Janus Kinase 3; Kidney; Kidney Transplantation; Male; Peptide Fragments; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Inbred F344; Rats, Inbred Lew; Signal Transduction; Treatment Outcome | 2018 |
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Topics: Animals; Bone Marrow; Cell Communication; Disease Models, Animal; Drug Repositioning; Humans; Janus Kinases; Mesenchymal Stem Cells; Mice; Multiple Myeloma; Phosphoproteins; Piperidines; Plasma Cells; Protein Kinase Inhibitors; Proteome; Proteomics; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Elderly-Onset Varicella Pneumonia in a Patient With Rheumatoid Arthritis Treated With Tofacitinib.
Topics: Aged; Arthritis, Rheumatoid; Chickenpox; Female; Herpesvirus 3, Human; Humans; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2018 |
Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Topics: Administration, Oral; Adult; Alopecia Areata; Female; Humans; Male; Middle Aged; Nail Diseases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies | 2018 |
Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Topics: Adult; Antibodies, Monoclonal, Humanized; China; Colitis, Ulcerative; Cost-Benefit Analysis; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Severity of Illness Index; Tumor Necrosis Factor-alpha; United Kingdom | 2018 |
Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Logistic Models; Male; Methotrexate; Middle Aged; Patient Compliance; Physicians; Piperidines; Prescriptions; Pyrimidines; Pyrroles; Risk Factors | 2018 |
Tofacitinib in steroid-dependent relapsing polychondritis.
Topics: Biological Products; Humans; Piperidines; Polychondritis, Relapsing; Pyrimidines; Pyrroles | 2019 |
Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Topics: Case-Control Studies; Cells, Cultured; Down-Regulation; Early Growth Response Protein 1; Humans; Interleukin-22; Interleukins; Janus Kinases; Keratinocytes; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; S100 Calcium Binding Protein A7; Signal Transduction; STAT Transcription Factors | 2018 |
Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis.
Topics: Administration, Topical; Adolescent; Alopecia; Alopecia Areata; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hair; Humans; Male; Pediatrics; Piperidines; Pyrimidines; Pyrroles; Sampling Studies; Treatment Outcome | 2018 |
JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Energy Metabolism; Fibroblasts; Humans; Inflammation Mediators; Janus Kinases; Mitochondria; Oncostatin M; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Synovial Membrane | 2018 |
Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis.
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Humans; Inactivation, Metabolic; Janus Kinase Inhibitors; Male; Models, Biological; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Severity of Illness Index; Tissue Distribution | 2018 |
Treatment of halo naevus with the topical Janus kinase inhibitor tofacitinib 1.5.
Topics: Administration, Topical; Back; Child; Dermatologic Agents; Humans; Lip Neoplasms; Male; Nevus, Halo; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms | 2018 |
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Inflammation; Methotrexate; Phenotype; Piperidines; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Signal Transduction | 2018 |
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical Decision-Making; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Drug Costs; Drug Substitution; Humans; Methotrexate; Models, Economic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; United States | 2018 |
Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib.
Topics: Acquired Hyperostosis Syndrome; Adult; Antirheumatic Agents; Autoimmunity; Bone and Bones; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Immunologic Tests; Janus Kinase Inhibitors; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Tomography, Emission-Computed; Treatment Outcome | 2018 |
Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
Topics: Acrylamides; Administration, Oral; Animals; Ankle Joint; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured; Janus Kinase Inhibitors; Janus Kinases; Macrophages; Male; Mice, Inbred C57BL; Piperidines; Primary Cell Culture; Prodrugs; Pyrimidines; Pyrroles; Rats; Rats, Inbred Lew; Signal Transduction; STAT6 Transcription Factor; Tissue Distribution; Treatment Outcome; X-Ray Microtomography | 2018 |
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model.
Topics: Administration, Topical; Animals; Cells, Cultured; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Female; Ganglia, Spinal; Hypochlorous Acid; Immunoglobulin E; Mice; Neurons; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin | 2018 |
Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost Savings; Cost-Benefit Analysis; Humans; Models, Economic; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Treatment Outcome; United States | 2018 |
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.
Topics: Adult; Colitis, Ulcerative; Databases, Factual; Female; Humans; Infant, Newborn; Janus Kinase Inhibitors; Male; Maternal Exposure; Paternal Exposure; Piperidines; Pregnancy; Pregnancy Outcome; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult | 2018 |
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
Topics: Adult; Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Female; Gastrointestinal Agents; Humans; Induction Chemotherapy; Male; Middle Aged; Piperidines; Placebos; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Calcification Induced by Type I Interferon in Human Aortic Valve Interstitial Cells Is Larger in Males and Blunted by a Janus Kinase Inhibitor.
Topics: Aortic Valve; Aortic Valve Stenosis; Apoptosis; Bone Morphogenetic Protein 2; Calcinosis; Cell Differentiation; Cells, Cultured; Cytokines; Female; Humans; Interferon Type I; Janus Kinase Inhibitors; Lipopolysaccharides; Male; NF-kappa B; Osteoblasts; Piperidines; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Sex Factors; Signal Transduction; STAT Transcription Factors; Toll-Like Receptor 4 | 2018 |
Tofacitinib and Risk of Peripheral Neuropathy? Experience of 2 Cases in Patients With Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Peripheral Nervous System Diseases; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Tofacitinib and TPCA-1 exert chondroprotective effects on extracellular matrix turnover in bovine articular cartilage ex vivo.
Topics: Amides; Animals; Cartilage, Articular; Cattle; Chondrocytes; Collagen Type II; Extracellular Matrix Proteins; Imidazoles; Osteoarthritis; Oxazines; Piperidines; Proteoglycans; Pyridines; Pyrimidines; Pyrroles; Thiophenes | 2019 |
Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.
Topics: Adult; Aged; Dermatomyositis; Drug Therapy, Combination; Female; Ferritins; Glucocorticoids; Humans; Interferon-Induced Helicase, IFIH1; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Survival Rate; Treatment Outcome | 2018 |
Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.
Topics: Adolescent; Adult; Child; Female; Gain of Function Mutation; Humans; Immunologic Deficiency Syndromes; Janus Kinases; Male; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; STAT1 Transcription Factor; STAT3 Transcription Factor; Treatment Outcome | 2018 |
Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.
Topics: Antibodies, Monoclonal, Humanized; Biological Products; Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Spondylarthropathies | 2019 |
Tofacitinib for psoriatic arthritis (PsA) is now approved by the European Commission.
Topics: Arthritis, Psoriatic; Drug Approval; Europe; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2018 |
First Oral Drug for Moderate-To-Severe Ulcerative Colitis.
Topics: Colitis, Ulcerative; Drug Approval; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2018 |
Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils.
Topics: Caspase 1; Cells, Cultured; Gene Expression; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Inflammasomes; Interleukin-1beta; Neutrophils; NLR Family, Pyrin Domain-Containing 3 Protein; Piperidines; Pyrimidines; Pyrroles | 2018 |
Comments on the article "Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study".
Topics: Arthritis, Rheumatoid; Cohort Studies; Humans; Piperidines; Pyrimidines; Pyrroles | 2018 |
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Young Adult | 2019 |
Determination of Tofacitinib in Mice Whole Blood on Dried Blood Spots Using LC-ESI-MS/MS: Application to Pharmacokinetic Study in Mice.
Topics: Administration, Oral; Animals; Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Drug Stability; Injections, Intravenous; Janus Kinase 3; Male; Mice; Models, Animal; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2019 |
Tofacitinib for the treatment of alopecia areata in preadolescent children.
Topics: Administration, Oral; Age Factors; Alopecia Areata; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Janus Kinase Inhibitors; Male; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Quality of Life; Risk Assessment; Sampling Studies; Treatment Outcome | 2019 |
Ruxolitinib for the treatment of severe alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hair; Humans; Male; Middle Aged; Nitriles; Patient Satisfaction; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Retrospective Studies; Sampling Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2019 |
Therapeutic synergy between contact dermatitis from a wig-fixing device and tofacitinib on alopecia areata.
Topics: Adult; Alopecia Areata; Dermatitis, Contact; Hair; Humans; Male; Piperidines; Pyrimidines; Pyrroles; Silicone Gels; Treatment Outcome | 2019 |
Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus.
Topics: Cytokines; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Janus Kinases; Pemphigus; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Th2 Cells | 2018 |
Tofacitinib for the treatment of lichen planopilaris: A case series.
Topics: Administration, Oral; Adult; Aged; Alopecia; Dermatologic Agents; Drug Administration Schedule; Female; Humans; Janus Kinase Inhibitors; Lichen Planus; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Retrospective Studies; Scalp; Scalp Dermatoses; Skin; Time Factors; Treatment Outcome | 2018 |
Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study.
Topics: Administration, Oral; Adolescent; Adult; Alopecia; Cyclopropanes; Cyclosporine; Female; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Steroids; Time Factors; Treatment Outcome; Young Adult | 2019 |
High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Animals; Autoimmune Diseases; CD8-Positive T-Lymphocytes; Disease Models, Animal; Female; Follow-Up Studies; Hair Follicle; High-Throughput Nucleotide Sequencing; Humans; Lymph Nodes; Male; Mice; Mice, Inbred C3H; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Pilot Projects; Piperidines; Pyrimidines; Pyrroles; Receptors, Antigen, T-Cell; Scalp; Treatment Outcome; Young Adult | 2018 |
Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism.
Topics: Adiposity; Adult; Aged; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Body Composition; Diet, High-Fat; Female; Glucose; Humans; Janus Kinase Inhibitors; Lipolysis; Mice; Mice, Inbred C57BL; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Weight Gain | 2018 |
Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice.
Topics: Animals; Bone Morphogenetic Protein 4; Carrier Proteins; Hair; Hair Follicle; Male; Mice; Mice, Inbred C57BL; Minoxidil; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Physiological Phenomena; Vasodilator Agents | 2018 |
Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
Topics: Aged; Arthritis, Rheumatoid; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Herpes Zoster; Humans; Incidence; Janus Kinase Inhibitors; Male; Medicare; Methotrexate; Middle Aged; Multivariate Analysis; Piperidines; Pyrimidines; Pyrroles; Risk Assessment; Time Factors; United States | 2019 |
Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis.
Topics: Humans; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2018 |
An Immune Suppression-associated EBV-positive Anaplastic Large Cell Lymphoma With a BRAF V600E Mutation.
Topics: Aged; Arthritis, Rheumatoid; Epstein-Barr Virus Infections; Humans; Immunocompromised Host; Lymphoma, Large-Cell, Anaplastic; Male; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Pyrroles | 2019 |
Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Movement; Cell Proliferation; Cerebellar Neoplasms; Cisplatin; Dasatinib; Drug Synergism; Humans; Medulloblastoma; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; src-Family Kinases; STAT3 Transcription Factor; Tumor Cells, Cultured | 2019 |
JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis.
Topics: Cell Proliferation; Computer Simulation; Dermatitis, Atopic; Filaggrin Proteins; Humans; Imaging, Three-Dimensional; Intermediate Filament Proteins; Janus Kinase 1; Keratinocytes; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Sensitivity and Specificity; STAT6 Transcription Factor | 2019 |
First Reported Case of Pulmonary Arterial Hypertension Secondary to Tofacitinib Treatment for Undifferentiated Arthritis.
Topics: Antirheumatic Agents; Arthritis; Humans; Piperidines; Pulmonary Arterial Hypertension; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Dr. Charles-Schoeman and E. Bananis Reply.
Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Piperidines; Pyrimidines; Pyrroles | 2018 |
Effects of Co-medication with Glucocorticoids in Biologics Trials.
Topics: Arthritis, Rheumatoid; Biological Products; Glucocorticoids; Humans; Piperidines; Pyrimidines; Pyrroles | 2018 |
Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Topics: Adult; Female; Histocytochemistry; Humans; Immunohistochemistry; Immunologic Factors; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyoderma Gangrenosum; Pyrimidines; Pyrroles; Skin; Treatment Outcome; Young Adult | 2019 |
Decrease in 14-3-3η protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib.
Topics: 14-3-3 Proteins; Adult; Arthritis, Rheumatoid; Biomarkers; Cohort Studies; Female; Humans; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; B-Lymphocytes; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Humans; Incidence; Infections; Janus Kinase Inhibitors; Killer Cells, Natural; Lymphocyte Count; Piperidines; Pyrimidines; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes; Time Factors | 2019 |
Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis.
Topics: Adult; Animals; Colitis, Ulcerative; Female; Hospitals; Humans; Immunologic Factors; Induction Chemotherapy; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2019 |
Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Topics: Animals; Antipruritics; Behavior, Animal; Disease Models, Animal; Imiquimod; Interleukin-22; Interleukin-23; Interleukins; Janus Kinase Inhibitors; Male; Mice, Inbred C57BL; Nerve Fibers; Piperidines; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Skin | 2019 |
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Topics: Abatacept; Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Comorbidity; Diabetes Mellitus; Enthesopathy; Etanercept; Evidence-Based Medicine; Exercise; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Infliximab; Interleukin-12; Interleukin-17; Interleukin-23; Occupational Therapy; Physical Therapy Modalities; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Smoking Cessation; Societies, Medical; Spondylitis; Tumor Necrosis Factor-alpha; Ustekinumab; Weight Loss | 2019 |
Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Cohort Studies; Eyebrows; Eyelashes; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Treatment Outcome; Young Adult | 2019 |
Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.
Topics: Adult; Alopecia Areata; Female; Humans; Janus Kinases; Middle Aged; Nitriles; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Recurrence; Withholding Treatment | 2019 |
Tofacitinib for familial Mediterranean fever: a new alternative therapy?
Topics: Adolescent; Familial Mediterranean Fever; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2019 |
Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Databases, Factual; Female; Humans; Incidence; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pulmonary Embolism; Pyrimidines; Pyrroles; Tumor Necrosis Factor Inhibitors; Venous Thromboembolism; Venous Thrombosis | 2019 |
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.
Topics: Female; Humans; Immunohistochemistry; Janus Kinases; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Sarcoidosis; Sarcoidosis, Pulmonary; Sequence Analysis, RNA; Signal Transduction; Skin; Skin Diseases; STAT Transcription Factors | 2018 |
Tofacitinib: a new oral Janus kinase inhibitor for psoriasis.
Topics: Humans; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2019 |
Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective.
Topics: Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Inflammatory Bowel Diseases; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; United States | 2019 |
Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy.
Topics: Abatacept; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Virus Replication | 2019 |
Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.
Topics: Adult; Aged; Dermatomyositis; Female; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retreatment; Treatment Outcome | 2019 |
Tofacitinib: A Jak of All Trades.
Topics: Humans; Piperidines; Pyoderma Gangrenosum; Pyrimidines; Pyrroles | 2019 |
Tofacitinib therapy for children with severe alopecia areata.
Topics: Alopecia; Alopecia Areata; Child, Preschool; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index | 2019 |
2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Decision Making; Drug Substitution; Drug Therapy, Combination; Glucocorticoids; Humans; Hydroxychloroquine; Leflunomide; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Societies, Medical; Sulfasalazine | 2018 |
A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function.
Topics: Animals; Cells, Cultured; Colitis; Dextran Sulfate; Female; Humans; Janus Kinase 1; Macrophages; Mice; Mice, Inbred C57BL; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2019 |
Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients.
Topics: Adolescent; Adult; Alopecia Areata; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2019 |
Alopecia universalis. Partial response to tofacitinib.
Topics: Adult; Alopecia; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.
Topics: Animals; Antibodies; Arginase; Breast Neoplasms; Cell Line, Tumor; Cytokines; Disease Models, Animal; Female; Immunoconjugates; Immunotherapy; Immunotoxins; Macrophages; Mice; Mice, Nude; Monocytes; Neoplasms; Neutrophils; Piperidines; Pyrimidines; Pyrroles; RNA, Messenger; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Topics: Administration, Oral; Adult; Colitis; Colitis, Ulcerative; Drug Administration Schedule; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Pouchitis; Pyrimidines; Pyrroles; Remission Induction; Retrospective Studies; Tertiary Care Centers; Time Factors; Treatment Outcome | 2019 |
Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab.
Topics: Adolescent; Drug Therapy, Combination; Female; Gastrointestinal Agents; Humans; Infliximab; Piperidines; Protein Kinase Inhibitors; Pyoderma Gangrenosum; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Reversible eruption of neurofibromatosis associated with tofacitinib therapy for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Fibroma; Humans; Middle Aged; Neurofibromatosis 1; Piperidines; Pyrimidines; Pyrroles; Skin Neoplasms | 2019 |
Comment on: Tofacitinib for familial Mediterranean fever: a new alternative therapy?: reply.
Topics: Familial Mediterranean Fever; Humans; Piperidines; Pyrimidines; Pyrroles | 2019 |
Comment on: Tofacitinib for familial Mediterranean fever: a new alternative therapy?
Topics: Familial Mediterranean Fever; Humans; Piperidines; Pyrimidines; Pyrroles | 2019 |
A Macromolecular Janus Kinase (JAK) Inhibitor Prodrug Effectively Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice.
Topics: Animals; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Inflammation; Janus Kinases; Male; Methacrylates; Mice; Piperidines; Polymers; Prodrugs; Pyrimidines; Pyrroles | 2019 |
Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases.
Topics: Calcinosis; Dermatomyositis; Female; Humans; Lung Diseases, Interstitial; MAP Kinase Kinase 4; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2019 |
Occurrence of Extensive Cutaneous Human Papillomavirus Infection After Initiation of Tofacitinib Therapy.
Topics: Female; Humans; Middle Aged; Papillomavirus Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Diseases, Viral | 2019 |
Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis.
Topics: Animals; Cell Line; Cell Proliferation; Curcumin; Disease Models, Animal; Epithelial Cells; Humans; Janus Kinase 2; Kidney; Mice; Phosphorylation; Piperidines; Polycystic Kidney, Autosomal Dominant; Pyrimidines; Pyrroles; TRPP Cation Channels; Up-Regulation | 2019 |
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
Topics: Adult; Arthritis, Rheumatoid; Asia; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Recovery of Function; Remission Induction; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Disorders of Hypopigmentation
Topics: Administration, Cutaneous; Administration, Oral; Autoimmune Diseases; CD8-Positive T-Lymphocytes; Counseling; Dermatologic Agents; Diagnosis, Differential; Epidermis; Humans; Janus Kinases; Melanocytes; Mycosis Fungoides; Nitriles; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quality of Life; Skin Pigmentation; Tinea Versicolor; Vitiligo | 2019 |
Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Biological Products; Colitis, Ulcerative; Crohn Disease; Databases, Factual; Gastrointestinal Agents; Health Services Accessibility; Humans; Infliximab; Insurance Coverage; Insurance, Health; Piperidines; Pyrimidines; Pyrroles; United States; Ustekinumab | 2019 |
Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis.
Topics: Adolescent; Arthritis, Juvenile; Female; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Oral Tofacitinib Treatment of Erosive Pustular Dermatosis of the Scalp.
Topics: Administration, Oral; Aged; Female; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Scalp Dermatoses; Skin Diseases, Vesiculobullous; Treatment Outcome | 2019 |
Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo.
Topics: Administration, Oral; Animals; Butanols; Disease Models, Animal; Humans; Janus Kinase Inhibitors; Mice; Mice, Hairless; Mice, Transgenic; Piperidines; Pyrimidines; Pyrroles; Skin Lightening Preparations; Skin Pigmentation; Treatment Failure; Vitiligo | 2019 |
An urticarial drug eruption caused by tofacitinib for alopecia universalis.
Topics: Alopecia; Drug Eruptions; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Urticaria; Young Adult | 2019 |
Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib.
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Cell Proliferation; Chemokine CCL2; Fibroblasts; Humans; Interleukin-6; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Synovial Membrane | 2019 |
Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma.
Topics: Administration, Inhalation; Allergens; Animals; Anti-Asthmatic Agents; Asthma; Drug Compounding; Drug Stability; Female; Mice; Mice, Inbred BALB C; Piperidines; Pyrimidines; Pyroglyphidae; Pyrroles | 2019 |
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
Topics: Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Mutation; Nitriles; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles | 2019 |
JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type.
Topics: Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 3; Lymphoma, T-Cell; Male; Middle Aged; Mutation; Phosphorylation; Piperidines; Positive Regulatory Domain I-Binding Factor 1; Pyrimidines; Pyrroles; STAT3 Transcription Factor | 2019 |
Rapid Onset of Tofacitinib Induction Therapy for the Treatment of Ulcerative Colitis.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2019 |
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
Topics: Adalimumab; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Cost-Benefit Analysis; Etanercept; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Young Adult | 2019 |
Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre.
Topics: Adolescent; Adult; Arthritis; Exanthema; Female; Humans; Lupus Erythematosus, Systemic; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2019 |
A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
Topics: Administration, Cutaneous; Adult; Combined Modality Therapy; Facial Dermatoses; Female; Humans; Male; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Skin Cream; Ultraviolet Therapy; Vitiligo | 2019 |
Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib.
Topics: Adiposity; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Female; Humans; Intra-Abdominal Fat; Male; Middle Aged; Obesity, Abdominal; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Waist Circumference | 2019 |
Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Herpesvirus 3, Human; Humans; Immunity, Cellular; Interferon-gamma; Lectins, C-Type; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, CCR5; Receptors, CXCR3; Th1 Cells | 2019 |
Chronic Inguinal Lymphadenitis in a Patient With Rheumatoid Arthritis Being Treated With Tofacitinib: Remission With Antituberculous Therapy and Discontinuation of JAK Inhibition.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lymphadenitis; Piperidines; Pyrimidines; Pyrroles | 2020 |
Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cisplatin; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Janus Kinases; Killer Cells, Natural; Ligands; Lung Neoplasms; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT Transcription Factors; Tumor Cells, Cultured | 2019 |
A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase III as Topic; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Reproducibility of Results; Severity of Illness Index; Skin; Treatment Outcome; Young Adult | 2019 |
Budget impact of introducing tofacitinib to the public hospital formulary in Hong Kong, 2017-2021.
Topics: Arthritis, Rheumatoid; Biological Products; Health Care Costs; Hong Kong; Hospitals, Public; Humans; Linear Models; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.
Topics: Adult; Aged; Biopsy; Female; Granuloma Annulare; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Remission Induction; Sarcoidosis; Severity of Illness Index; Skin; Treatment Outcome | 2020 |
Tofacitinib: raising awareness of mycoses.
Topics: Aged; Arthritis, Rheumatoid; Fingers; Humans; Male; Mycoses; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata.
Topics: Alopecia Areata; Animals; Mice; Piperidines; Pyrimidines; Pyrroles; Thalidomide | 2020 |
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Topics: Administration, Oral; Arthritis, Juvenile; Female; Humans; Janus Kinase Inhibitors; Macula Lutea; Macular Edema; Piperidines; Pyrimidines; Pyrroles; Tomography, Optical Coherence; Uveitis, Anterior; Visual Acuity; Young Adult | 2019 |
Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells.
Topics: Cell Adhesion; Cell Line; Cytoprotection; Endothelial Cells; Humans; L-Lactate Dehydrogenase; Lipoproteins, LDL; Monocytes; NF-kappa B; Piperidines; Pyrimidines; Pyrroles; Reactive Oxygen Species | 2019 |
IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSs.
Topics: Animals; Arthritis, Rheumatoid; Azetidines; Biomarkers; Female; Gene Expression; Humans; Inflammation; Interferon Regulatory Factor-1; Interferons; Janus Kinase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Transgenic; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides; Synovial Membrane; Synoviocytes; Tumor Necrosis Factor-alpha | 2019 |
Tofacitinib as a treatment of alopecia areata in adolescents.
Topics: Administration, Oral; Adolescent; Alopecia Areata; Female; Humans; Male; Mexico; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2019 |
Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report.
Topics: Female; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2020 |
Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema; Male; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Inbred Lew | 2019 |
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
Topics: Arthritis, Rheumatoid; Azetidines; Biomarkers; Cytokines; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Leukocytes, Mononuclear; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides | 2019 |
Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Biological Products; Female; Humans; Inflammatory Bowel Diseases; Infliximab; Insurance Claim Review; Male; Medication Adherence; Medication Therapy Management; Middle Aged; Piperidines; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; United States | 2019 |
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Topics: Aged; Arthritis, Rheumatoid; Blood Sedimentation; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2019 |
Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice.
Topics: Animals; Cell Differentiation; Cell Proliferation; Dendritic Cells; Disease Models, Animal; Immunity, Innate; Lung Diseases, Interstitial; Male; Mice; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Th17 Cells | 2019 |
Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study.
Topics: Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Symptom Flare Up | 2019 |
Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Databases, Factual; Female; Humans; Male; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Assays; Humans; Ketoconazole; Male; Microsomes, Liver; NADP; Piperidines; Pyrimidines; Pyrroles | 2019 |
Breastfeeding with Inflammatory Bowel Disease.
Topics: Aminosalicylic Acid; Biological Products; Breast Feeding; Female; Humans; Inflammatory Bowel Diseases; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2019 |
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Biological Products; Biosimilar Pharmaceuticals; Deprescriptions; Humans; Magnetic Resonance Imaging; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiography; Societies, Medical; Spondylarthropathies; Spondylitis, Ankylosing; Tumor Necrosis Factor Inhibitors | 2019 |
Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
Topics: Acquired Hyperostosis Syndrome; Adult; Female; Humans; Janus Kinase 3; Lymphangioleiomyomatosis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Docking structurally similar analogues: Dealing with the false-positive.
Topics: Algorithms; Janus Kinase 3; Molecular Dynamics Simulation; Piperidines; Protein Binding; Pyrimidines; Pyrroles; Quantitative Structure-Activity Relationship | 2019 |
Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease.
Topics: Biological Products; Child; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Piperidines; Pyrimidines; Pyrroles | 2019 |
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
Topics: Adult; Aged; Cohort Studies; Colitis, Ulcerative; Female; Humans; Incidence; Male; Middle Aged; Piperidines; Pulmonary Embolism; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Venous Thromboembolism; Venous Thrombosis; Young Adult | 2019 |
Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.
Topics: Autoantibodies; Dermatomyositis; Humans; Piperidines; Pyrimidines; Pyrroles | 2019 |
Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.
Topics: Autoantibodies; Dermatomyositis; Humans; Interferon Type I; Piperidines; Pyrimidines; Pyrroles | 2019 |
Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo.
Topics: Humans; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Vitiligo | 2020 |
Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata.
Topics: Administration, Oral; Adolescent; Adult; Alopecia; Alopecia Areata; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice.
Topics: Animals; Hepatitis, Autoimmune; Interferon-gamma; Interleukin-10; Janus Kinase Inhibitors; Liver; Male; Mice; Mice, Inbred C57BL; Piperidines; Pyrimidines; Pyrroles; T-Lymphocytes, Regulatory; Th17 Cells | 2019 |
Tofacitinib Receives New Boxed Safety Warning.
Topics: Drug Dosage Calculations; Drug Labeling; Humans; Patient Safety; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Thrombosis | 2019 |
Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; beta Catenin; Biological Transport; Colon; Epithelial Cells; HT29 Cells; Humans; Insulin; Intestinal Mucosa; Janus Kinase 3; Mice; Mice, Knockout; Neoplasm Proteins; Obesity; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; Tissue Inhibitor of Metalloproteinase-1 | 2019 |
Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Administration Schedule; Fluorodeoxyglucose F18; Janus Kinase Inhibitors; Joints; Male; Mice, Inbred DBA; Piperidines; Positron-Emission Tomography; Predictive Value of Tests; Pyrimidines; Pyrroles; Radiopharmaceuticals; Whole Body Imaging | 2019 |
Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children.
Topics: Adolescent; Child; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Response of alopecia areata of the beard to oral tofacitinib.
Topics: Administration, Oral; Adult; Aged; Alopecia Areata; Cheek; Chin; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Scalp; Treatment Outcome; Young Adult | 2020 |
Dexamethasone and Tofacitinib suppress NADPH oxidase expression and alleviate very-early-onset ileocolitis in mice deficient in GSH peroxidase 1 and 2.
Topics: Animals; Apoptosis; Crohn Disease; Dexamethasone; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Ileum; Inflammation; Inflammatory Bowel Diseases; Mice; Mice, Inbred C57BL; NADPH Oxidase 1; NADPH Oxidases; Oxidation-Reduction; Peroxidases; Piperidines; Pyrimidines; Pyrroles | 2019 |
Metabolic Activation of Tofacitinib Mediated by Myeloperoxidase
Topics: Acetylcysteine; Activation, Metabolic; Animals; Antirheumatic Agents; Hypochlorous Acid; Leukocytes; Leukopenia; Peroxidase; Piperidines; Pyrimidines; Pyrroles; Rats, Sprague-Dawley | 2019 |
Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes.
Topics: Animals; Aspirin; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Interleukin-6; Janus Kinases; Male; NF-kappa B; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Serum Amyloid A Protein; Signal Transduction; STAT Transcription Factors; Tumor Necrosis Factor-alpha | 2019 |
Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Cohort Studies; Colitis, Ulcerative; Endoscopy, Gastrointestinal; Female; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Humans; Induction Chemotherapy; Infliximab; Maintenance Chemotherapy; Male; Middle Aged; Patient Reported Outcome Measures; Piperidines; Prevalence; Pyrimidines; Pyrroles; Remission Induction; Young Adult | 2020 |
Tofacitinib for the Treatment of Refractory Polymyositis.
Topics: Antirheumatic Agents; Biopsy; Disease Progression; Drug Resistance, Multiple; Electromyography; Female; Humans; Janus Kinase Inhibitors; Medication Therapy Management; Middle Aged; Monitoring, Immunologic; Muscle Strength; Muscle Weakness; Piperidines; Polymyositis; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.
Topics: Adolescent; Colitis, Ulcerative; Female; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Takayasu Arteritis; Treatment Outcome | 2020 |
Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis.
Topics: Adult; Arthritis, Rheumatoid; Cytokines; Female; Humans; Interleukin-17; Interleukin-6; Interleukins; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha | 2019 |
IgA Vasculitis Developed as an Adverse Effect of Tofacitinib Taken for Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunoglobulin A; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Vasculitis | 2020 |
Alterations of voluntary behavior in the course of disease progress and pharmacotherapy in mice with collagen-induced arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Models, Animal; Disease Progression; Humans; Joints; Male; Mice, Inbred DBA; Motor Activity; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Synovitis; Temperature | 2019 |
Treatment-resistant eosinophilic oesophagitis successfully managed with tofacitinib.
Topics: Adult; Arthralgia; Diagnosis, Differential; Eosinophilic Esophagitis; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cell Line; Cytokines; Enzyme Assays; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Janus Kinase 1; Janus Kinase Inhibitors; Male; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Cytokine; Sulfonamides; Triazoles | 2019 |
"Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4": Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping.
Topics: Cytochrome P-450 CYP3A; Epoxy Compounds; Glutathione; Piperidines; Pyrimidines; Pyrroles | 2020 |
Inferring disease severity in rheumatoid arthritis using predictive modeling in administrative claims databases.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Humans; Insurance Claim Review; Male; Middle Aged; Models, Biological; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index | 2019 |
Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen.
Topics: Adult; Alopecia Areata; Cost Savings; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome; Young Adult | 2019 |
Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing.
Topics: Cell Differentiation; Cell Hypoxia; Cell Movement; Cell Survival; Cells, Cultured; Chondrogenesis; Collagen Type I; Collagen Type I, alpha 1 Chain; Core Binding Factor Alpha 1 Subunit; Humans; Janus Kinase Inhibitors; Janus Kinases; Mesenchymal Stem Cells; Osteogenesis; Piperidines; Pyrimidines; Pyrroles | 2020 |
Letter: new insights on tofacitinib dose de-escalation.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2020 |
Methotrexate-Induced Pneumonitis in Rheumatoid Arthritis: Long-term Treatment With Tofacitinib Therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pneumonia; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2020 |
Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.
Topics: Adolescent; Adult; Aged; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retreatment; Still's Disease, Adult-Onset | 2020 |
A case of refractory chronic pouchitis successfully treated with tofacitinib.
Topics: Adolescent; Adult; Colitis, Ulcerative; Female; Humans; Piperidines; Pouchitis; Proctocolectomy, Restorative; Pyrimidines; Pyrroles; Young Adult | 2020 |
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib.
Topics: Aged; Arthritis, Rheumatoid; Combined Modality Therapy; Female; Follow-Up Studies; Herpes Zoster Vaccine; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome; Vaccines, Live, Unattenuated | 2020 |
Multicentric reticulohistiocytosis: A case report treated with tofacitinib.
Topics: Histiocytosis, Non-Langerhans-Cell; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Female; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Takayasu Arteritis | 2020 |
Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcerative Colitis: Clinical Decision Support Tool.
Topics: Adult; Ambulatory Care; Biological Products; Clinical Decision-Making; Colitis, Ulcerative; Decision Support Techniques; Drug Therapy, Combination; Humans; Immunologic Factors; Methotrexate; Piperidines; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Severity of Illness Index | 2020 |
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Topics: Adult; Antibodies, Monoclonal, Humanized; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; Middle Aged; Netherlands; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Registries; Treatment Outcome; Tumor Necrosis Factor-alpha; Ustekinumab | 2020 |
Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
Topics: Child; Humans; Phototherapy; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Ultraviolet Therapy; Vitiligo | 2020 |
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
Topics: Adult; Arthritis, Psoriatic; Double-Blind Method; Humans; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Quality of Life; Treatment Outcome | 2020 |
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Topics: Arthritis, Rheumatoid; Azetidines; Betacoronavirus; Colitis, Ulcerative; Coronavirus Infections; COVID-19; Cytokines; Dermatitis, Atopic; Heterocyclic Compounds, 3-Ring; Humans; Immunomodulation; Janus Kinases; Nitriles; Pandemics; Piperidines; Pneumonia, Viral; Primary Myelofibrosis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; SARS-CoV-2; STAT Transcription Factors; Sulfonamides | 2020 |
Comparison of the effects of tofacitinib and adalimumab on transcolonoscopic ph and calprotectin levels in patients with ulcerative colitis.
Topics: Adalimumab; Adolescent; Adult; Aged; Colitis, Ulcerative; Female; Humans; Hydrogen-Ion Concentration; Leukocyte L1 Antigen Complex; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Young Adult | 2020 |
Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Spain; Treatment Outcome | 2020 |
Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome.
Topics: Aged; Fatal Outcome; Female; Humans; Janus Kinases; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Still's Disease, Adult-Onset | 2020 |
Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation.
Topics: Acquired Hyperostosis Syndrome; Adult; Female; Humans; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2020 |
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2020 |
Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib.
Topics: Adult; Betacoronavirus; Colitis, Ulcerative; Colonoscopy; Comorbidity; Coronavirus Infections; COVID-19; Female; Humans; Medication Therapy Management; Pandemics; Patient Acuity; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; SARS-CoV-2; Symptom Assessment; Treatment Outcome | 2020 |
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Colitis, Ulcerative; Colonoscopy; Feces; Gastrointestinal Agents; Humans; Infliximab; Leukocyte L1 Antigen Complex; Outcome Assessment, Health Care; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2020 |
Full histological and clinical regression of morphea with tofacitinib.
Topics: Humans; Piperidines; Pyrimidines; Pyrroles; Scleroderma, Localized | 2020 |
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2020 |
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2020 |
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp-A Usability Study.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Computer Security; Female; Humans; Medication Adherence; Mobile Applications; Piperidines; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2020 |
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study.
Topics: Abatacept; Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Betacoronavirus; Coronavirus Infections; COVID-19; Disease Susceptibility; Female; Hospitalization; Humans; Interleukin 1 Receptor Antagonist Protein; Italy; Janus Kinase Inhibitors; Logistic Models; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Proportional Hazards Models; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rheumatic Diseases; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sulfonamides; Tumor Necrosis Factor Inhibitors; Ustekinumab | 2020 |
Reply to Letter to Editor from Veeravalli and Dash on "Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4: Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping".
Topics: Cytochrome P-450 CYP3A; Epoxy Compounds; Glutathione; Piperidines; Pyrimidines; Pyrroles | 2020 |
Successful therapy of palmoplantar pustulosis with tofacitinib-Report on three cases.
Topics: Humans; Piperidines; Psoriasis; Pyrimidines; Pyrroles | 2020 |
Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.
Topics: Colitis; Colitis, Ulcerative; Humans; Piperidines; Programmed Cell Death 1 Receptor; Pyrimidines; Pyrroles | 2020 |
Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Chemokine CXCL13; Female; Gene Expression Regulation; Hypochlorous Acid; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Lung; Lung Diseases, Interstitial; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; Nitriles; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Immunologic; Scleroderma, Systemic; Suppressor of Cytokine Signaling 3 Protein | 2020 |
Two cases in which tofacitinib effectively treated both ulcerative colitis and alopecia areata.
Topics: Adult; Alopecia Areata; Colitis, Ulcerative; Female; Humans; Infliximab; Male; Piperidines; Pyrimidines; Pyrroles; Young Adult | 2020 |
Tofacitinib in Hypertrophic Lichen Planus.
Topics: Humans; Lichen Planus; Piperidines; Pyrimidines; Pyrroles | 2020 |
Folliculitis decalvans responsive to tofacitinib: A case series.
Topics: Alopecia; Folliculitis; Humans; Piperidines; Pyrimidines; Pyrroles | 2020 |
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Comment on 'Successful treatment of recalcitrant nodular prurigo with tofacitinib'.
Topics: Humans; Piperidines; Prurigo; Pyrimidines; Pyrroles | 2020 |
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Topics: Adult; Aged; Antirheumatic Agents; Clinical Trials as Topic; Female; Humans; Incidence; Male; Middle Aged; Observational Studies as Topic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Thromboembolism | 2020 |
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Topics: Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms; Treatment Outcome | 2021 |
Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Blood Glucose; Drug Synergism; Drug Therapy, Combination; Hypoglycemic Agents; Interleukin-6; Janus Kinases; Lipids; Male; NF-kappa B; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Signal Transduction; Sitagliptin Phosphate; STAT Transcription Factors; STAT3 Transcription Factor; Toll-Like Receptor 4 | 2020 |
Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy.
Topics: Alopecia Areata; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
[Successful treatment of adult Still's disease with tofacitinib in a HIV-2 positive female patient].
Topics: Adult; Female; HIV Infections; HIV-2; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Still's Disease, Adult-Onset; Treatment Outcome | 2020 |
Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?
Topics: Antibodies, Monoclonal, Humanized; Colitis, Ulcerative; Comparative Effectiveness Research; Cost-Benefit Analysis; Dermatologic Agents; Humans; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Safety; Treatment Outcome; Tumor Necrosis Factor-alpha; Ustekinumab | 2020 |
Tofacitinib-induced Ramsay- Hunt Syndrome in a Patient with Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; Female; Herpes Zoster Oticus; Humans; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2021 |
Tofacitinib in Vogt-Koyanagi-Harada disease.
Topics: Humans; Piperidines; Pyrimidines; Pyrroles; Uveomeningoencephalitic Syndrome | 2020 |
Commentary: Janus kinase inhibitors and their use in autoimmune ocular inflammatory disorders.
Topics: Autoimmune Diseases; Humans; Janus Kinase Inhibitors; Piperidines; Pyrimidines; Pyrroles; Uveomeningoencephalitic Syndrome | 2020 |
Tofacitinib in recalcitrant scleritis: First case report from India.
Topics: Aged; Humans; Immunosuppressive Agents; India; Male; Piperidines; Pyrimidines; Pyrroles; Scleritis | 2020 |
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Incidence; Lung Diseases, Interstitial; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
[Successful treatment of alopecia totalis with tofacitinib in a Danish patient].
Topics: Adult; Alopecia; Denmark; Humans; Male; Piperidines; Pyrimidines; Pyrroles | 2020 |
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cholesterol; Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Heart Disease Risk Factors; Humans; Inflammation; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome | 2021 |
Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis.
Topics: Adult; Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Piperidines; Pyrimidines; Pyrroles | 2021 |
Treatment of refractory anti-NXP2 and anti-TIF1γ dermatomyositis with tofacitinib.
Topics: Autoantibodies; Dermatomyositis; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.
Topics: Autoantibodies; Dermatomyositis; Female; Humans; Interferon-Induced Helicase, IFIH1; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence | 2020 |
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Incidence; Piperidines; Psoriasis; Pulmonary Embolism; Pyrimidines; Pyrroles | 2020 |
Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan.
Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Female; Herpes Zoster; Humans; Incidence; Interferon-gamma; Lymphocyte Count; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes; Taiwan | 2020 |
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Medicare; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; United States | 2021 |
[Alopecia areata with good response to tofacitinib].
Topics: Alopecia; Alopecia Areata; Female; Humans; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2021 |
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium.
Topics: Crohn Disease; Humans; Inflammatory Bowel Diseases; Piperidines; Pyrimidines; Pyrroles | 2021 |
Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.
Topics: Aged; Arthritis, Rheumatoid; Castleman Disease; Fatal Outcome; Female; Humans; Janus Kinase Inhibitors; Multiple Organ Failure; Piperidines; Pyrimidines; Pyrroles; Thrombocytopenia | 2020 |
Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
Topics: Alopecia; Alopecia Areata; Humans; Minoxidil; Piperidines; Pyrimidines; Pyrroles | 2021 |
Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.
Topics: Humans; Livedo Reticularis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Diseases, Vascular; Skin Ulcer; Vascular Diseases | 2020 |
Good Response to Tofacitinib in Refractory Amyopathic Dermatomyositis.
Topics: Dermatomyositis; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Correspondence on 'The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series'.
Topics: Abatacept; Antirheumatic Agents; Hepatitis B; Humans; Pyrroles; Treatment Outcome | 2023 |
CNS demyelination during tofacitinib therapy: First report.
Topics: Animals; Demyelinating Diseases; Humans; Piperidines; Pyrimidines; Pyrroles | 2020 |
Challenges of securing insurance approval for oral tofacitinib for the treatment of alopecia areata: a multi-institution retrospective review.
Topics: Aged; Alopecia Areata; Humans; Insurance; Medicare; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Retrospective Studies; United States | 2022 |
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cohort Studies; Female; Humans; Methotrexate; Middle Aged; Pharmaceutical Preparations; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bone Density; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Pediatric Game Changers∗: Oral tofacitinib for the treatment of alopecia areata in children.
Topics: Alopecia; Alopecia Areata; Child; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Alopecia areata flare patterns in children and young adults while on systemic tofacitinib.
Topics: Alopecia; Alopecia Areata; Child; Humans; Piperidines; Pyrimidines; Pyrroles; Young Adult | 2022 |
[Granulomatous rosacea-like dermatitis under therapy with tofacitinib].
Topics: Adult; Dermatitis; Female; Humans; Piperidines; Pyrimidines; Pyrroles; Rosacea | 2021 |
Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Topics: Administration, Topical; Alopecia Areata; Animals; Azetidines; CD8-Positive T-Lymphocytes; Cytokines; Isonicotinic Acids; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Macrophages; Mice, Inbred C3H; Nitriles; NK Cell Lectin-Like Receptor Subfamily K; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2021 |
Development and evaluation of tofacitinib transdermal system for the treatment of rheumatoid arthritis in rats.
Topics: Administration, Cutaneous; Animals; Arthritis, Rheumatoid; Drug Delivery Systems; Piperidines; Pyrimidines; Pyrroles; Rats; Transdermal Patch | 2021 |
Topical tofacitinib for the treatment of alopecia areata affecting facial hair.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Tofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Tofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review-Authors' Reply.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.
Topics: Antiviral Agents; Humans; Keratinocytes; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes | 2021 |
The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
Topics: Body Mass Index; Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.
Topics: Body Mass Index; Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
A Case of Disseminated Cutaneous
Topics: Humans; Mycobacterium chelonae; Piperidines; Pyrimidines; Pyrroles | 2021 |
Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome | 2021 |
Adherence to treatment with tofacitinib in patients with rheumatoid arthritis in daily clinical practice.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2022 |
Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia.
Topics: Biological Products; Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis.
Topics: Animals; Arthritis, Experimental; Endothelial Cells; Humans; Mice; Piperidines; Pyrimidines; Pyrroles; Synovial Membrane | 2021 |
5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness?
Topics: Biological Products; Cost-Benefit Analysis; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Granulomatous disease and the two faces of Janus: divergent effects of tofacitinib therapy for inflammatory arthritis.
Topics: Antirheumatic Agents; Arthritis; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2022 |
Tofacitinib inhibits CD4 T cell polarisation to Th1 during priming thereby leading to clinical impact in a model of experimental arthritis.
Topics: Animals; Arthritis, Experimental; CD4-Positive T-Lymphocytes; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2022 |
Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report.
Topics: COVID-19; Humans; Immunologic Factors; Piperidines; Pyrimidines; Pyrroles; SARS-CoV-2 | 2021 |
Systemic inflammatory responses after orthopedic surgery in patients with rheumatoid arthritis treated with tofacitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Infant, Newborn; Orthopedic Procedures; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2021 |
Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Humans; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2022 |
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
Topics: Colitis, Ulcerative; Humans; Marketing; Piperidines; Pyrimidines; Pyrroles | 2022 |
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population.
Topics: Alopecia; Alopecia Areata; Humans; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Saudi Arabia; Treatment Outcome | 2022 |
Disseminated Tuberculosis in a Patient Treated with Tofacitinib for Ulcerative Colitis.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Tuberculosis | 2022 |
Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
Topics: Adolescent; Alopecia; Alopecia Areata; Child; Female; Humans; Male; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2022 |
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2022 |
Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Topics: Alopecia; Alopecia Areata; Humans; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies | 2022 |
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.
Topics: Abatacept; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Cohort Studies; Humans; Interleukin-6; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rituximab; Sulfonamides; Sweden; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2022 |
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Psoriatic; Humans; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2022 |
Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open.
Topics: Colitis, Ulcerative; Humans; Longitudinal Studies; Piperidines; Pyrimidines; Pyrroles | 2022 |
Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Efficiency; Humans; Latin America; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Work Performance | 2022 |
Refractory alopecia universalis associated with dermatomyositis successfully treated with tofacitinib.
Topics: Adult; Alopecia; Alopecia Areata; Dermatomyositis; Female; Humans; Interferons; Piperidines; Pyrimidines; Pyrroles | 2022 |
Topical Janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: A case series.
Topics: Dermatitis; Humans; Janus Kinases; Piperidines; Pruritus; Pyrimidines; Pyrroles | 2022 |
Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study.
Topics: Etanercept; Herpes Zoster; Herpesvirus 3, Human; Humans; Neoplasms; Piperidines; Pyrimidines; Pyrroles | 2022 |
Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection.
Topics: Alopecia; Alopecia Areata; COVID-19; Humans; Piperidines; Pyrroles | 2023 |
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Mobile Applications; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2022 |
Tofacitinib for Treatment of Alopecia Areata: Real-world Evidence and Factors Associated with Therapeutic Response.
Topics: Alopecia; Alopecia Areata; Humans; Piperidines; Pyrimidines; Pyrroles | 2022 |
Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; COVID-19; Female; Humans; India; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2022 |
Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Humans; Prospective Studies; Pyrroles; Treatment Outcome | 2023 |
Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open.
Topics: Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2022 |
Oral tofacitinib for successful treatment of refractory alopecia areata in preschool children.
Topics: Alopecia; Alopecia Areata; Child, Preschool; Humans; Piperidines; Pyrimidines; Pyrroles | 2022 |
[What do the results of the ORAL surveillance study mean for the treatment of rheumatoid arthritis with tofacitinib?]
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reproducibility of Results; Treatment Outcome | 2022 |
Tofacitinib as a possible treatment for arthritis in an APDS2 patient.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2023 |
Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Pyrroles; Republic of Korea; Rheumatology; Treatment Outcome | 2023 |
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Proteins; Chemokines; Humans; Inflammation; Interleukin-6; Protein Kinase Inhibitors; Pyrroles; Treatment Outcome | 2022 |
Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
Topics: Adult; Alopecia; Alopecia Areata; Arabs; Child; Cohort Studies; Female; Humans; Male; Prospective Studies; Pyrroles | 2022 |
A Retrospective Review of Tofacitinib in the Treatment of Refractory Dermatomyositis.
Topics: Dermatomyositis; Humans; Immunologic Factors; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2022 |
Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open.
Topics: Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Pyrroles; Quality of Life; Treatment Outcome | 2023 |
Tofacitinib for sarcoidosis, a new potential treatment.
Topics: Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sarcoidosis | 2022 |
Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Product Surveillance, Postmarketing; Prospective Studies; Pyrroles; Republic of Korea; Treatment Outcome | 2023 |
Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy.
Topics: Alopecia Areata; Female; Humans; Pyrroles; Vitiligo | 2022 |
Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2022 |
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Incidence; Pyrroles; Risk Factors; Treatment Outcome | 2023 |
Tofacitinib in Ulcerative Colitis-evolving Efficacy and Safety.
Topics: Colitis, Ulcerative; Humans; Piperidines; Pyrimidines; Pyrroles | 2023 |
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; Herpes Zoster; Humans; Protein Kinase Inhibitors; Pyrroles; Remission Induction; Treatment Outcome | 2023 |
Letter: tofacitinib in the real world - do clinical trial data stand up?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles | 2023 |
Drug-induced liver injury due to tofacitinib: a case report.
Topics: Adolescent; Alopecia Areata; Chemical and Drug Induced Liver Injury; Female; Humans; Iran; Protein Kinase Inhibitors; Pyrroles | 2023 |
Development of a sensitive biochemical assay for the detection of tofacitinib adherence.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Pyrroles; Tandem Mass Spectrometry | 2023 |
Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Humans; Patient Satisfaction; Personal Satisfaction; Pyrroles; Quality of Life; Treatment Outcome | 2023 |
Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Pyrroles; Treatment Outcome | 2023 |
Drug Survival and Long-term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study.
Topics: Alopecia Areata; Humans; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies | 2023 |